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 Zusammenfassung 
5-Oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid) ist ein sehr potenter chemo-taktischer 
Faktor für Granulozyten, der mittels eines selektiven G-Protein-gekoppelten Rezeptors agiert. 
Dieser potenziell wichtige Entzündungsbotenstoff wird durch Oxidation von dem 5-
Lipoxygenaseprodukt 5-HETE (5S-Hydroxy-6,8,11,14-eicosatetraensäure) gebildet. Diese 
Reaktion wird von 5-Hydroxyeisosanoid Dehydrogenase (5h-dh) unter Verwendung von 
NADP+ als Reduktionspartner katalysiert. Obwohl gezeigt wurde, daß Entzündungszellen und 
Thrombozyten dieses Enzym expremieren, war wenig über dessen Regulation bekannt. Das 
Ziel der vorliegenden Studie war es, die der 5-oxo-ETE-Produktion zugrunde liegenden 
Regulationsmechanismen aufzuklären. Wir gingen diese Aufgabe aus drei Richtungen an, 
indem wir die Expression von 5h-dh in unbehandelten und differenzierten myeloiden 
Zelllinien, den Einfluß oxidativen Stresses und Glukose, sowie die Expression von 5h-dh in 
nicht-myeloiden Zelllinien untersuchten. 
Die erste Zielstellung dieser Arbeit war es zu klären, ob die promyeloide Zelllinie HL-60 
und die promonozyte Zelllinie U-937 diese 5h-dh enthalten und ob sich deren Aktivität 
während myeloider Zelldifferenzierung verändert. Um den zellulären Gehalt abzuschätzen, 
wurden Zellen zunächst mit PMS (Phenazine Methosulfat), das NADPH nicht-enzymatisch in 
NADP+ umwandelt, vorbehandelt und danach mit dem Substrat 5-HETE inkubiert. Im 
Vergleich zu Monozyten oder Granoluzyten produzieren undifferenzierte HL-60 und U-937 
Zellen vergleichbare Mengen von 5-oxo-ETE. Darüber hinaus verdreifacht eine dreitägige 
Behandlung von U-937 Zellen mit PMA (Phorbol 12-myristate 13-acetate) die Enzymaktivtät 
im Vergleich zu der mit Lösungsmittel behandelten Kontrollgruppe. In ähnlicher Weise 
verdoppelte die Behandlung von HL-60 Zellen mit dh-VitD3 (1,25-dihydroxy-Vitamin D3) für 
den identischen Zeitraum die 5-oxo-ETE-Produktion im Vergleich zur Lösungsmittelkontrolle. 
Der Einfluß von PMA auf 5h-dh wurde darüber hinaus in der mikrosomalen Fraktion von 
U-937 Zellen unter Zuhilfenahme der Michaelis-Menten-Kinetik untersucht und mit 
neutrophilen Mikrosomen verglichen. Nach der Differenzierung dieser Zelllinie mit PMA 
verdreifachte sich auch die spezifische Enzymaktivität im Vergleich zu Lösungsmittel-
behandelten Zellen. Der KM-Wert ist vergleichbar in U-937 Zellen und Neutrophilen und wird 
durch die Differenzierung nicht beeinflußt. 
Das zweite Hauptanliegen dieser Arbeit war es zu untersuchen, ob die Produktion von 
5-oxo-ETE durch oxidativen Stess und Glukose beinflußt wird. Obwohl Leukozyten und 
Thrombozyten eine hohe mikrosomale 5h-dh-Aktivität besitzen, wandeln  unstimulierte Zellen 
nur wenig 5-HETE in 5-oxo-ETE um. Um dieses Dilemma zu lösen, untersuchten wir die 
Möglichkeit, daß die Produktion von 5-oxo-ETE durch oxidativen Stress angeregt wird. Wir 
fanden, daß H2O2 und t-butyl Hydroperoxid die Synthese von 5-oxo-ETE in monozytischen 
U-937 Zellen sehr stark stimulierten. Dieser Effekt hing von dem GSH-Redoxzyklus ab, da er 
durch Depletion von GSH oder durch Inhibierung der GSH-Reduktase geblockt und mittels 
Diamid-induzierter Oxidation von GSH zu GSSG simuliert werden kann. Aufgrund seiner 
Verarbeitung durch den Pentosephosphat Zyklus, der mittels Dehydroepiandrosterone 
unterbrochen werden kann, inhibierte Glucose den stimulierenden Effekt von H2O2. Die 
Synthese von 5-oxo-ETE wurde durch H2O2 auch in aus humanem Blut gewonnen Monozyten, 
Lymphocyten und Thrombozyten aber nicht in Neutrophilen angeregt. Im Gegensatz zu 
Monozyten zeigten sich Thrombozyten und Lymphozyten allerdings resistent gegenüber den 
 inhibierenden Einflüssen von Glukose. T-butyl Hydroperoxid ehöhte auch die Produktion von 
5-oxo-ETE nach Zugabe von Ionophore und Arachidonsäure zu mononukleären Blutzellen. 
Oxidativer Stress agiert möglicherweise durch Depletierung von NADPH, welches 
zwangsläufig zu NADP+, dem Cofaktor von 5h-dh, umgewandelt wird. Der Pentosephosphat-
Zyklus wirkt diesem Mechanismus entgegen, da in ihm unter Verbrauch von Glukose NADP+ 
wieder in NADPH umwandelt wird.  
Der dritte Schwerpunkt dieser Studie galt der Frage ob nicht-myeloide Humanzellen 5h-dh 
expremieren. Es ist bekannt, daß andere an der Biosynthese von Leukotrienen beteiligte 
Enzyme (z.B. LTA4-Hydrolase und LTC4-Synthase) wesentlich breiter im Körper verteilt sind 
als 5-Lipoxygenase, die den ersten Schritt der Leukotrien- und 5-oxo-ETE-Biosynthese 
katalysiert. Diese Ergebnisse veranlaßten uns zu der Vermutung, daß nicht-myeloide Zellen 
ebenfalls 5h-dh expremieren. Wir nahmen an, daß Zellen, die wichtig für die 
Leukozytenmigration sind und oxidativem Stress unterliegen, dieses Enzym enthalten. 
Zunächst überprüften wir mehrere sekundäre Epithelzelllinien auf ihr Vermögen 5-oxo-ETE zu 
produzieren, indem wir PMS und 5-HETE zugaben. Wir fanden, daß alle untersuchten 
Epithelzelllinien in der Lage sind, erhebliche Mengen von 5-oxo-ETE zu produzieren. Um 
abzuklären, daß das für diese Reaktion verantworliche Enzym mit dem zuvor in Leukozyten 
beschriebenen identisch ist, untersuchten wir diese Reaktion genauer in Zellfraktionen von 
A549 Zellen, einer Typ-II alveolaren Epithelzelllinie. Drei Indizien lassen vermuten, daß die 
epithele 5h-dh der myeloiden entspricht: (i) die enzymatische Aktivtät liegt vor allem in der 
mikrosomalen Fraktion vor, (ii) bei dem Kofaktor handelt es sich um NADP+ und nicht um 
NAD+, und (iii) 5S-HETE ist das bevorzugte Substrat. Weitere Studien zeigten, daß auch 
primäre humane Aorta-Endothelzellen 5h-dh expremieren. Die geringe Verfügbarkeit dieser 
Zellen erlaubte uns allerdings keine weitergehende biochemische Charakterisierung von 
endotheler 5h-dh. Vergleichbar zu Entzündungszellen wird die Produktion von 5-oxo-ETE 
auch in Endothel- und in Epithelzellen durch oxidativen Stress angeregt. 
 Die hier vorgelegten Ergebnisse untermauern die Annahme, daß es sich bei 5-oxo-ETE um 
einen wichtigen Entzündungsbotenstoff handelt. 5-oxo-ETE wird am Enzündungsort 
möglicherweise sowohl von Entzündungs- als auch von Gewebezellen gebildet. Oxidativer 
Stress ist moglicherweise ein wichtiger Mechanismus, um die Produktion von 5-oxo-ETE 
anzuregen, was schließlich die weitere Infiltration von Granulozyten fördert und somit den 
Entzündungsprozeß verlängert. 
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 Abstract 
5-Oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid) is a highly potent granulocyte 
chemoattractant that acts through a selective G-protein coupled receptor. This potentially 
important inflammatory mediator is formed by oxidation of the 5-lipoxygenase product 5-
HETE (5S-hydroxy-6,8,11,14-eicosatetraenoic acid) by 5-hydroxyeicosanoid dehydrogenase 
(5h-dh) with NADP+ as the electron acceptor. Although it had been shown that this enzyme is 
expressed in inflammatory cells and platelets, little was known about its regulation. The 
objective of this study was to investigate underlying regulatory mechanisms of 5-oxo-ETE 
production in human cells. We addressed this matter from three directions by investigating the 
expression of 5h-dh in undifferentiated myeloid cell and the impact of differentiation, the 
effects of oxidative stress and glucose on 5-oxo-ETE synthesis by blood cells and myeloid 
cells, and the expression of 5h-dh in non-myeloid cells. 
The first objective of this study was to determine whether the HL-60 promyelocytic cell line 
and the U-937 monoblastic cell line contain this 5h-dh and if its activity changes during 
myeloid cell differentiation. To evaluate cellular 5h-dh content, cells were preincubated with 
PMS (phenazine methosulfate), which converts NADPH to NADP+, the cofactor of this 
enzyme, followed by the addition of the substrate 5-HETE. Undifferentiated U-937 and HL-60 
cells produce similar amounts of 5-oxo-ETE compared to monocytes or neutrophils. 
Furthermore, incubation of U-937 cells with PMA for 3 days resulted in a 3-fold increase in 
production of 5-oxo-ETE compared to vehicle treated cells. Similarly, incubation of HL-60 
cells with dh-VitD3 for an identical period resulted in a 2-fold increase in 5-oxo-ETE 
production compared to vehicle treatment. The impact of PMA on 5h-dh was further 
investigated in the microsomal fraction of U-937 cells and compared to neutrophil microsomes, 
using the Michaelis-Menten kinetics. After differentiation of this cell line with PMA the 
specific 5h-dh activity is increased by threefold compared to vehicle-treated cells. The KM of 
5h-dh is similar in U-937 cells and neutrophils and is not affected by differentiation.  
The second objective was to investigate whether 5-oxo-ETE production could be regulated 
by oxidative stress and glucose levels. Although leukocytes and platelets display high 
microsomal 5h-dh activity, unstimulated intact cells do not convert 5-HETE to appreciable 
amounts of 5-oxo-ETE. To attempt to resolve this dilemma we explored the possibility that 
5-oxo-ETE synthesis could be enhanced by oxidative stress. We found that H2O2 and t-butyl 
hydroperoxide strongly stimulate 5-oxo-ETE formation by U-937 monocytic cells. This was 
dependent on the GSH redox cycle, as it was blocked by depletion of GSH or inhibition of 
glutathione reductase and mimicked by oxidation of GSH to the GSSG by diamide. Glucose 
inhibited the response to H2O2 through its metabolism by the pentose phosphate pathway, as its 
effect was reversed by the glucose-6-phosphate dehydrogenase inhibitor 
dehydroepiandrosterone. 5-Oxo-ETE synthesis was also strongly stimulated by hydroperoxides 
in blood monocytes, lymphocytes, and platelets, but not neutrophils. Unlike monocytic cells, 
lymphocytes and platelets were resistant to the inhibitory effects of glucose. 5-Oxo-ETE 
synthesis following incubation of peripheral blood mononuclear cells with arachidonic acid and 
calcium ionophore was also strongly enhanced by t-butyl hydroperoxide. Oxidative stress could 
act by depleting NADPH, resulting in the formation NADP+, the cofactor for 5h-dh. This is 
opposed by the pentose phosphate pathway, which converts NADP+ back to NADPH at the 
expense of glucose. 
 The third objective was to determine whether non-myeloid human cells express 5h-dh. It has 
been shown that the distribution of enzymes involved in leukotriene synthesis (LTA4 hydrolase 
and LTC4 synthase) is considerably wider than that of 5-lipoxygenase, which catalyzes the first 
step in leukotriene and 5-oxo-ETE synthesis. This led us to hypothesize that non-myeloid cells 
may express 5h-dh activity as well. We speculated that cells that are important for leukocyte 
trafficking and are subject to oxidative stress in vivo might contain this enzyme. We first 
screened several secondary epithelial cell lines for their ability to synthesize 5-oxo-ETE by 
adding 5-HETE and PMS and found that are all are capable of synthesizing substantial amounts 
of his substance. To clarify whether the enzyme responsible for this activity in epithelial cells is 
similar to inflammatory cell 5h-dh, we studied the synthesis of 5-oxo-ETE in more detail in 
subcellular fractions of A549 cells, a lung type II alveolar epithelial cell line. Three lines of 
evidence suggest that the epithelial 5h-dh and the inflammatory cell 5h-dh are identical: (i) the 
enzymatic activity is localized in the microsomal fraction, (ii) the cofactor is NADP+ and not 
NAD+, and (iii) 5S-HETE is the preferred substrate. We also found that primary human aortic 
endothelial cells express 5h-dh. However, limitations in their availability did not permit 
extensive investigation of the biochemical characteristics of endothelial 5h-dh. 5-oxo-ETE 
production by both endothelial and epithelial cells is regulated by oxidative stress in a manner 
similar to inflammatory cells. 
The results of this study support the notion that 5-oxo-ETE is an important inflammatory 
mediator. At the site of inflammation, it could be produced by both inflammatory cells and 
structural cells. Oxidative stress could be an important mechanism for stimulating 5-oxo-ETE 
formation in inflammation, promoting further infiltration of granulocytes thus prolonging 
inflammation.  
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Für meine Eltern. 
 
 
 
 
 
 
 
 
 
 
One does not discover new lands without consenting to lose sight of the shore for 
a very long time. 
Andre Gide (1869-1951) 
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Abbreviations 
List of most frequently used abbreviations. Additional descriptions for enzyme subclasses within 
the text are explained when introduced. See Appendix for selected eicosanoid structures and most 
frequently used chemicals. 
AA arachidonic acid; 5Z,8Z,11Z,14Z-eicosatetraenoic acid 
ASM Airway smooth muscle 
3-AT 3-Amino-1,2,4-triazole 
BCNU 1,2-bis[2-chloroethyl]-1-nitrosourea; carmustine 
CAPS 3-(cyclohexylamino)-1-propane sulfonic acid 
cPLA2 Cytosolic phospolipase A2
CYP Cytochrome P-450 
Cys-LTs Cysteinyl-leukotrienes 
DA Diamide 
DHA 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid 
DHEA Dehydroepiandrosterone 
dh-VitD3 1,25-dihydroxy-Vitamin D3
5,15-diHETE 5S,15S-dihydroxy-6E,8Z,11Z,13E-eicosatetraenoic acid 
5,20-diHETE 5S,20-dihydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid 
DMSO Dimethylsulfoxide 
EC50 Effective concentration leading to 50% of the maximal response 
EPA 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid 
EPO Eosinophil peroxidase 
ERK Extracellular signal-regulated kinase 
FBS Fetal bovine serum 
fMLP N-Formylmethionyl-leucyl-phenylalanine 
FOG7 5-oxo-7-glutathionyl-8Z,11Z,14Z-eicosatrienoic acid 
G6P-dh Glucose-6-phosphate dehydrogenase 
G-CSF Granulocyte-colony stimulating factor 
GM-CSF Granulocyte macrophage-colony stimulating factor 
GPCR G protein-coupled receptor 
GPx Glutathione peroxidase 
GST Glutathione-S-transferase 
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5h-dh 5S-hydroxyeicosanoid dehydrogenase 
15h-PG-dh 15-hydroxyprostaglandin dehydrogenase 
HAEC Human aorta endothelial cells 
HEPPSO (2-Hydroxyethyl)-piperazine-N'-(2-hydroxypropanesulfonic acid) 
HETEs Hydroxyeicosatetraenoic acids 
  5-HETE 5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid 
  5-HpETE 5S-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid 
12-HETE 12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid 
15-HETE 15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid 
12-HHTrE 12-hydroxy-5,8,10-Heptadecatrienoic acid
  5-HpETE   5S-hydroperxy-6E,8Z,11Z,14Z-eicosatetraenoic acid 
13-HODE 13S-hydroxy-9Z,11E-octadecadienoic acid  
13-HpODE 13S-hydroperoxy-9Z,11E-octadecadienoic acid 
IC50 Concentration leading to 50% of maximal inhibition 
IL Interleukin 
JNK c-jun-NH2-terminal kinases 
MES 2-morpholinoethanesulfonic acid 
5-oxo-ETE    5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid 
12-oxo-ETE  12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid 
15-oxo-ETE  15-oxo-5Z,8Z,11Z,13E-eicosatetraenoic acid 
5o-ETrE 5-oxo-8Z,11Z,14Z-eicosatrienoic acid 
5o-20-HETE 5-oxo-20-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid 
5-LO 5-Lipoxygenase 
LOOH Lipid hydroperoxide 
LPS Lipopolysaccharide 
LT Leukotriene 
LTA4  5S-trans-5,6-oxido-7E,9E,11Z,14Z-eicosatetraenoic acid 
LTB4 5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid 
LTC4 5S-hydroxy-6R-(S-glutathionyl)-7E,9E,11Z,14Z-eicosatetraenoic acid 
LTC4-S LTC4 synthase  
LXA4 Lipoxin A4
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LXB4 Lipoxin B4
MAPK Mitogen activated protein kinase 
MAPKK MAPK kinase 
MPO  Myeloperoxidase 
NEM N-Ethylmaleimide 
OXE 5-oxo-ETE receptor 
PAF Platelet activating factor 
PBMC Peripheral blood mononuclear cells 
PBS+/- Phosphate buffered saline ((+) 2 mM Ca++, 2 mM Mg++; (-) No Ca++/Mg++) 
PGB2 Prostaglandin B2, 9-oxo-15S-hydroxy-prosta-5Z,8(12),13E-trien-1-oic acid 
PKC Protein kinase C 
PLC Phospholipase C 
PMA Phorbol 12-myristate 13-acetate 
PMNL Polymorphonuclear leukocytes 
PMS Phenazine methosulfate 
PMSF Phenylmethanesulfonyl fluoride 
PPAR Peroxisome proliferator-activated receptor 
PPP Pentose-phosphate pathway 
Prx Peroxiredoxin; thioredoxin peroxidases 
PTP Protein tyrosine phosphatase 
PUFA Polyunsaturated fatty acids 
RA Retinoic acid  
RP-HPLC Reverse phase-high pressure lipid chromatography 
SA Sodium azide 
SOD Superoxide Dismutase 
tBuOOH tert-Butyl hydroperoxide 
TLC Thin layer chromatography 
TNF-α Tumor necrosis factor-α 
Trx Thioredoxin 
TrxR Thioredoxin reductase 
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I  INTRODUCTION 
I.1. Eicosanoids in Inflammation 
The focus of this thesis is the production of 5-oxo-ETE by inflammatory and tissue cells 
and its regulation by oxidative stress. Before describing the body of acquired knowledge on 
5-oxo-ETE, oxidative stress and the regulation of 5-lipoxygenase (5-LO) in more detail, a brief 
overview of eicosanoid production will be presented. As eicosanoids can be formed by the 
interaction of different cell types, this will be followed by a brief introduction to transcellular 
metabolism. Finally, the biological effects of eicosanoids on leukocytes will be dissected, with 
particular emphasis being placed on their potent effects on eosinophil migration. 
I.1.1 Formation of Eicosanoids 
Almost all mammalian cells except red blood cells produce eicosanoids, the collective name 
for oxygenation products of arachidonic acid (AA) and other polyunsaturated 20-carbon fatty 
acids. Eicosanoids are hormone-like, in that they have profound physiological effects at very 
low concentrations (EC50 in the range of 1-10 nM). They act mainly by stimulating 7-
transmembrane receptors coupled to various second messenger pathways through G-proteins 
(GPCRs). The International Union of Pharmacology (IUPHAR) designated the eicosanoid 
receptors based on their agonist and antagonist selectivity and on the binding affinities of the 
cloned receptors. The committee receptors of 5-LO derived products are denominated as BLT1 
and BLT2 (for LTB4), cysLT1 (for LTD4), cysLT2 (for LTC4 and LTD4), ALX (for lipoxins), 
and OXE (for 5-oxo-ETE) [1,2]. Unlike hormones, however, eicosanoids are not transported in 
the blood stream to their site of biological action. Instead, these chemically and biologically 
unstable substances are metabolized and degraded within minutes or less in the body or in 
vitro, and act as autocrine and paracrine mediators, executing their effects in close proximity to 
their site of synthesis.  
In humans, the most important eicosanoid precursor is arachidonic acid (5,8,11,14-
eicosatetraenoic acid). Arachidonate is stored in cell membranes esterified at the SN2 position 
of phospholipids. The production of eicosanoids is controlled by arachidonate release from 
phospholipids, which is facilitated by a phospholipase A2 (PLA2). Cytosolic PLA2 (cPLA2) is 
the major pathway in the release of AA during inflammatory responses in leukocytes and its 
activation is crucial for eicosanoid formation [3]. Among the wide family of phospholipases, 
two secretory PLA2s, sPLA2-IIA and sPLA2-V have also been implicated in some specific 
inflammatory processes [3]. In contrast to other mediators such as histamine, which are 
preformed and stored in granules, eicosanoids are newly synthesized upon cell activation. As 
shown in Figure I.1, two main pathways exist for arachidonic acid metabolism during 
inflammation. The cyclooxygenase (COX) pathway forms the prostanoids, including 
prostaglandins (PGs) D2, E2, F2α, and I2 and thromboxane A2 (TXA2). The 5-LO pathway leads 
to the production of leukotrienes (LTs) and 5-oxo-ETE [4]. In contrast to prostaglandins, 
which can be formed by two isoenzymes (COX-1 and COX-2) in a wide range of cells, 5-LO 
is largely restricted to white blood cells and mast cells. Various inflammatory and 
hypersensitivity disorders (such as asthma) are associated with elevated levels of LTs. The 
different enzymes involved in LT formation as well as the LT receptors are now targets of 
several drugs in clinical use. There are also other lipoxygenases in humans, including 12-LO 
INTRODUCTION   9 
[5], which generates 12-HETE and the Hepoxilins, and 15-LO [6], which produces 15-HETE 
and the lipoxins. Lipoxins are produced by interaction of these pathways (see below) with 
5-LO. 
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Figure I.1  Predominant pathways of eicosanoid formation in human leukocytes 
The formation of eicosanoids during inflammation is initiated by the release of AA from 
phospholipids by cPLA2. AA is then metabolized by COX, leading to the formation of 
thromboxanes and prostaglandins, or by 5-LO, which produces LTA4, the precursor of 
leukotrienes. The 5-LO reaction intermediate 5-HpETE can be reduced by GPx or GST to 
5-HETE. 5h-dh, the subject of this study, can convert 5-HETE to 5-oxo-ETE. See text for 
abbreviations and further information. 
LTs result from the catalytic activity of 5-LO, a single protein possessing both dioxygenase 
activity necessary for the synthesis of 5S-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid 
(5-HpETE), and epoxygenase activity leading to leukotriene A4 (LTA4) formation. Depending 
on the cell type and activation state, LTA4 can be converted by the action of LTA4 hydrolase 
into LTB4, or it may be conjugated with reduced glutathione by LTC4 synthase (LTC4-S) to 
produce LTC4, the first member of the cysteinyl-LT family. 5-HpETE, the intermediate of 5-
LO can be released from the enzyme. Although it is stable in buffer, it is rapidly reduced in 
cells by a ubiquitous peroxidase to 5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-
HETE). 5-HETE is often the predominant, but relatively inactive metabolite of AA in cells 
containing 5-LO [7,8]. 5-Hydroxyeicosanoid dehydrogenase (5h-dh) oxidizes and biologically 
activates 5-HETE to 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) utilizing NADP+ 
as the electron acceptor (see I.2.3 for details). 
I.1.2 Transcellular Biosynthesis of Lipoxygenase Products 
Transcellular biosynthesis of eicosanoids is a special mode of cell communication whereby 
the production of eicosanoids by mixed cell populations differs from that expected from each 
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individual cell type. Intermediates produced in the synthesis of eicosanoids (e.g. PGH2 and 
LTA4) can be released into the extracellular milieu and converted by other cells to biologically 
active products, a process which is known as intercellular, or transcellular metabolism. 
Formation of the cysteinyl-LTs (LTC4, LTD4, and LTE4), LTB4, and lipoxins can all be formed 
by this mechanism. Transcellular biosynthesis of LTC4 occurs via transfer of the highly 
unstable 5-LO product LTA4 from neutrophils to nearby acceptor cells devoid of 5-LO activity 
such as platelets or endothelial cells [9]. In humans, LTC4-S is expressed mainly in 
eosinophils, basophils, and platelets. In human endothelial cells, microsomal glutathione-S-
transferase type-2 (mGST-2) also produces LTC4 [10]. Transcellular synthesis of cysteinyl-
LTs (cys-LTs) also occurs in the liver [11]: LTA4, synthesized by Kupffer cells, is taken up by 
hepatocytes, converted into LTC4, and then released into the extracellular space, acting in a 
paracrine way on Kupffer and sinusoidal endothelial cells. Thus, hepatocytes cannot directly 
oxidize arachidonic acid to eicosanoids. In the bloodstream, leukocytes may release LTA4, 
which is converted into LTC4 by endothelial cells. Endothelial and potentially epithelial cells 
can produce eicosanoids in the form of prostanoids without transcellular metabolism, as they 
either posses constitutively expressed COX-1 or inducible COX-2 [12,13]. 
Another important example of transcellular metabolism is the production of lipoxins, which 
were initially identified as the only inhibitory or anti-inflammatory eicosanoids that act via an 
agonist role as a “stop signal” by ALX activation [1], by the combined actions of leukocyte 5-
LO and either 12-LO, 15-LO, or COX-2. A lipoxygenase product may be released from one 
cell and then converted by a second lipoxygenase in a different cell type (for review see [14]). 
Depending on the cellular composition, different routes exist for lipoxin-formation. For 
example, the abundant platelets contain highly active 12-LO, which can convert neutrophil 
derived LTA4 to lipoxin A4 or lipoxin B4. 15-LO, present in eosinophils, airway epithelial 
cells, and IL-4/IL-13 treated monocytes, can also facilitate lipoxin formation [14]. Lipoxins 
can thus be produced by several pathways involving transcellular biosynthesis in the lung, and 
increased levels of these substances are found in BAL fluid from subjects with asthma and 
other lung diseases [15]. In addition to prostaglandins, cyclooxygenase converts AA to small 
amounts of 11-HETE and 15-HETE. However, when COX-2 is treated with aspirin, unlike 
COX-1, it remains catalytically active and converts AA to 15R-HETE rather than PGH2 [16]. 
15R-HETE can then be converted by 5-LO in other cell types to 15R-LXA4 (15-epi-LXA4), 
which has the opposite chirality at C15 to LXA4 generated by other mechanisms. For example, 
coincubation of neutrophils with aspirin-treated endothelial cells or A549 airway epithelial 
cells in which COX-2 has been induced leads to the formation of “aspirin-triggered lipoxins” 
[14]. As the receptor for LXA4 interacts similarly with 15R- and 15S-LXA4, the aspirin-
triggered 15-epi-LXA4 has a high biological potency.  
I.1.3 Eicosanoids as Mediators in Inflammation 
Infections with pathogens or allergic responses trigger an acute inflammatory response in 
which cells of the immune system move into the affected site [17]. This process is regulated by 
lipid mediators, cytokines, and chemokines. However, this section will focus on the role of 
eicosanoids on leukocyte infiltration, with emphasis on the eosinophils, as these cells are the 
major target for 5-oxo-ETE. A detailed discussion of the role of cytokines and chemokines 
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would go beyond the scope of this dissertation but an excellent review on this subject by Busse 
and Lemanske is advisable [18].  
 
Figure I.2  Role of inflammatory mediators in eosinophil chemotaxis and activation 
Peripheral blood eosinophils first roll on and then tightly adhere to the endothelium by interaction 
of selectins and integrins with the endothelial cell receptors. Following a concentration gradient 
of chemoattractants, they undergo diapedeisis between endothelial cells and then migrate to the 
site of inflammation. In the tissue, the life span of the eosinophil may be enhanced by cytokines, 
i.e. IL-5 and GM-CSF. When the eosinophil is fully activated it releases large amounts of granule 
proteins, reactive oxygen species such as superoxide (O2•−) and its metabolites, and 5-LO 
products such as LTC4, LTD4, and 5-oxo-ETE. Among other cell types, mast cells and tissue 
macrophages also produce lipid mediators. Eicosanoids enhance the inflammatory process by 
stimulating integrin and selectin expression, inducing chemotaxis, stimulate cytokine expression, 
respiratory burst, and degranulation. 
Pronounced tissue eosinophilia is a hallmark of a number of diseases including allergic 
disorders and parasitic infections [19]. In asthmatic subjects, increased numbers of these cells 
are found in airways and in bronchoalveolar lavage fluid following allergen challenge [20]. 
Eosinophils develop in the bone marrow in response to the stimulation of eosinophil progenitor 
cells by interleukin-5 and other cytokines [19]. Fully mature eosinophils are then released in 
the blood stream. To participate in inflammatory responses, the eosinophil must migrate from 
the circulation into the tissue. First, they roll on the blood vessel wall due to loose connections 
that are established primarily through the interaction of selectins with receptors on endothelial 
cells for these molecules [19]. When given proper stimuli, tight adhesion of these leukocytes to 
the endothelium is established, mainly mediated by the binding of integrins to their surface 
receptors. Eicosanoids can induce shedding of L-selectin from the surface of leukocytes, which 
is then replaced by other cell surface adhesion molecules such as integrins, thus establishing 
tighter adhesion [19]. The expression of active integrins on the surface of leukocytes can be 
induced by certain eicosanoids, enhancing adhesion to the endothelium by exocytosis of 
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receptor molecules. On exposure to chemoattractant mediators, eosinophils undergo diapedesis 
between endothelial cells and migrate into the tissues. An internal compass interprets the 
gradient of an external chemoattractant to orientate the eosinophils polarity in the right 
direction. Thus, in contrary to bacteria, which swim in a jerky trajectory using a temporal 
strategy to interpret the gradient, eukaryotes implement a spatial strategy. The accumulation of 
eosinophils in tissue is further regulated by the generation of survival and activation factors 
(IL-3, IL-5, and granulocyte–macrophage colony-stimulating factor [GM-CSF]) by T cells, 
monocytes, and probably mast cells. The indirect effect of 5-oxo-ETE on eosinophil survival 
by inducing cytokine expression in monocytes is described in more detail in chapter I.2.1. 
At the site of inflammation, the leukocytes are activated. In eosinophils, the respiratory 
burst is induced in order to produce reactive oxygen species (ROS). In addition, eosinophils 
kill pathogens at the site of inflammation by releasing major basic protein and a matrix 
composed of eosinophil cationic protein, eosinophil-derived neurotoxin, and eosinophil 
peroxidase (EPO) by degranulation [19]. In chronic inflammatory diseases however, both 
cytotoxic actions lead to unwanted tissue destruction. Simultaneously, eosinophils start to 
release inflammatory mediators such as chemokines and eicosanoids, initiating further 
recruitment of leukocytes to the site of inflammation. Inflammatory mediators such as 
eicosanoids act at many steps of this complex process. Although in vitro experiments often 
focus on a single mediator, it is important to keep in mind that cells are never exposed to only 
one specific stimulus but to a variety of endogenous agonists derived from different cell types. 
Certain cytokines for example may prime cells to respond to another agonist. In this case, the 
cytokine may not induce the cellular response by itself but enable the cell to respond to a 
second agonist or enhance the potency of the second agent. 
Eicosanoids are involved in tissue migration of leukocytes at all steps. 5-oxo-ETE, the 
subject of this study, can induce a variety of these responses at several steps of the 
inflammatory process (described in detail in section I.2.1, below). 5-Oxo-ETE enhances the 
expression of integrins, is a very potent chemoattractant for eosinophils and other leukocytes, 
induces GM-CSF release from monocytes, and is capable of terminally activating leukocytes. 
Leukotrienes appear to possess additional biological functions. Besides participating in 
leukocyte tissue migration, cys-LTs are involved in airway smooth muscle (ASM) constriction, 
explaining at least in part the cause of asthmatic bronchoconstriction [21]. Cys-LTs also appear 
to have a distinct effect on vascular permeability, which leads to the formation of edema. LTC4 
and LTD4 have been shown to increase mucus secretion by globlet cells of airway epithelium. 
Based on these findings LTs were deemed potential targets for anti-asthma drugs, and new LT 
receptor antagonists have resulted in a better quality of life for at least a subset of asthma 
patients [21]. 
I.2. 5-oxo-ETE 
I.2.1 Biological Activity of 5-Oxo-ETE 
Since the discovery of the pathways for the formation of 5-oxo-ETE in 1992 [22], many 
biological effects of this compound on myeloid and structural cells have been discovered. 
5-oxo-ETE is unique; besides 12-oxo-ETE (12-KETE) it is the only keto-derivative of a HETE 
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with a higher potency than its parent compound. To date, research has focused on the role of 
5-oxo-ETE in inflammatory processes involving leukocyte recruitment and activation. 
5-Oxo-ETE shows the most pronounced effects on eosinophils, but also activates neutrophils 
and monocytes. In this context, 5-oxo-ETE is best known to evoke leukocyte chemotaxis. 
Additional experiments showed that 5-oxo-ETE is a potent signal for certain non-myeloid cells 
as well. 
Stimulatory Effects of 5-Oxo-ETE on Leukocytes In Vitro 
Various stages of the inflammatory response can be investigated using different in vitro 
assays. As indicated above, leukocytes leave the blood stream and migrate into the tissue. The 
necessary steps in this process are rolling and adherence to endothelial cells. 5-oxo-ETE has 
been shown to induce integrin (e.g. CD11b) expression in neutrophils and eosinophils [23,24] 
and is able to induce L-selectin shedding [24] as measured by flow cytometry. The Boyden 
Chamber system has been utilized to study leukocyte migration [25]. In this setting, 
5-oxo-ETE proved to be a potent chemoattractant for eosinophils [7], neutrophils [26]. 
Although 5-oxo-ETE is less potent than LTB4 as a neutrophil agonist [23,26], it acts via the 
specific 5-oxo-ETE receptor OXE. 5-oxo-ETE effects are self limiting, suggesting 
desensitization of OXE, as other neutrophil agonists like LTB4 or other unrelated agonists do 
not inhibit its activity [23,26-29]. In contrast, 5-oxo-ETE is a very potent eosinophil 
chemoattractant [24,30]. Compared to other chemoattractants, it is about 2.5 times more active 
than platelet activating factor (PAF) and nearly 40 times more active than LTB4. 5-oxo-ETE 
also induces a weak chemotactic response in monocytes, but is about 30 times less potent and 
is 40% less efficacious [31]. 5-oxo-ETE also induces the migration of eosinophils through 
Matrigel®, which resembles the basement membrane, a thin structure constituted mainly of 
collagen IV, laminin and proteoglycans [32]. 
Actin polymerization, a crucial component of chemotaxis, is induced by 5-oxo-ETE in 
eosinophils [24,33], neutrophils [23,28], and monocytes [31]. Elevation of intracellular Ca++ is 
also an important intracellular signal, but is not as important as actin polymerization for 
chemotaxis. However, most chemoattractants also induce a rise in intracellular Ca++ and its 
measurement is of great importance for studying receptor pharmacology. 5-Oxo-ETE has been 
shown to induce Ca++ release in eosinophils [7,24,30] and neutrophils [23,29,34,35], but not in 
monocytes [31]. 5-oxo-ETE possess additional effects on cell signaling, as it induces 
extracellular signal-regulated kinase (ERK) stimulation [27,36] and phosphatidylinositol-
biphosphate 3-kinase [28] in PMNL. Stimulation of ERK, a mitogen activated protein kinase 
(MAPK), in these cells by 5-oxo-ETE leads to the phosphorylation and subsequent activation 
of cPLA2 as measured by AA release [27].  
5-oxo-ETE Induces GM-CSF Release from Monocytes 
5-oxo-ETE may enhance inflammatory responses by inducing GM-CSF release from 
monocytes. Stamatiou and coworkers recently discovered that 5-oxo-ETE enhances eosinophil 
survival [37]. Further investigations revealed that this effect is not mediated by direct induction 
of survival mechanisms in eosinophils, but rather by release of GM-CSF from monocytes [37], 
which can contaminate eosinophil preparations in small numbers. GM-CSF in turn enhances 
the life-span of eosinophils [19]. Since GM-CSF is a central cytokine in several immune 
regulatory mechanisms, 5-oxo-ETE may play a role in additional settings. Moreover it is 
possible that 5-oxo-ETE could induce other cytokines as well. 
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Limitations of 5-oxo-ETE responses 
5-oxo-ETE shares the effects described above with other chemotactic factors, such as 
fMLP, IL-8, eotaxin, RANTES, LTB4, and PAF but is more selective in its responses. 
Although 5-oxo-ETE is a potent stimulator of many biological effects in the absence of 
priming agents, by itself it is only a weak inducer of nitric oxide production (NO•) [38], PAF 
synthesis [28], degranulation [27], fMLP receptor induction [28], and priming agent for fMLP 
induced O2?─ production [27,28] in PMNL. Contrary to 5-oxo-ETE, these biological responses 
are induced by other chemoattractants such as LTB4 [27,28,38]. One study showed that 
5-oxo-ETE alone failed to induce degranulation in eosinophils [30], while another showed a 
weak response [39]. 5-oxo-ETE induces O2•− production in PMNL, but the efficacy is very low 
(1/60th) in comparison to fMLP and only two-fold increases cPLA2 activity in PMNL [40]. 
This might be surprising, as 5-oxo-ETE stimulates the ERK pathway and induces Ca++ influx, 
two important requirements for cPLA2 activation (see Figure I.8, page 35). However, one has 
to keep in mind that timing is important. The 5-oxo-ETE induced ERK phosphorylation is 
transient in comparison to GM-CSF, similar to the increase in intracellular Ca++ in comparison 
to fMLP [26,27]. Therefore the signals induced by 5-oxo-ETE alone may be too transient in 
order to be translated into a substantial AA release or O2•− formation.   
Synergistic Effects of 5-oxo-ETE and Other Inflammatory Mediators 
In vivo, cells are never exposed to a single mediator and the ultimate response would result 
from an integration of signals. During pulmonary inflammation for example, lipid mediators, 
interleukins, and chemokines are released from numerous sources. It would seem likely that 
both classes of chemoattractants, lipid mediators and chemokines, contribute to eosinophil 
infiltration into the lungs in asthma. Furthermore, it is possible that there could be synergy 
between lipid mediators and chemokines or interleukins as they act by distinct receptor-
mediated mechanisms. As described for the effect of GM-CSF and LT synthesis, one agonist 
may prime a cell to respond to a second signal without inducing the response by itself. Based 
on this hypothesis, several studies have been conducted to examine the cross talk of 
5-oxo-ETE with other agents. Indeed, 5-oxo-ETE potentiates eosinophil migration in response 
to platelet activating factor (PAF) at low concentrations [7]. C-C chemokines show synergistic 
effects with 5-oxo-ETE on human monocytes and appear to prime eosinophils for 5-oxo-ETE 
responses. 5-oxo-ETE increases monocyte migration in response to monocyte chemotactic 
protein-1 (MCP-1) and MCP-2 [31]. In the same study, 5-oxo-ETE also lowered the EC50 of 
MCP-1 induced AA release from monocytes. Eotaxin and RANTES increased the potency of 
5-oxo-ETE-induced eosinophil chemotaxis at threshold concentrations, at which both 
chemokines show minimal activity by themselves, shifting the dose-response for 5-oxo-ETE 
curve to the left [41]. 
The effects of 5-oxo-ETE can also be enhanced by cytokines, such as IL-5, GM-CSF, and 
G-CSF. As described above, 5-oxo-ETE and 5-oxo-15-HETE are normally not capable of 
inducing appreciable superoxide production and degranulation for human PMNL [28], but 
pretreatment of these cells with GM-CSF or G-CSF renders these otherwise ineffective agents 
potent inducers of these responses [27,35]. 5-oxo-ETE can induce eosinophil migration 
through basement membrane components by itself, but addition of IL-5 however enhances the 
efficacy of this process [42].  
INTRODUCTION   15 
Effects of 5-oxo-ETE on Non-myeloid Cells 
Besides the widely studied effects of 5-oxo-ETE on inflammatory responses in leukocytes, 
this eicosanoid also shows biological activity with epithelial cells that may not be signaled 
through the “classical” 5-oxo-ETE receptor OXE. These alternative signal pathway, a putative 
5-HETE receptor and peroxisome proliferator-activated receptors (PPARs), are discussed 
below. Diarrhea is an important aspect of innate immunity, it serves to wash out bacteria 
before they cause harm. In the mammalian gut, chloride secretion by epithelial cells is a major 
determinant of diarrhea. It occurs mainly in the crypt regions of the epithelium. Several 
inflammatory mediators are released into the lamina propria including kinins [43], and AA 
derived factors such as cys-LTs [43,44], prostaglandins [45], and the 5-oxo-ETE precursor 5-
HETE [46]. In leukocytes 5-HETE and 5-oxo-ETE share the 5-oxo-ETE receptor, which has 
much lower affinity for 5-HETE [26,47-49]. This suggests that many of the biological effects 
activated by 5-HETE could be due to its interaction with OXE. This prompted examination of 
the effects of 5-oxo-ETE on the shrinkage of guinea pig jejunal crypt epithelial cells, an effect 
already known for 5-HETE [50]. 5-Oxo-ETE caused rapid shrinkage of these cells to a reduced 
but stable volume. This response was due to induction of Cl─ secretion, since it was prevented 
by Cl─ and K+ channel blockers. Furthermore, inhibitors of protein kinase C (PKC) also 
abolished the volume reduction induced by 5-oxo-ETE, suggesting that this response to 
5-oxo-ETE is mediated by PKC. In this setting 5-oxo-ETE showed an extremely high potency, 
while the previously studied cys-LTs and 5-HETE demonstrated much lower potencies, and 
LTB4 showed no activity. In contrast to its effects on crypt cells, 5-oxo-ETE had no effect on 
the volume of jejunal villus cells, which were still responsive to bradykinin. This suggests that 
OXE may be selectively expressed in crypt cells in the guinea pig. 
Bronchoconstriction is one feature of asthma that greatly affects the patients quality of life. 
In the acute phase of an allergic response in the lung, mast cells and macrophages induce the 
release of proinflammatory mediators such as histamine, eicosanoids and ROS [18,20,21]. The 
cys-LTs have been recognized to be strong inducers of airway smooth muscle contraction 
(ASM), the underlying mechanism of bronchoconstriction [18,20,21]. Although 5-HETE is 
only a weak stimulus for guinea pig ASM contraction, it enhances the response to histamine, 
indicating a regulatory role of this eicosanoids in bronchoconstriction [51,52].  
5-oxo-ETE has recently been shown to induce constriction of guinea pig ASM in vitro [53]. 
The inotropic effect of 5-oxo-ETE is presumably not direct, as this response is prostanoid-
dependent and its EC50 is much higher in comparison to other biological effects of 5-oxo-ETE. 
5-oxo-ETE appears to induce the release of prostanoids and acts predominantly through 
thromboxane A2 (TXA2), as TP receptor antagonists inhibit this process. The response of ASM 
is calcium dependent, as it can be reduced by Ca++ depletion. The Rho-kinase inhibitor Y-
27632 blocked the tonic responses induced by 5-oxo-ETE, suggesting that 5-oxo-ETE acts in 
part by sensitizing myofilaments to intracellular free Ca2+ [53]. It has yet to be confirmed 
whether 5-oxo-ETE induces similar responses in human ASM. 
5-oxo-ETE enhances the survival of prostate epithelial cells. The effects of fatty acids on 
these cells have been studied extensively, because epidemiological studies indicate that dietary 
fat plays a role as a risk factor for the growth and development of prostate cancer. AA and its 
precursor, linoleic acid (LA), are major components of animal fat and many vegetable oils as 
part of diets are used in regions where prostate cancer is common. Ghosh and Myers [54] 
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showed that exogenous arachidonic acid induces mitogenesis in PC3 and LNCaP cells, two 
commonly used prostate cancer cell lines. The addition of MK886, a 5-LO activating protein 
(FLAP) antagonist (for FLAP see page 35), inhibits not only the mitogenic effect of 
arachidonate, but also decreases the growth rate of PC3 cells below control levels. Similar 
effects were observed with NDGA (nonspecific lipoxygenase inhibitor), AA861 (specific 
5-LO inhibitor), but not with ibuprofen (COX inhibitor), baicalein (12-LO inhibitor), or SKF-
525A (CYP inhibitor). The authors speculated that this effect is due to inhibition of 5-LO and 
that leukotrienes or 5-HETE are integral components of PC3 cell mitogenesis. Indeed, addition 
of 5-HETE and 5-oxo-ETE overcome the inhibitory effects of MK886 induced growth arrest. 
Furthermore, 5-HETE and 5-oxo-ETE were also able to induce PC3 cell growth while LTB4, 
LTC4, and LTD4 were not effective. In a later study [55], the same group showed that human 
prostate cancer cells rapidly undergo apoptosis when they are deprived of arachidonic acid or 
when the subsequent metabolism of arachidonic acid by the 5-lipoxygenase pathway is 
interrupted with MK886. This effect was also overcome by the exogenous addition of 5-HETE 
or 5-oxo-ETE. They surmised that prostate cancer cells form endogenous 5-HETE, as they 
detected 5-HETE by radioimmunoassay. However, this technique may be questionable, given 
that 5-HETE posses a rather simple structure, in comparison to cys-LTs for example, so it is 
possible that it could cross-react to other fatty acids. To examine the presence of 5-LO in these 
cells, other techniques, such as LC-MS/MS should be employed. The authors did not elaborate 
whether 5-oxo-ETE and 5-HETE are inter-converted in these prostate epithelial cells.  
In Vivo Actions of 5-oxo-ETE 
In vivo experiments are essential in order to evaluate the physiological relevance of a 
mediator. 5-oxo-ETE may be an important mediator of inflammation, because it is a potent 
stimulator of leukocyte chemotaxis in vivo. Similar to LTB4, 5-oxo-ETE has been shown to 
induce pulmonary eosinophilia in Brown Norway rats [56] when instilled intratracheally. This 
effect is not shared by the cys-LTs and can be abolished by monoclonal antibodies to the 
integrins VLA-4 and LFA-1. 5-oxo-ETE also elicits the infiltration of eosinophils and 
neutrophils into the skin of human beings in vivo after intradermal administration [57]. 
Macrophage numbers were also increased at the highest concentrations tested, but the numbers 
of mast cells and lymphocytes were unchanged. Zimpfer and colleagues reported that injection 
of 5-oxo-ETE into rabbit subcutis causes a severe edema with an inflammatory cell infiltrate 
resembling an urticarial lesion [58]. These findings indicate that 5-oxo-ETE may play a role in 
cellular recruitment to the dermis. 
I.2.2 5-oxo-ETE Receptor 
Leukocyte Based Receptor Studies 
It was long speculated that the biological effects of 5-oxo-ETE on leukocytes are mediated 
through a specific 7-transmembrane G-protein coupled receptor (GPCR), as the effects of 
5-oxo-ETE on monocytes, neutrophils and eosinophils are diminished by pertussis toxin 
[27,31,33,34]. Structure-activity studies indicate that this receptor is highly selective for 5-oxo-
ETE, is subject to homologous, but not heterologous desensitization, and is not blocked by 
selective antagonists of other chemoattractant receptors. Binding studies involving 5-oxo-ETE 
have been hampered by its metabolism and especially by its esterification into triglycerides 
(see page 26). O’Flaherty and colleagues circumvented this problem by using the acyl-CoA 
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synthetase blocker triacsin C to inhibit the first step of esterification. They were then able to 
demonstrate high specific affinity (Kd, 4 nM) binding sites for this substance [59]. The 
affinities of related compounds for these binding sites paralleled their biological activities, 
whereas ligands for other receptors were unable to compete with 5-oxo-[3H]ETE for these 
sites. 5-oxo-ETE binding to this receptor can be inhibited by excessive amounts of GTP or its 
analog GTPγS [59]. 5-oxo-ETE also stimulates the binding of GTP to membrane fractions 
from neutrophils [60]. Both responses are characteristic for GTP/GDP exchange reactions 
conducted by GPCRs [60]. 
In leukocytes, the 5-oxo-ETE-receptor signals mainly through Gi2. G proteins fall into four 
sub-families based on the homology of their α-chains: Gi (inhibitory), Gs (stimulatory), Gq, and 
G12/13. There are also 6 β and 12 γ isoforms, but the different βγ combinations are thought to 
exhibit similar effects on cell signaling in mammals. The α-chains transmit very specific 
biological responses. As a result, one GPCR can induce different responses in one cell by 
binding to different Gα subtypes. The different biological effects of agonists are largely due to 
different interaction patterns of their GPCRs with Gα-chains and the G protein expression 
levels in the cells. The knowledge of the α-subtype that interacts with a GPCR and its 
expression state within a cell type allows, within certain limitations, prediction of the 
biological response to the GPCR agonist in vitro. The specific α-subtype that binds to a GPCR 
can be identified pharmacologically or by using the proper expression systems, but the GPCR 
sequence has to be known for the latter approach. Pertussis toxin totally inhibits the effects of 
5-oxo-ETE on various biological responses in PMNL [23,27,33,34], but does not totally block 
the effects of other chemoattractants (e.g. C5a, fMLP, PAF and LTB4). This suggests that OXE 
has an absolute requirement for Gi proteins, whereas other chemoattractants can also signal 
through other G protein such as Gq and G12/13. Biochemical and pharmacological evidence led 
to the conclusion that the receptor for 5-oxo-ETE is bound to Gαi2 in PMNL [27,60], while it 
was not possible to determine the specific βγ subunits. This finding may explain the limited 
activation pattern of 5-oxo-ETE in comparison to other chemotactic factors. 
Cloning of the 5-oxo-ETE Receptor 
The story leading to the cloning of OXE is quite intriguing. On one hand, the purification of 
putative GPCRs, such as OXE, from leukocytes with standard biochemical techniques is 
extremely difficult due to low expression levels. On the other hand, vigorous in silico 
searching and cloning of novel genes with sequence motifs characteristic for GPCRs have 
outpaced the identification of novel endogenous ligands. This led to the accumulation of 
putative GPCRs, commonly known as orphan receptors, for which the ligands have not been 
identified. In their effort to identify ligands of proposed eicosanoid orphan receptors, 
researchers at MerckFrost® always included 5-oxo-ETE in their ligand library (Julie Evans, 
personal communications) without finding a potential 5-oxo-ETE receptor. In the meantime, 
Hosoi and colleagues from Tanabe Seiyaku Co. were searching for novel peptide binding 
GPCRs. They stumbled upon the 5-oxo-ETE receptor by accident. They screened over a 
thousand molecules, mainly peptides and chemokines (Tesuo Ohnuki, personal 
communications), before they found 5-oxo-ETE was indeed the specific agonist for clone 
TG1019 [48]. Simultaneously, researchers at Novartis Pharmaceuticals Co. also came across 
an orphan GPCR [clone R527] that binds 5-oxo-ETE [47]. The two receptor sequences proved 
to be identical (99.7%). The latter one differs from the former by a single point mutation (Leu 
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? Val) at amino acid 368 and by a 39 amino acid truncation at the C-terminal. Since the 
results of both studies are remarkably similar, these differences don’t seem to affect the 
biological activity.  
The knowledge of the 5-oxo-ETE GPCR sequence enables new approaches to study the 
physiological role of 5-oxo-ETE by determining the tissue distribution of its receptor. The 
expression of OXE was examined by PCR and northern blots [47,48]. The mRNA of the gene 
encoding this receptor is expressed in many tissues excluding the brain. Dot blot analysis 
showed somewhat strong expression in the liver and the kidneys. Three hybridization bands 
with molecular lengths of 6.5, 3.3 and 1.8 kb were identified by northern hybridization. The 
1.8 kb transcript is expressed in peripheral leukocytes, lungs, placenta, small intestine, spleen, 
thymus, colon, heart, skeletal muscle, liver, and kidneys. In contrast, the 6.5 and 3.3 kb 
transcripts are expressed only in liver, kidneys, and, to a smaller degree, in skeletal muscle. 
The expression pattern of the receptor in leukocytes, as analyzed by real-time PCR, agrees to 
the functional studies described above. The 1.8 kb transcript is mainly expressed in 
eosinophils, and to a lesser degree in neutrophils and alveolar macrophages and barely 
detectable in T cells or differentiated epithelial cells (normalized transcript numbers are 210, 
5.8, 1, 0.06, and 0.012, respectively). 
Expression of a GPCR in a controlled environment enables direct binding studies of the 
receptor to G proteins and direct binding studies with potential agonists or antagonists. The 
5-oxo-ETE GPCR TG1019 [48] binds to Gαi and to a much smaller extent to Gαq, but does not 
interact with GαsL, Gαi1, or Gαqa. The EC50 for 5-oxo-ETE to induce Ca++ via Gα16-coupling 
(member of the Gq subfamily) in the expression assay was much higher than the EC50 for 
5-oxo-ETE to induce the same response in PMNL or the Gαi coupled assay of forskolin-
stimulated cAMP inhibition. Forskolin is a potent agonist for adenylate cyclase, the enzyme 
that inhibited by Gαi. These results are supporting the notion that the natural partner of the 
5-oxo-ETE GPCR is indeed Gαi. The substrate specificity of OXE was confirmed. It does not 
interact in an agonistic or antagonistic manner with leukotrienes (7 tested), prostaglandins (8 
tested), HETEs other than 5-HETE (7 tested), 15-oxo-ETE, thromboxane B2, or either lipoxin 
A4 or B4. The rank order of the potencies of agonists, as determined in a Gαi mediated GTPγS-
binding assay, is 5-oxo-ETE >> 5-HpETE  > AA = 5Z,8Z,11Z-eicosatrienoic acid = 5S-HETrE 
= 5(R,S)-HETE [48]. This result is surprising, since 5-HpETE is known to stimulate Ca++ 
responses in PMNL [61], but the responsible receptor had not been identified. Furthermore, the 
lack of stereospecificity of the receptor for 5-HETE was unexpected. The stimulatory action of 
100 nM 5-oxo-ETE on GTPγS binding can be antagonized by addition of 
4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid (DHA), dihomo-γ-linolenic acid, 11Z,14,Z17Z-
eicosatrienoic acid, and EPA. 
5-oxo-ETE Signals through a Novel 5-HETE GPCR in PC3 Cells 
The underlying signal transduction mechanisms of 5-oxo-ETE on PC3 cells were further 
investigated by O’Flaherty and coworkers [36]. They confirmed that 5-HETE and 5-oxo-ETE 
stimulate cell proliferation and inhibit MK-886 induced apoptosis in PC3 cells. 5-HETE is 
more potent than 5-oxo-ETE in this regard and the authors concluded that a novel 5-HETE-
specific receptor exists on this cell line is responsible for this effect. Since growth stimulation 
can only be detected at longer culture times, they investigated the effects of 5-LO products on 
ERK and Akt phosphorylation. Although 5-oxo-ETE is about 10 times more potent by 
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inducing ERK1/2 phosphorylation in human PMNL [27], the reverse is seen in PC-3 cells [36]. 
Here, 5-HETE is 10 times more potent than 5-HETE and more efficacious than 5-oxo-ETE in 
inducing cell growth and ERK stimulation, whereas 5-oxo-15-HETE is not active at all. These 
results suggest that these cells posses a novel receptor for 5-HETE that is selective for 5-HETE 
over 5-oxo-ETE. 
PPARα as an Alternative Signal Pathway? 
The mechanism of MK886 induced growth arrest and apoptosis remains controversial [62]. 
In agreement with the studies mentioned above [36,54,55], Ayyub and colleagues  
demonstrated that the two potent lipoxygenase inhibitors MK886 and BWA4C block 
proliferation and DNA synthesis in HL-60, K562 and Jurkat cells [62]. However, the effects 
are only seen at 100-times the concentration needed to inhibit leukotriene generation in whole 
blood or leukocytes, suggesting that the inhibition of LT synthesis is not responsible for the 
anti-mitogenic and apoptotic effects of MK886 [62]. Indeed, it was shown recently that 
MK886 does not induce apoptosis and growth arrest via FLAP. Downregulating FLAP 
expression with antisense oligonucleotides had no influence on the potency of MK886 in 
inducing apoptosis [63]. Vice versa, overexpression of FLAP showed no effect either [64]. 
Based on this, Kehrer and coworkers investigated alternative routes of action for MK886 [65]. 
Since FLAP, the proposed target of MK886, is a fatty-acid binding protein, it is conceivable 
that MK886 may affect other such proteins. They speculated that peroxisome-proliferator-
activated receptors (PPARs), which have been implicated in apoptosis and are known to bind 
eicosanoids, represent a target for MK886. Using different expression and cell culture systems, 
the authors showed in an excellent study that MK886 inhibits PPARα activation [65]. 
Substantially less inhibition was evident with the β and γ isoforms of PPAR [65] (for review 
on the PPAR family please see [66]). In opposite to classical receptors, which are highly 
selective in their choice of agonists, PPARα posses a broad range of stimuli. This is due to the 
non-specific nature of its binding site that consists of a hydrophobic pocket that closes after 
binding in a mouse trap mechanism [67]. Due to the broad ligand specificity, it is conceivable 
that 5-oxo-ETE and 5-HETE may signal through a PPAR-subtype as well.  
I.2.3 5-oxo-ETE Synthesis by 5h-dh 
Biochemical characterization of 5h-dh 
5-Oxo-ETE is synthesized from the 5-LO product 5S-HETE by the highly specific NADP+-
dependent 5-hydroxyeicosanoid dehydrogenase (5h-dh), and its formation is regulated by the 
availability of the cofactor. 5h-dh has so far been reported to be present in neutrophils [22], 
eosinophils [7], monocytes [68], lymphocytes [68], human blood monocyte derived dendritic 
cells [69], and platelets [70]. In order to determine the subcellular localization, Powell and 
coworkers used differential centrifugation to separate granules, microsomes, and cytosol [22]. 
The formation of 5-oxo-ETE from 5-HETE in the presence of NADP+ was highest in the 
microsomal fraction and negligible in the cytosol. However, significant activity was found in 
the granule fraction as well. 5h-dh is selective for NADP+ over NAD+, and is highly substrate 
specific. It requires the presence of a 5-hydroxyl group in the S-configuration followed by a 6-
trans double bond, as occurring in 5S-HETE. For this reason, 5h-dh does not oxidize the 
closely related 5-LO product LTB4, which also has a 5S-hydroxyl group, but has the 6-trans-
double bond in the cis-configuration [22]. Similarly, 5R-HETE, which has the required 6-
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double bond, but possesses the wrong configuration of the 5-hydroxyl group is also a poor 
substrate. The enzyme prefers the hydroxyl group to be in the 5-position, as HETEs with 
hydroxyl-groups in the 8-, 9-, 11-, 12-, or 15-positions are not oxidized. However, 5h-dh 
metabolizes other fatty acids that fulfill the substrate requirements, including the 6-trans 
isomers of LTB4 and 5,15-diHETE, although the KMs for these fatty acids are higher than that 
for 5-HETE. 
Formation of 5-oxo-ETE in Cells is limited by NADP+ Levels 
The availability of the cofactor NADP+ appears to be a critical limiting factor in the ability 
of cells to synthesize 5-oxo-ETE, because the reaction is reversible and little 5-oxo-ETE is 
formed from 5-HETE in resting cells. Although human peripheral blood neutrophils possess 
high levels of microsomal 5h-dh activity. Resting, unstimulated neutrophils however form only 
small amounts of 5-oxo-ETE from exogenous 5S-HETE [22,71]. Instead, they transform 
5-HETE to 5,20-diHETE by NADPH dependent ω-oxidation [72]. Preincubation of 
neutrophils with phorbol 12-myristate 13-acetate (PMA), dramatically increases the ratio of 
5-oxo-ETE to 5,20-diHETE from 0.07 to 1.9 [71]. PMA, which bears some structural 
remembrance of diacylglycerols, stimulates PKC in neutrophils [73]. PKC in turn stimulates 
superoxide generation by phosphorylating one (p47phox) and inducing membrane translocation 
of two (p47phox and p67phox) cytosolic components of the NADPH oxidase complex. The 
stimulatory effect of PMA on 5-oxo-ETE generation appears to be caused by an inrease in the 
NADP+/NADPH ratio due to stimulation of NADPH oxidase [74]. Inhibition of NADPH 
oxidase by mild heating or by diphenylene iodonium completely reverses the effect of PMA. 
The effect of PMA is not due to superoxide (H2O2), as it is not blocked by superoxide 
dismutase (SOD) or mimicked by addition of xanthine/xanthine oxidase. The hypothesis that 
5h-dh activity is regulated by its cofactor levels is further supported by the stimulatory effect 
of phenazine methosulfate (PMS) on 5-oxo-ETE formation. This substance is known to 
promote the non-enzymatic conversion of NADPH to NADP+ but does not directly affect 
5h-dh [75,76]. These findings are very relevant to the present study on the regulation of 5h-dh 
activity. The formation of 5-oxo-ETE from 5-HETE (defined here as forward reaction: NADP+ 
+ 5-HETE ? NADPH + 5-oxo-ETE) by 5h-dh appears to be a fully reversible reaction as 
neutrophil microsomes also catalyze the backward reaction (defined as 5-oxo-ETE + NADPH 
? 5-HETE + NADP+) in the presence of NADPH [22]. In contrast to neutrophils, in platelets 
it is the reverse reaction that is predominant [70]. However, it is not clear from the literature 
whether 5h-dh catalyzes both reactions, or whether this is due to a distinct 5-keto-reductase 
enzyme. 
One aim of this study was to examine additional pathways that regulate the synthesis of 
5-oxo-ETE from 5-HETE, as not all cells that contain 5h-dh, i.e. platelets and lymphocytes 
possess functional NADPH oxidase [68,70]. As described in more detail below, oxidative 
stress leads to the depletion of the NADPH pool. We hypothesized that the formation of 
5-oxo-ETE may be enhanced during oxidative stress (I.3.4, page 32) as an alternative pathway 
to the activation of NADPH oxidase. 
Other Hydroxyeicosanoid Dehydrogenases 
In addition to 5h-dh, other hydroxyeicosanoid dehydrogenases oxidize HETEs. 15-
Hydroxyprostaglandin dehydrogenases (15h-PG-dh), the first such eicosanoid-metabolizing 
enzymes to be discovered, convert prostanoids and other 15-hydroxy-eicosanoids to their 
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biologically inactive 15-oxo metabolites [77], whereas 12-hydroxy-eicosanoid dehydrogenases 
(12h-dh) convert LTB4, 12-HETE and similar compounds to 12-oxoeicosanoids [29] (see also 
page 24). The biochemistry of 15h-PG-dh has been studied in detail in several settings, while 
little is known of the biochemistry of 5h-dh. 15h-PG-dh may serve therefore as model for 
future studies of 5h-dh. 
The NAD+-dependent 15h-PG-dh (type I) is considered the key catabolic enzyme that 
controls the biological activity of the prostaglandins [77]. This enzyme catalyzes the reversible 
oxidation of the 15-hydroxyl group of prostaglandins to produce a 15-keto metabolite with 
greatly reduced biological activity. The pH optimum of human placental 15h-PG-dh type-I for 
the forward reaction (15-HETE ? 15-oxo-ETE) is between 9.0 and 9.5, while that for the 
rabbit lung enzyme is between 10 and 10.4 [77]. The reverse reaction (15-oxo ? 15-HETE) of 
these enzymes is favored at a pH < 7 [77]. Kinetic analysis has been used to determine the 
enzymatic mechanism of the human placental enzyme and the porcine kidney enzyme. Based 
on the results of initial velocity, product inhibition, and dead-end inhibition studies, an ordered 
Bi-Bi mechanism has been proposed where NADP+ binds first to the enzyme followed by the 
prostaglandin. Following oxidation of the substrate the 15-keto metabolite is first released 
followed by NADH. In addition to the NAD+-dependent 15h-PG-dh, a NADP+-dependent 
15h-PG-dh (type II) has also been identified and characterized [78]. The type II enzyme 
prefers NADP+ as a cofactor but can also use NAD+ and it appears to have a much broader 
range of substrates than the type I enzyme. The type II enzyme is identical to general carbonyl 
reductase and also posses 9-keto reductase activity besides the 15-hydroxy dehydrogenase 
activity (for more details see [78]). 
I.2.4 Alternative Pathways of 5-oxo-ETE Formation 
Several 5h-dh-independent pathways have been shown to yield oxo-fatty-acids via free 
radical-dependent mechanisms. These include heavy metals, heme-proteins, and other 
biological agents that catalyze peroxidation of unsaturated fatty acids and decomposition of 
peroxy products (see [35] for references). Researchers in the group of Robert Murphy 
specifically investigated the 5-HETE-independent formation of 5-oxo-ETE in murine 
macrophages and human red blood cell membranes. 
5-oxo-ETE is formed by an Alternative Pathway in Murine Macrophages. 
Zarini and Murphy found that murine peritoneal macrophages convert racemic 5R,S-HpETE 
to 5-oxo-ETE [79]. Examining mechanisms for this reaction, it became evident that it was not 
due to 5h-dh, because (i) the catalytic activity is due to a trypsin- and heat-insensitive 
substance that is located in the cytosol and microsomes, (ii) the formation of 5-oxo-ETE by 
this pathway is not cofactor dependent, (iii) racemic 5-HpETE (a mixture of 5R,S-HpETE) is 
the substrate, and (iv) 5S-HETE is not converted to 5-oxo-ETE by these cells. Based on the 
lack of stereospecificity, the authors proposed a redox-mechanism for the conversion of 
racemic 5-HpETE to 5-oxo-ETE, in which an iron-containing factor initially catalyzes the on
 e-electron reduction of 5-HpETE to the 5-alkoxy radical intermediate followed by a one-
electron oxidation by removal of the C-5 hydrogen atom (Figure I.3). Size exclusion 
experiments revealed that a 55 kDa protein facilitates this reaction rather than a low molecular 
weight substance such as inorganic iron or a small molecule like hematin, the oxidized from of 
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heme. However, this study did not specifically determine whether the microsomal fraction 
from these cells contains 5h-dh. It has to be established whether mice do express 5h-dh at all 
and if 5-oxo-ETE can be formed by a similar mechanism in human cells in addition to 5h-dh. 
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Figure I.3  Proposed mechanism of 5-HpETE to 5-oxo-ETE conversion 
Based on this scheme, 5-HpETE is first reduced by an iron-containing factor to the 5-alkoxy 
radical. In a second oxidation of this radical 5-oxo-ETE is formed as the product [79].  
 
5-oxo-ETE can be formed in Red Blood Cell (RBC) Ghosts by Lipid Peroxidation. 
Lipid peroxidation leads to 5-oxo-ETE formation within the plasma membranes of red 
blood cells (RBC) by a free radical reaction. The oxidation of free arachidonic acid by the 
iron-containing enzymes of the LO- and the COX-families is carefully controlled. However, 
the discovery of compounds isomeric to prostaglandins (isoprostanes) led to the hypothesis 
that peroxides might also be formed from arachidonate by non-enzymatic free radical 
reactions. Isoprostanes have found significant utility in serving as biomarkers of the initiation 
of free radical events within pathological states [80]. Hall and Murphy [61] incubated RBC 
ghosts, which lack the enzymatic and low molecular weight antioxidant defense mechanisms, 
with high concentrations (10 mM) of the organic hydroperoxide tert-butyl hydroperoxide 
(tBuOOH). They extracted the glycerophospholipids, hydrolyzed the fatty acids, separated the 
fatty acids by RP-HPLC, and analyzed the capacity of different fractions to induce a Ca++-
response in PMNL. Only after treatment with tBuOOH, were fatty acids found that responded 
positively in this bioassay. Using LC-MS/MS, the authors detected several oxidized 
polyunsaturated fatty acids (HpETEs, HETEs, oxo-ETEs, HpODEs, HODEs, oxo-ODEs, and 
epoxyeicosatrienoic acids (EETs)) [61,81,82], which were esterified to glycerophospholipids. 
Further analysis revealed that the biological activity was exclusively due to 5-HpETE, 
5-HETE, and 5-oxo-ETE. The peroxidation mechanism of RBC ghosts lipids is a typical 
radical chain reaction [83]. First, Fe3+-catalyzes the formation of a tBuOOH alkoxyl radical, 
which in turn removes a bis-allylic proton from a polyunsaturated fatty acyl moiety. This 
initial phospholipid radical then reacts with molecular oxygen to form the lipid hydroperoxide. 
The reaction leading to the formation of 5-oxo-ETE in this setting is similar to the reaction 
described above for murine macrophages. RBC ghosts cannot convert 5-HETE to 5-oxo-ETE 
even if tBuOOH or NADP+ is added to the incubation medium, and 5-oxo-ETE is formed from 
5-HpETE under these circumstances [61]. After 90 min incubation 270 pmol 5-oxo-ETE / mg 
protein were formed from RBC ghosts. Due to the high concentration of tBuOOH, the 
esterification of the fatty acids, and the absence of antioxidants in this setting it remains to be 
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elucidated whether this pathway leads to the formation of free 5-oxo-ETE under physiological 
conditions.  
LTA4-Hydrolysis Forms a 5-oxo-ETE-Isomer with Biological Activity 
In the literature, another compound is also referred to as 5-oxo-ETE. Falgueyret and 
Riendeau found recently that 5-oxo-(7E,9E,11Z,14Z)-eicosatetraenoic acid is a non-enzymatic 
hydrolysis product of LTA4 [84]. Unfortunately, they denoted this eicosanoid 5-oxo-ETE as 
well. As seen in Figure I.4, both analogs have the same molecular mass, but differ in the 
location and stereochemistry of their double bounds. 5-oxo-(7E,9E,11Z,14Z)-eicosatetraenoic 
acid induces a Ca++ influx in neutrophils as does 5-oxo-(6E,8Z,11Z,14Z)-eicosatetraenoic acid. 
However, the EC50 for the degradation product is about 250-times higher than that for the 
5h-dh product [34,84]. It is more likely that it signals through the LTB4 receptor rather than the 
5-oxo-ETE receptor, because calcium mobilization by this 5-oxo-ETE isomer was inhibited by 
the specific LTB4 receptor antagonist LY223982 and desensitized by pretreatment with LTB4 
[84]. To date it is not clear whether this compound also has chemotactic effects. 
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Figure I.4  Two known isomers of 5-oxo-ETE 
5-oxo-(6E,8Z,11Z,14Z)-eicosatetraenoic acid (5-oxo-ETE) is formed by 5h-dh from 5S-HETE and 
stimulates OXE in peripheral blood leukocytes. The isomer 5-oxo-(7E,9E,11Z.14Z)-
eicosatetraenoic acid is a non-enzymatic hydrolysis product of LTA4 and activates BLT1. 
I.2.5 Catabolism 
Several pathways have been described which metabolize 5-oxo-ETE and may lead to its 
transformation in vivo and these are summarized in Figure I.5. 
Reconversion into 5-HETE 
As indicated above, the enzymatic conversion of 5S-HETE into 5-oxo-ETE is reversible and 
depends in part on the availability of the cofactor NADP+ [22]. Since healthy cells maintain a 
high NADPH/NADP+ ratio (see PPP, page 31), under some circumstances the reverse reaction 
is favored over the forward reaction, as is the case for platelets [70]. Both the forward and the 
backward reaction are likely to be catalyzed by 5h-dh, as the reaction is reversible in 
neutrophil microsomes [22], but this has not yet been clearly demonstrated and it is possible 
that a distinct 5-ketoreductase exists. More details of the 5h-dh-mediated reaction have to be 
known to answer this question. The binding affinities for substrates (5-HETE and 5-oxo-ETE) 
and cofactors (NADP+ and NADPH) to 5h-dh have yet to be measured. The standard free 
energy change (∆G°) and thus the equilibrium constant are also unknown. 
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Figure I.5  Catabolic pathways of 5-oxo-ETE metabolism 
To date seven pathways have been described by which 5-oxo-ETE is metabolized.  
ω-Oxidation of 5-Oxo-ETE 
In human neutrophils, 5-oxo-ETE and its precursor 5-HETE are metabolized by the 
NADPH-dependent LTB4 hydroxylase, a member of the CYP4F family. In humans, LTB4 can 
be hydroxylated by two subtypes of this family, CYP4F2 and CYP4F3A [85]. CYP4F3A 
expression is restricted to myeloid cells, while CYP4F2 is expressed in various tissues except 
myeloid cells [85]. In human neutrophils, 5-HETE and 5-oxo-ETE are metabolized by LTB4 
hydroxylase CYP4F3 (Figure I.5) [34,72,86]. Recombinant CYP4F3A has a preference for the 
6Z,8E,10E-triene-bond configuration found in LTB4 and for the chirality of 5S-and 12R-
hydroxyl groups [87]. CYP4F3A has dramatically higher KM- and lower kcat-values for 
5-HETE and 6-trans-LTB4, and presumably for 5-oxo-ETE, than for LTB4. The enzymatic 
activity of CYP4F3 depends on cytochrome b and the cofactor NADPH as the electron donor. 
However, due to the wide tissue distribution of cytochrome b, only the expression of 
CYP4F3A is limiting for LTB4 inactivation by this pathway. The expression of CYP4F3A is 
confined to myeloid cells, especially granulocytes. Its expression is coordinated with that of 
myeloid differentiation markers such as CD11b and also increases concomitantly with MPO 
during the maturation of bone marrow cells [88]. There are also species-dependent differences. 
Mouse macrophages and rat neutrophils, which lack the 20-hydroxylase enzyme, convert 
5-oxo-ETE and/or LTB4 to18- and 19-hydroxylated products [89,90]. 
Conversion of 5-oxo-ETE by 12-LO 
In contrast to unstimulated platelets, which reduce 5-oxo-ETE to 5-HETE, the main 
pathway for the metabolism of 5-oxo-ETE by activated platelets is conversion to 5-oxo-12S-
HETE and its 8-transisomer by 12-LO (Figure I.5) [70]. Platelets can also convert 6-trans 
isomers of LTB4 to similar products by the action of 5h-dh [70]. Although neither 5-oxo-12-
HETE nor its 8-trans isomer posses significant agonist activity, both substances seem to have 
some antagonist activity, because they were able to inhibit 5-oxo-ETE-induced calcium 
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mobilization. In the case of the 8-cis derivative, the calcium response to 5-oxo-ETE was 
virtually abolished at low µmolar concentrations [70]. 
Glutathionylation of 5-oxo-ETE to FOG7
Recently, two novel glutathione adducts of 5-oxo-ETE have been identified. Bowers and 
colleagues identified FOG7 (Figure I.5), a glutathione adduct of 5-oxo-ETE after incubation of 
this substance with murine peritoneal macrophage [91]. FOG7 is biologically active but its 
effects are more limited than those of 5-oxo-ETE. While FOG7 induces actin polymerization in 
neutrophils and eosinophils, as does 5-oxo-ETE, in contrast to the later compound it does not 
increase the cytosolic Ca++ concentration in these leukocytes. In murine macrophages FOG7 is 
formed in a 1,4-Michael addition reaction, probably catalyzed by the microsomal LTC4-S [92]. 
Recombinant human LTC4-S also catalyzes this reaction and human platelets too convert 
5-oxo-ETE into FOG7. Surprisingly, the KM of LTC4-S for 5-oxo-ETE is similar to that for 
LTA4, which had previously been the only recognized substrate of this enzyme. The same 
study revealed that this is not the only glutathione adduct formed within murine macrophages 
[92]. At least one of the cytosolic GSTs leads to the formation of another, biological inactive 
glutathione adduct from 5-oxo-ETE. Since this compound cannot be separated from FOG7 by 
RP-HPLC, and shows a similar MS spectrum, it is a stereoisomer of FOG7 [92]. 
Inactivation of 5-Oxo-ETE by an Olefin-Reductase 
Many eicosanoids are metabolized in the sequence of dehydrogenases, reductases, and keto-
reductases (Figure I.6). The first stage is the oxidation of a hydroxyl groups by a NADP+- or 
NAD+-dependent dehydrogenase to the corresponding keto- (oxo-) group. The products are 
then further metabolized by reduction of an adjacent double bond by an olefin reductase in the 
presence of NADH or NADPH. This may be followed by the reduction of the keto-group by a 
keto-reductase or by the original dehydrogenase. This process has been described for several 
prostaglandins, which are first oxidized to their biologically inactive 15-oxo metabolites and 
then reduced to dihydro-15-oxo-PGs, which can in turn be further reduced to dihydro-PGs 
([93] and references within). Similar reactions have been demonstrated for lipoxygenase 
products such as 12-HETE, 15-HETE, and LTB4. LTB4 is normally first converted to 12-oxo-
LTB4 by a NAD+-dependent dehydrogenase in PMNL and then further metabolized by a 
NADH-dependent ∆10-reductase and subsequently reduced to the corresponding dihydro 
compound by a keto-reductase. 
PMNL convert 6-trans isomers of LTB4, which are formed non-enzymatically from LTA4, 
but not LTB4 itself to 6-dihydro-metabolites [94,95]. It was proposed that a novel 
dehydrogenase facilitates the first step of this reaction (Figure I.6). Powell and coworkers [22] 
then hypothesized that 5-HETE, since its ∆6 carbon is in the trans-position, is converted in a 
similar fashion by this pathway. This hypothesis ultimately led to the discovery of 5-oxo-ETE 
[22]. 5-oxo-ETE resembles a rare exception from the above examples because it is a 
biologically active intermediate. Berhane and coworkers then showed that a specific NADPH-
dependent ∆6-reductase facilitates the inactivation of 5-oxo-ETE (Figure I.5) [93]. This 
enzyme is distinct from PG ∆13-reductase and is Ca++- and calmodulin-dependent. The product, 
6,7-dihydro-5-oxo-ETE (5o-ETrE) is 1000 times less potent than its precursor in mobilizing 
Ca++ in human neutrophils, a clear sign of biological inactivation. 
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Figure I.6  Common hydroxyeicosanoid metabolism 
Many eicosanoids are inactivated by the combined action of a dehydrogenase (DH), leading to 
the conversion of a hydroxyl to the oxo-group. This is followed by olefin-reductase (Olefin-Red), 
which reduces an adjacent double bound. The keto-group may be reduced back to a hydroxyl-
group by a keto-reductase (Keto-Red). The finding of 6-dihydro metabolites of 6-trans-LTB4 
originally sparked research leading to the discovery of 5h-dh. 
LXA4 and LXB4 are metabolized (see VII.1, page 107 for structures) in a similar manner by 
monocytes [96]. First, the hydroxyl-groups at position C-15 (LXA4) and C-5 (LXB4) are 
subject to dehydrogenation followed by subsequent reduction of the adjacent double bounds 
(∆12 for LXA4 and ∆6 for LXB4) to the corresponding dihydro-compounds. Both intermediates 
can be further reduced to the dihydro-Lipoxin by the action of a keto-reductase. As the 5-
position of LXB4 is similar to that of 5-HETE, it is possible that LXB4 is reduced to 5-oxo-
LXB4 by 5h-dh. However, this needs to be further investigated.  
Conversion of 5-oxo-ETE by 15-LO 
Eosinophils convert 5-oxo-ETE to 5-oxo-15-HETE by 15-LO (Figure I.5) [30]. However 
this is pathway does not remove its biological activity, as 5-oxo-15-HETE induces similar 
biological responses as its parent compound in granulocytes. The potency of 5-oxo-15-HETE 
is lower than that of 5-oxo-ETE, but it is much higher than that of 15-HETE, 15-oxo-5-HETE, 
or 15-oxo-ETE [7,26-28,30,60].  
Esterification into Lipids 
During their examination of radioactively labeled AA from human neutrophils, Stenson and 
Parker discovered that endogenously produced 5-HETE can be esterified into cellular lipids 
[97]. This is a major pathway for eicosanoid catabolism and is not restricted to 5-HETE, as 
other fatty acids, among them many lipoxygenase products, are also incorporated into lipids. 
However, this process is not universally applied to all eicosanoids, as different exogenous 
lipoxygenases products are differentially distributed among lipid classes in a murine 
macrophage cell line [98]. In this study, AA was taken up very rapidly, whereas 5-HETE, 
12-HETE, and 15-HETE were incorporated more slowly. The final destination of the different 
HETEs differs from one another and from AA. 5-HETE was esterified to a greater extent than 
the other HETEs into neutral lipids. 15-HETE was mainly incorporated into 
phosphatidylinositol, while 5-HETE and 12-HETE were incorporated into all phospholipid 
classes (PC, PE, PI) tested. In contrast to the HETEs, LTB4 was not incorporated into cellular 
lipids over a period of 20 min. The lipid fraction into which a fatty acid would be primarily 
incorporated is unpredictable, because the final destination of AA and its lipoxygenases 
products is not only substrate but also tissue specific. Bovine smooth muscle cells, for 
example, incorporate both 12-HETE and 5-HETE mainly into triglycerides [99]. In opposite to 
the smooth muscle cells, cultured bovine aortic endothelial cells esterify 5-HETE only in 
triglycerides whereas 12-HETE was incorporated equally into phospholipids and triglycerides. 
Both cell types preferentially incorporate AA into phospholipids. The HETEs are esterified in 
the same way by a standard fatty acid processing pathway: a triacsin C sensitive synthetase 
forms fatty acid-CoA, which is the substrate for a transacylase to incorporate the fatty acid into 
lipids [100-102]. The esterification of 5-HETE into lipids by neutrophils is, however, 
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concentration dependent. At higher substrate concentrations, 5-HETE is mainly converted into 
ω-oxidation products rather than into lipids [72,86]. In neutrophils the acylation pathway 
appears to have a high affinity but low capacity for substrate, whereas the ω-oxidation pathway 
has a high capacity but a low affinity [59]. 
In their study of the binding of 5-oxo-ETE to neutrophils, O’Flaherty and colleagues 
discovered that this substance is also incorporated into cellular lipids, thus hampering the 
establishment of a binding assay [59]. Low amounts (100 pM) of both, radiolabeled 
5-oxo-ETE and 5-HETE were taken up by these cells and incorporated primarily into 
triacyglycerols as detected by thin layer chromatography (TLC). After treatment of the lipid 
fraction of 5-oxo-ETE-incubated neutrophils with triglycerides lipase only radioactive 5-HETE 
was recovered. The authors concluded that 5-oxo-ETE was reduced to 5-HETE and then 
esterified by the process described above [59]. Given the abundance of the Acyl-CoA 
synthetase it is likely that 5-oxo-ETE is potentially directly esterified into lipids as well, but is 
not detectable in this setting due to the low 5-oxo-ETE concentration and the reversibility of 
5h-dh [22,59]. Indeed, 5-oxo-ETE is esterified into lipids by neutrophil plasma membrane 
fractions, which lack 5h-dh [59].  
I.3. Oxidative Stress 
Oxygen is essential to aerobic life but, paradoxically, can be toxic even at the partial 
atmospheric pressure. Over 95% of the oxygen we breathe undergoes a concerted tetravalent 
reduction to produce water in a reaction catalyzed by the omnipresent cytochrome oxidase 
(cytochrome c, oxygen oxidoreductase), which is part of complex IV of the mitochondrial 
electron transport chain (O2 + 4e- + 4H+ ? 2 H2O). Cytochrome oxidase is the terminal 
electron acceptor in the chain and must hand its reducing equivalents over to oxygen to allow 
for continued electron transport. In fact, the major function of the respiratory and 
cardiovascular system is the delivery of oxygen for use in aerobic energy production by 
oxidative phosphorylation. Thus, the major role of oxygen for all aerobic processes is simply 
to act as a sink or dumping ground for electrons. This chapter contains a description of major 
ROS sources, antioxidant mechanisms, some aspects of the role of ROS in cell signaling, and a 
hypothetical model of ROS effects on 5-oxo-ETE synthesis.  
I.3.1 Definition of Oxidative Stress 
Before describing the reaction pathways of reactive oxygen species and anti-oxidant 
defense mechanisms in humans, I want to clarify the term oxidative stress as it is used within 
this thesis. Youngson describes in a remarkable book chapter [103] how the term stress was 
introduced into medicine by the Austrian-born Canadian physician Hans Selye. The terms 
stress and strain originate from the science of engineering and are frequently confused with 
each other. Stress defines the force that causes a body to deform. Strain is defined as the extent 
to which a body is deformed when it is subjected to stress. Selye defined stress as the non-
specific response of the human body to any demands (fear, distress, sleep-deprivation, etc) 
made upon it. He had, similar to the author of this dissertation, some difficulties with the 
English language and admitted later in life that he mistook stress for strain; he meant strain 
when he developed the concept of stress. This confusion is still present after the term oxidative 
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stress was introduced in the field of ROS and antioxidant defense mechanisms [104]. Hence, 
the term oxidative stress is in need of clarification. It is now generally understood that 
oxidative stress describes the imbalance between ROS and antioxidants in favor of the former 
[105]. Normally there are sufficient antioxidants present to ensure that the production of small 
amounts of ROS is inconsequential. Oxidative stress occurs when either antioxidants are 
diminished or the production of reactive oxygen species is increased. Peroxides, i.e. H2O2 and 
organic peroxides such as tBuOOH or cumin hydroperoxide are commonly used to simulate 
oxidative stress in vitro by increasing the stress on the cell, while glutathione depletion or 
glucose withdrawal enhance the strain on a cell at a given stress level. However, both 
strategies will lead to oxidative stress as defined above.  
I.3.2 Sources of Reactive Oxygen Species 
Endogenous Sources of Reactive Oxygen Species 
Within the body, there are normal metabolic processes that lead to the formation of ROS as 
byproducts and “professional” superoxide manufacturers. As mentioned above, the 
mitochondrial electron transport chain leads to the highly coordinated reduction of oxygen. 
However, due to the special nature of oxygen, this process is not fool proof. Atmospheric 
oxygen is a biradical with two unpaired electrons (•O-O•) with parallel spins. To overcome its 
spin restrictions, oxygen accepts electrons one at a time, leading to the initial formation of 
superoxide (Figure I.7). It is estimated that 1-2% of the electron flux in mitochondria might 
form superoxide [106]. This makes the electron transfer chain the largest contributor of 
reactive oxygen species in the body. Additional major sources of superoxide in metabolic 
processes are the cytochrome P450 (CYP) and the b5 family of oxidoreductases in the 
endoplasmic reticulum (reviewed in [107]). Lipid hydroperoxides (fatty acid-OOH) are also 
side products of arachidonic acid metabolizing enzymes cyclooxygenases and lipoxygenases. 
There are several additional cytosolic and peroxisomal enzymes leading to substantial 
formation of ROS. For additional information see [107-111] and references within. 
O2 H2O2 OH
• H2O
NO•
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Figure I.7  Reactive Oxygen Species 
This figure shows the formation of some reactive 
oxygen species (ROS). Sequential electron addition 
to oxygen results in the formation of ROS: 
Superoxide (O2•−), hydrogen peroxide (H2O2), and 
hydroxyl radical (OH•). O2•− and nitric oxide can 
react to form peroxynitrite (ONOO−/ONOOH).  
At sites of inflammation, “professional” phagocytes, especially neutrophils, but also 
eosinophils and macrophages, produce very large quantities of ROS to destroy invading 
microbes. In granulocytes, NADPH oxidase, a multicomponent enzyme which includes the 
membrane-bound cytochrome b558 consisting of two subunits, p22phox and gp91phox is mainly 
responsible for superoxide formation [112]. Its activity is absolutely dependent on the presence 
of three cytosolic factors, p47phox, p67phox, and rac 2, a ras-related small GTP-binding protein 
[113]. NADPH oxidase transfers electrons from cytoplasmic NADPH to oxygen, thus 
generating superoxide: NADPH + 2 O2 ? NADP+ + H+ + 2 O2•−. Given the potential damage 
that can be inflicted by ROS, it is not surprising that tight control mechanisms have evolved to 
minimize the risk of collateral tissue damage due to an uncontrolled oxidative burst (for review 
on granulocyte NADPH oxidase please refer to [114]). Because of its relatively low 
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antibacterial potency, it is probably not O2•− itself that kills the microbes. Within the 
phagosome, O2•− is converted either spontaneously or by superoxide dismutase (SOD) to 
H2O2. H2O2 may then react with O2•− to generate hydroxyl radicals (OH•) and singlet oxygen, 
both highly reactive and toxic compounds. O2•− can also react with NO• to yield the highly 
reactive nitrogen intermediate peroxynitrite (ONOO-). The importance of the NADPH oxidase 
complex becomes evident in case of chronic granulomatous disease, a rare and typically X-
chromosome linked genetic disorder. These patients have a compromised ability to kill 
bacteria due to disturbed NADPH oxidase complex formation. They suffer from severe and 
frequent bacterial and fungal infections [114]. 
MPO and EPO are heme enzymes that convert H2O2 and halides (chlorine and bromine) to 
hypohalous acids. In case of chlorine the product is hypochlorous acid (HOCl): H2O2 + HCl ? 
HOCl + H2O. HOCl is used in phagocytes to aid the killing of bacteria. MPO and EPO also 
metabolize H2O2 and thiocyanate (SCN-) to equimolar amounts of OSCN- (hypothiocyanite) 
and OCN- (cyanate) [115], two bacteriostatic and bactericidal compounds. MPO is expressed 
in neutrophils and monocytes while EPO is exclusively expressed in eosinophils. Because of 
their large capacity to metabolize H2O2, these enzymes can compete with GPx thus lowering 
the effective concentration of this peroxide when added to cells, without affecting the 
NADPH/NADP+-ratio. As with many other heme enzymes, MPO, catalase, and EPO are 
inhibited by sodium azide [116,117]. 
Exogenous Sources and Inducers of ROS 
The separation of endogenous and exogenous sources of ROS is not trivial, as many 
exogenous sources of ROS are not oxygen radicals by themselves but induce the formation of 
endogenous ROS or act as catalysts for ROS production. The main direct exogenous sources of 
ROS are cigarette smoke and pollution. For instance, cigarette smoke inhalation results in 
increased exposure to both superoxide and hydrogen peroxide. Although the gas phase of 
cigarette smoke contains some H2O2, O2•−, and O3 , the tar content is more harmful, as it 
contains a quinone-hydroquinone-semiquinone system that leads to the endogenous formation 
of superoxide and oxidative stress [118]. CYPs further metabolize some tar contents to their 
reactive intermediates. Air pollution is another source of environmental ROS since it contains 
ozone [119]. In addition, particulates in pollution can be taken up by alveolar macrophages or 
neutrophils, thereby inducing ROS formation through activation of NADPH oxidase [120]. 
They can also lead to epithelial damage and subsequent apoptosis. In this case, ROS 
production can be either catalyzed by the metal content [121], as well as being a consequence 
of apoptosis itself [122].  
Ingestion of xenobiotics or alcohol can also be detrimental. Some xenobiotics or their toxic 
metabolites deplete intracellular GSH pools by more than 90%, thus compromising the liver 
antioxidant capacity. The analgesic/antipyretic acetaminophen can produce centrilobular 
hepatic necrosis by this mechanism. It is metabolized by a CYP to N-acetyl-p-benzoquinone 
imine (NAPQI), which reacts rapidly with GSH [123]. Ethanol can induce a certain CYP 
(P4502E1, or CYP2E1), which leads to the formation of ROS and may explain the 
hepatotoxicity of ethanol [123]. As CYP2E1 also metabolizes acetaminophen to NAPQI, 
alcohol and this pain reliever can act synergistically to induce severe oxidative stress and 
subsequent liver damage GSH depletion. 
INTRODUCTION   30 
I.3.3 Antioxidant defense 
Introduction 
 During the course of evolution, many antioxidant defense strategies have developed 
leading to redundant systems that include both, enzymes and low molecular weight-molecules. 
These are present in all cell types and body fluids and collaborate to detoxify ROS and their 
byproducts. The antioxidants involved in protection from ROS are grouped together into 
enzymes/molecules that directly scavenge and metabolize ROS (first line of defense), and 
those that repair ROS-induced damage to cells and tissue.  
One common feature of antioxidant biology is that ROS undergo a controlled sequential 
degradation. The more toxic ROS are scavenged by abundant antioxidant molecules and 
converted into less aggressive compounds. Subsequently all components of the antioxidant 
network either decay through dismutation or undergo redox-reactions. As a rule, antioxidants 
are regenerated at the expense of NADPH, which is mainly provided by the pentose phosphate 
shunt (PPP), but also by other specific metabolic pathways. This redox recycling of 
antioxidants markedly increases their biological efficacy by diminishing the need for de novo 
synthesis or large uptake of antioxidant nutrients. Another important feature is the synergistic 
interaction of the components. They do not only interact in the destruction of the ROS but also 
protect each other against ROS. For example, SODs protect catalase and glutathione 
peroxidase (GPx) from inactivation by O2•−.  
Non-enzymatic Scavengers 
Hydrophilic and hydrophobic enzyme-independent antioxidant scavengers (for review see 
[124]) are either chemical traps of oxidizing free radicals and activated oxygen species, or 
physical quenchers of exited singlet oxygen 1O2 (O-O:) and triplet states of photosensitizers. 
The most important hydrophilic scavengers are ascorbate (vitamin C) and glutathione, which 
are found in the cytosolic, mitochondrial and nuclear aqueous compartments as well as 
extracellularly. They scavenge oxidizing free radicals by means of one-electron or hydrogen 
atom transfer. Their intracellular concentrations are typically between 1 and 10 mM, much 
higher than those of other nucleophilic and reducing biomolecules. Hydrophobic scavengers 
are found in membranes and lipoproteins and include α-tocopherol (vitamin E), carotenoids, 
and possibly ubiquinol. They act by either interrupting the propagation step of lipid 
peroxidation, by destroying peroxyl radicals (ROO•), or by blocking the formation of 
hydroperoxides from 1O2. Through the regeneration of α-tocopherol, ascorbate can also 
indirectly contribute to the prevention of lipid peroxidation. The kinetics of their scavenging 
reactions are very fast compared to other biological processes. Free radical products formed by 
the reaction of ROS with scavengers do not undergo uncontrolled chain reactions, but they 
decay through dismutaion, recombination or reduction by secondary scavengers. Oxidized and 
radical derivatives of ascorbate are less aggressive than ROS and are recycled by GSH or 
thioredoxin related pathways. Dehydroascorbate may be reduced by GSH-dependent or GSH-
independent dehydroascorbate reductase and thioredoxin (Trx) [124,125]. Ascorbyl free 
radicals representing one-electron oxidized ascorbate are recycled by thioredoxin reductase 
(TrxR) [126]. 
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Enzymatic Defense Mechanisms and Redox State 
In humans, two Cu/Zn-SODs are present in the cytosol and mitochondria, whereas 
Mn-SOD, a remnant of its bacterial ancestor, is present only in the mitochondrial matrix [127]. 
SODs catalyze the one-electron dismutation of superoxide into hydrogen peroxide and oxygen: 
2 O2•− + 2H+ ? H2O2 + O2. Although O2•− undergoes non-enzymatic dismutation at 
physiological pH in buffer, this reaction is catalyzed by SOD in vitro, because the turnover rate 
of superoxide with SOD is very high (> 2 × 109 M-1 s-1) over a wide range of pH [128]. The 
main function of SOD is to inactivate O2•− before any uncontrolled reactions take place. 
In mammals, catalase (H202:H2O2 oxidoreductase) is mainly expressed in peroxisomes, but 
is also present in the cytosol and in very small amounts in the mitochondrial matrix. Catalase is 
a porphyrin-containing enzyme of high molecular weight which converts H2O2 in a two-
electron dismutation into water: 2 H2O2 ? 2 H2O + O2. Since the KM of catalase for H2O2 is 
very high (close to 1 mM) [129], the physiological role of catalase in mammalian cells as an 
antioxidant is not well established. The KM of catalase for H2O2 is higher than the KM of GPx, 
which suggests that catalase scavenges H2O2 efficiently only at high H2O2 concentrations 
[130]. Even in erythrocytes, which have an unusually high catalase content, H2O2 is mainly 
degraded by the glutathione-redox cycle [131]. Catalase and SOD are dismutases, and 
therefore do not consume cofactors or require energy and do not rise the redox state of the cell 
(see below).  
The glutathione redox cycle, consisting of GPx and glutathione reductase (GRed) may play 
a more important role in protecting cells against physiologically relevant oxidants. A wide 
variety of both, cytosolic and membrane bound glutathione peroxidases (GPx) [132] exist, as 
well as some isoforms of glutathione-S-transferase [133] reduce H2O2 to water or organic 
peroxides to their corresponding alcohols: H2O2 + 2GSH ? 2 H2O + GSSG or R-OOH + 
2GSH ? R-OH + H2O + GSSG. Due to the wide substrate spectrum of the GPx (for review on 
the GPx-family please see [132,133]) and GST families [133,134], the glutathione redox cycle 
is an integral part of the antioxidant defense mechanism. While the oxidant substrates of the 
GPxs range from H2O2 to organic-hydroperoxides, GSH is the common electron donor for 
substrate reduction and is oxidized to GSSG. Under most circumstances, H2O2 is reduced by 
selenium-dependent GPx. GSSG is in turn reduced by glutathione reductase (GRed) to GSH, 
using NADPH as the redox partner. 
An additional enzymatic defense mechanism is the thioredoxin system. It consists of the 
three antioxidant enzymes peroxiredoxin (Prx; thioredoxin peroxidase), thioredoxin (Trx), and 
Trx reductase (TrxR). Trx represents a ubiquitous family of proteins with oxidoreductase 
activity of which three distinct variants encoded by separate genes have so far been cloned and 
characterized in humans (for review on Prx, Trx, TrxR see [126]). Similar to GPx, Prx can 
directly reduce both H2O2 and different alkyl hydroperoxides using TrxRED as the electron 
donor. TrxR catalyzes the reduction of the active site disulfide in TrxOX using NADPH as 
cofactor. The addition of peroxides can significantly affect the NAPH/NADP+ ratio in cells 
through the GSH/GSSG or the TrxRED/TrxOX redox cycles. The importance of the thioredoxin 
pathway can be distinguished from the GSH redox cycle by use of auranofin, a highly specific 
TrxR-inhibitor [135], as then only the GSH redox cycle will affect NADPH levels. 
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ROS affect the cellular redox status of mammalian cells as described above [136]. The term 
redox state is widely used but often not well defined in biological sciences. Historically, the 
term “redox state” has been used to describe the ratio of a specific redox couple (e.g. 
[NAD+]/[NADH]). However, the definition is now normally used to represent the sum of all 
redox systems in the cell. As the concentrations of GSH and GSSG are higher than those of 
other redox-couples, their ratio is a good indication of the cellular redox buffer. The overall 
redox state of a cell is therefore approximated by the half-cell reduction potential and the 
reducing capacity of GSH and GSSG. 
GSH and other antioxidants are maintained in the reduced state within the cytosol by 
NADPH dependent enzymes. High cytosolic NADPH/NADP+ ratios are maintained by the 
pentose-phosphate pathway (PPP), which is often considered a member of the second line of 
the antioxidant defense system. In the oxidative part of the PPP, G6P is oxidized and 
decarboxylated to ribulose-6-phosphate (Ru5P) with the concomitant reduction of 2 molecules 
NADP+ to NADPH per cycle. Within the regenerative part of the PPP, excess Ru5P is 
converted to glycolitic intermediates, fructose-6-phosphate and glyceraldehydes-3-phosphate, 
which can be recycled to G6P by gluconeogenesis. Thus, including the regenerative part of the 
PPP, the total oxidation of one molecule glucose via this pathway yields 12 molecules 
NADPH. In addition to the provision of reducing equivalent for GSSG and TrxOX reduction, 
NADPH is also consumed by many endergonic reactions, notably the reducing biosynthesis of 
fatty acids and cholesterol. The activity of the initial enzyme of the PPP, glucose-6-phosphate 
(G6P) dehydrogenase (G6Pdh), controls the flux through this pathway and thus the rate of 
NADPH production. In vivo, the activity of this enzyme is regulated by the 
NADP+ concentration. For experimental purposes, the ability of cells to maintain a high 
NADPH/NADP+ ratio can be modified with dehydroepiandrosterone (DHEA), a commonly 
used G6Pdh inhibitor, or by glucose depletion [137-139]. The subsequent NADPH depletion 
will lead to GSSG accumulation during oxidative stress and therefore affect the reductive state 
of the cell. 
I.3.4 Proposed Effect of Oxidative Stress on 5-oxo-ETE Formation 
Because of its effect on the NADPH/NADP+-ratio, oxidative stress may affect the formation 
of 5-oxo-ETE. In the present study, we hypothesized that hydroperoxides could enhance 
5-oxo-ETE synthesis through their metabolism by GPx, which would result in the formation of 
GSSG from GSH and its subsequent NADPH-dependent reduction by GRed. This would 
provide the NADP+ necessary for the oxidation of 5-HETE to 5-oxo-ETE by 5h-dh. This could 
serve as an alternative pathway to NADPH oxidase. In addition, lowering NADPH levels 
would reduce the metabolism of 5-HETE and 5-oxo-ETE by ω-oxidation and the ∆6-reductase. 
All the above effects would be opposed by the metabolism of G6P by the PPP, which would 
reduce the NADP+ generated by GRed and NADPH oxidase. 
I.3.5 Oxidative Stress and Cell signaling 
In addition to affecting the cellular redox state and NADP+ levels, ROS have important 
effects on cell signaling. The classical view of ROS effects on cells was that those induce 
excessive damage to DNA and phospholipids, thus overwhelming the defense mechanisms of 
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cells and subsequently leading to necrosis or apoptosis. However, there is growing evidence 
that ROS can mediate physiological responses in cells by interfering with signal cascades. 
H2O2 can inhibit tyrosine protein phosphatases (TPPs) that are critical in determining the 
phosphorylation state of MAP kinases (MAPKs), which among other kinases are important 
regulators of eicosanoid formation. For more details on ROS in signal transduction refer to an 
excellent review by Dröge [140]. 
Inhibition of Protein Tyrosine Phosphatases (PTPs) by H2O2
Phosphorylation of specific protein residues is a very important regulator of enzymatic 
activities. The phosphorylation state of a protein reflects the balance of the corresponding 
kinase and phosphatase activities. Exposure to high concentrations of hydrogen peroxide on 
the order of 1 mM generally leads to increased tyrosine phosphorylation in numerous proteins 
(for review see [141]). This effect is to some extent, albeit not exclusively, the consequence of 
the oxidative inhibition of PTPs. The cysteine residue is only a good target for the oxidizing 
action of H2O2 if it is deprotonated and exists in the form of a cysteine thiolate anion (-S-). 
PTPs contain an essential catalytic cysteine residue in their active sites with a lower pKa (~5.5) 
than the pKa (~8.0) of other cysteine residues in most proteins [142]. The low pKa makes their 
thiolate anion especially susceptible to the inhibitory action of H2O2. As fewer proteins are 
phosphorylated under lower H2O2 concentrations [141], one has to be cautious not to over-
interpret physiological relevance into data gained using high concentrations of peroxides. 
Indirect H2O2-induced Activation of MAPK pathways 
Mitogen-activated protein kinases (MAPK) are involved in the regulation of LT-synthesis 
and can be activated by H2O2. MAPKs consist of three different families, the p38 MAPK, the 
extracellular signal-regulated kinases (ERK), and the c-jun-NH2-terminal kinases (JNK). In an 
excellent study, Lee and Esselman examined the stimulation of those three MAPKs by H2O2 in 
Jurkat cells, a T lymphocyte cell line [143]. In those cells MAPKs are activated by members of 
the Src family, most likely Lck. T lymphocytes contain three major tyrosine phosphatases, 
CD45, SHP-1 and HePTP and their activities have been shown to play important roles in T cell 
activation. H2O2 exposure leads to increased phosphorylation of all three MAPKs, which is 
due to PTP inhibition [143]. In this setting, CD45 is the primary phosphatase controlling Src-
family kinases, SHP-1 is accountable for H2O2 stimulatory effects on JNK and in part on ERK, 
and HePTP dephosphorylates p38 and ERK, but has no influence on the activation state of 
JNK. Further studies revealed that phospholipase C (PLC) and protein kinase C (PKC) are 
crucial for ERK activation, but do not participate in p38 or JNK regulation. The implications 
of these findings on LT synthesis are discussed in more detail in chapter I.4.3. 
I.4. 5-Lipoxygenase 
5-LO is the enzyme responsible for the synthesis of LTs and 5-oxo-ETE. It possesses two 
distinct enzymatic activities leading to the formation of 5-HpETE, the precursor for 5-HETE 
and 5-oxo-ETE, and LTA4, the precursor for leukotrienes. 5-LO is mainly found in cells of the 
immune system, including neutrophils, eosinophils, macrophages, basophils, B-lymphocytes, 
and mast cells. 
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I.4.1 Role and Enzymatic Reaction of 5-Lipoxygenase 
5-LO catalyses the incorporation of molecular oxygen into AA (oxygenase activity) to form 
5-HpETE and the subsequent formation of the unstable epoxide LTA4 (LTA4 synthase activity) 
[144,145]. The first step is the abstraction of a hydrogen atom of the C7-position of AA, 
coupled with the addition of a molecule of oxygen at C5 to give 5S-HpETE. It then catalyzes 
the removal of a second hydrogen atom from C-10 of 5S-HpETE, which is coupled to a 
cyclization of the 5-hydroperoxy group to give the 5,6-epoxide LTA4. During this process, 
considerable amounts of 5S-HpETE are release from the enzyme and are reduced by 
ubiquitous GPx-family members [132,133] and some GSTs [133,134] to the corresponding 
hydroxy-compound 5S-HETE. The ratio of LTA4 to 5-HETE formed depends on the assay 
conditions, e.g. the relative concentrations of free AA, membrane association, and the amount 
of 5-LO [146-150]. The role of 5-LO activating protein (FLAP) in 5-LO metabolism is 
discussed below. 
In the active site of 5-LO, a non-heme iron acts as an electron acceptor and donator during 
catalysis. Using electron paramagnetic resonance spectroscopy, it was shown that the iron of 
isolated, inactive enzyme is in the ferrous state (Fe2+) and that treatment with fatty acid 
hydroperoxides restored the active, ferric (Fe3+) form [151]. Ferric 5-LO then reverts to the 
ferrous form in the presence of reducing agents. The reaction profile of 5-LO consists of an 
initiation phase, where 5-LO is converted to the active (ferric) state, a linear propagation phase 
associated with the highest conversion rate, and an irreversible inactivation phase. Although 
lipid hydroperoxides are needed to generate active ferric enzyme, oxidants formed during 
catalysis may be responsible for the rapid inactivation of 5-LO [152,153]. This process is 
termed suicide inactivation, as reactive reaction intermediates (LTA4 in the case of 5-LO) 
covalently bind irreversibly to the enzyme as it has been shown for 15-LO [153,154]. 
I.4.2 Activation of 5-Lipoxygenase 
5-LO activation is a complex process, facilitated by several different mechanisms that 
synergistically interact with each other. Unlike the cyclooxygenases (COX-1 and COX-2), 
5-LO is not active at the basal state within the cell even if sufficient substrate is present. It 
must be activated by a number of different factors of which a rise in cytosolic Ca++ is 
considered the most important. All lipoxygenases posses two domains, an amino terminal β-
barrel structure and a highly conserved carboxy structure consisting predominantly of α-
helices and contains the catalytic activity (for review see [155]). It is assumed that Ca++ 
stimulates 5-LO activity by promoting membrane association, a feature of many Ca++ binding 
enzymes, including cPLA2 [156] or PKC [157]. Ca++ binds to a specific S2-domain and 
thereby increases the hydrophobicity of purified 5-LO [158], resulting in the binding of 5-LO 
to phosphatidyl-choline vesicles [149]. This process is directed by the S2-domain of 5-LO 
[155]. In intact cells Ca++ stimulates 5-LO translocation to the nuclear envelope, where FLAP 
is located as well [158-161].  With 5-LO, cPLA2 also translocates to the nuclear membrane in 
response to Ca++ stimulation, thus assembling the different parts of the LT-producing 
machinery at this location [160]. A number of agonists, which activate the PLC?IP3?Ca++ 
pathway, are therefore good inducers of LT production, as they activate cPLA2 and 5-LO, the 
two critical steps of this process. 
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Figure I.8  Activation of 5-lipoxygenase. 
The production of leukotrienes can be activated by signals that induce Ca++ influx, 
phosphorylation of 5-LO and cPLA2, or both. Ca++ induced binding of these enzymes is required 
for optimal leukotriene biosynthesis. The oxidation of Fe2+ to Fe3+ is a requisite for 5-LO enzyme 
activity. This activation step can be facilitated by lipid hydroperoxides (L-OOH). Lipid 
hydroperoxides are subject to GPx mediated oxidation. Peroxides such as H2O2 can overcome 
the inhibitory effect of GPx and influencing the redox state of the cell or may promote L-OOH 
formation from AA via the hydroxyl radical HO•-. See text for abbreviations and additional details. 
Five Lipoxygenase Activating Protein (FLAP) 
FLAP is a 18 kDa membrane protein containing 3 membrane spanning regions and is 
closely related to LTC4-S [162]. It was discovered serendipitously when a potent 5-LO 
inhibitor (MK-886, Merck-Frosst) was developed. MK-886 inhibits 5-LO activity only in 
intact cells but does not affect the activity of purified 5-LO. MK-886 also inhibits LTC4-S, but 
the potency is much lower [92,162]. With photoaffinity-labeled MK-886, Dixon and 
colleagues [163] discovered a protein that had a greater affinity for this compound than other 
proteins of the LT synthesis pathway and demonstrated that this protein is essential for 5-LO 
activity in whole cells. FLAP was later shown to be located in the nuclear envelope [164], and 
to bind AA [165] as well as 12-HETE and 15-HETE. FLAP stimulates 5-LO activity by 
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presenting the substrates AA and 15-HETE to 5-LO, leading to the formation of 5-HETE/LTs 
[146] and 5,15-diHETE/lipoxins, respectively [165]. FLAP also increases the efficiency of 
5-LO mediated conversion of 5-HpETE to LTA4 [146]. FLAP is considered absolutely 
necessary for cellular LT synthesis (from endogenous substrate), but it is dispensable for 5-LO 
activity in cell homogenates [166]. However, there is no absolute requirement for FLAP when 
cells are stimulated in the presence of exogenous AA [146], and MK886 failed to suppress LT 
formation under such conditions [167]. 
Inhibition of 5-LO by Endogenous GPx 
Since lipid hydroperoxides or H2O2 are required to initiate the enzymatic activity of 5-LO 
by oxidizing the Fe2+ (see above), a negative regulatory role for peroxidases was postulated 
[168-172]. Indeed, selenium-dependent glutathione peroxidases are potent suppressors of 5-LO 
activity by reducing lipid hydroperoxides [170-172]. GSH-depleting agents like 1-chloro-2,4-
dinitrobenzene have been shown to stimulate 5-LO activity in human neutrophils, a first 
indication that GPx may play a regulatory role in tonically suppressing 5-LO activity [169]. 
Jakobsson and colleagues showed that human B lymphocytes do not form 5-LO products 
when stimulate with Ca++ ionophore and AA, even though they posses active 5-LO, as been 
shown by the formation of LTB4 and 5-HETE by sonicates from these cells under similar 
conditions [173]. HL-60 cells and BL41-E95-A cells, a B-lymphocytic cell line, also release 
only barely detectable amounts of LTs when stimulated with Ca++ ionophore and AA 
[171,172]. It was established that this inhibitory effect depends on serum presence during cell 
culture. The serum in the medium could be replaced with selenium, which was the first 
evidence for an involvement of selenium dependent GPx in 5-LO inhibition [171]. It was later 
shown that in B-lymphocytes and immature myeloid cells, GPx-4 is primarily responsible for 
the suppression of 5-LO activity [168]. In MonoMac6 cells, a monocytic cell line, 5-LO 
activity is inhibited by GPx-1 and not GPx-4 [174]. No study exists that compares the amounts 
of GPx family members in the different leukocyte populations. Total GPx activity 
measurements however indicated that PMNL contain the lowest activity (1.0 U/g) [175] in 
comparison to monocytes (3.0  U/g) [175], mononuclear cells (57.2  U/g) [176] and  
lymphocytes (13.6  U/g) [177]. Attention should be paid to the fact these studies were not 
conducted following identical protocols and that this may lead to some problems regarding 
direct comparison of these values. Nevertheless, these findings support the notion that a higher 
GPx content makes 5-LO activation more difficult. In contrast to this hypothesis, Werz and 
Steinhilber reported that granulocytic 5-LO is peroxidase-insensitive, and that the high 
baseline 5-LO activity in neutrophils can not be explained by low GPx activity [171].   
Phosphorylation of 5-LO and Direct Stimulation by ATP  
Phosphorylation had been shown to stimulate 5-LO activity [178-181]. There are two 
independent pathways leading to 5-LO phosphorylation: the p38/MK2 pathway, mainly 
activated by cellular stress, and the ERK pathway, which is mainly stimulated by mitogens. 
Stimulation of the p38 MAPK leads to the activation of MK2, a MAPK-activated protein 
(MAPKAP) kinase (MAPKAPK or MK), that in turn phosphorylates Ser271 [182] of 5-LO. In 
the second pathway stimulation of ERK-2 leads to the phosphorylation of SER663 [183]. 
Interestingly, the phosphorylation of 5-LO either MK2 or ERK-2 is greatly enhance by 
addition of AA [183].  
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A number of conditions prime cells for enhanced LT formation. A priming agent is 
considered an agent that does not induce the cellular response of interest but rather enhances 
the response to a second stimulus. Preincubation of neutrophils or whole blood with 
granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor-α (TNF-
α) or lipopolysaccharide (LPS) for 30 min greatly enhances LT production in response to N-
formylmethionyl-leucyl-phenylalanine (fMLP), platelet activating factor (PAF) or ionophore 
[184-186]. This is due to priming of both cPLA2 and 5-LO. It has been shown that GM-CSF 
signals through the ERK and fMLP through p38 MAPK [187]. ERK then phosphorylates and 
activates cPLA2 [187] and 5-LO [183]. 
It was known early on that 5-LO is stimulated by nucleotides. ATP is the most efficacious, 
while ADP, AMP, CTP, and UTP are less active. This effect is not due to phosphorylation, 
since Noguchi et al. showed that γ-S-ATP, a non-hydrolysable ATP analog, is at least as active 
as ATP itself [188]. The same report showed that ATP is not hydrolyzed by 5-LO itself, 
indicating a direct stimulatory effect. 5-LO does not have a consensus ATP-binding site, which 
previously raised questions whether or not this enzyme does indeed bind ATP. However, 
Zhang and coworkers showed in an excellent study that 5-LO has a single specific nucleotide-
binding site that differs from the classic ATP-binding site [189]. 
I.4.3 Regulation of Leukotriene Synthesis by Reactive Oxygen Species 
Hydroperoxides Directly Activate 5-LO by Oxidizing the Catalytic Iron 
As mentioned above, activation of resting 5-LO requires the oxidation of the iron at the 
active site to the ferric state. This switch between Fe2+ and Fe3+ during the catalytic cycle is 
crucial for enzyme activity. Among various hydroperoxides, 5-HpETE, 12-HpETE, and 
13-HpODE, but not the corresponding hydroxy compounds, have been shown to stimulate 
5-LO in homogenates by oxidizing the iron, whereas tBuOOH or cumene hydroperoxide failed 
in this respect [151,190]. However, fatty acid hydroperoxides are not specifically required for 
activation of 5-LO, as they can be replaced by H2O2 [191].  
Indirect Activation of 5-LO by Reactive Oxygen Species 
Oxidative stress enhances 5-LO activity by affecting the cellular redox state and potentially 
by greater MAPK activity. As mentioned above, GPx-1 and GPx-4 and potentially other GPxs 
or GSTs reduce stimulatory lipid hydroperoxides thus rendering 5-LO inactive by impairing 
the Fe2+ ? Fe3+-transition. It was surmised that agents which inhibit GPx or which change the 
reductive state within the cell could overcome the inhibitory effects of GPx. In agreement to 
this hypothesis, 5-LO activity can indeed be enhanced in MonoMac6 cells by addition of the 
specific GPx-1 inhibitor mercaptosuccinate or the broad GPx inhibitor iodoacetate [192]. 
Addition of exogenous 13-HpODE also upregulates 5-LO activity in cells through iron 
oxidation [192]. Analogous results were obtained with other cell types. B-lymphocytes express 
5-LO, and considerable amounts of LTs are formed in broken cell preparations [193], whereas 
stimulation of whole cells with the standard stimulus ionophore plus AA causes only marginal 
LT production [193]. However, conditions that lead to an elevated redox state, such as 
depletion of GPx by selenium removal [171], co-addition of H2O2 [172] or thiol-reactive 
agents, such as diamide or N-ethylmaleimide (NEM), that deplete the GSH pool [193] resulted 
in 5-LO activation and subsequent formation of LTs in response to ionophore plus AA. In 
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broken cell preparations of BL41-E95-A cells, 5-LO activity was strongly suppressed after 
reconstitution of GPx activity by addition of millimolar concentrations of thiols [171]. 
Compared to phagocytes, B-lymphocytes produce only low amounts of endogenous 
superoxide upon stimulation, and in BL41-E95-A cells superoxide formation was hardly 
detectable [172]. Intriguingly, ROS generated by exogenous xanthine oxidase or by treatment 
of cells with antimycin A, which leads to endogenous superoxide release from mitochondria, 
strongly activated cellular 5-LO in BL41-E95-A cells [172]. Co-addition of catalase, but not of 
superoxide dismutase abolished these effects, suggesting that hydroperoxides or hydrogen 
peroxide mediate 5-LO activation, rather than superoxide itself. Further experiments suggest 
that 5-LO activation is not only restricted to intercellular activation, but transcellular activation 
as well [172]. 
As outlined above, ERK and p38 MAPK can phosphorylate and thus activate 5-LO. As 
oxidative stress activates ERK and p38 MAPK, Werz and colleagues investigated the effects of 
H2O2 on 5-LO activity [180]. They found that H2O2 activates p38 MAPK and downstream 5-
LO kinases in BL41-E95-A cells. The hypothesis that H2O2 acts through p38 MAPK was 
further supported by the finding that addition of SB203580, a specific p38 inhibitor, reduced 
H2O2-induced 5-LO activity. Thus it is reasonable to hypothesize that pro-oxidative agents 
may stimulate 5-LO by two ways: (i) promotion of protein phosphorylation resulting in a 
peroxidase-insensitive 5-LO activity, and by (ii) promoting the formation of Fe3+ in the active 
site of 5-LO. It is further possible that H2O2 affects the expression level of 5-LO through its 
effects on MAPKs. However, there is yet no evidence for such a mechanism for 5-LO 
induction by H2O2. 
Inactivation of 5-LO by ROS 
With respect to LT synthesis, H2O2 is a double-edged sword, as it can stimulate as well as 
abrogate 5-LO activity. Endogenous H2O2 diminishes the formation of LTB4 by alveolar 
macrophages and PMNL after stimulation with fMLP or opsonized zymosan in vitro [194]. 
This effect can be overcome by addition of N-acetylcysteine (NAC), which scavenges 
endogenous ROS thereby increasing LTB4 production. LTB4 synthesis was not affected by 
SOD, but markedly enhanced by catalase, indicating that H2O2 rather than superoxide is 
responsible for this effect. The inhibitory effect of H2O2 appears to be caused by a direct effect 
on 5-LO and cannot be explained by non-enzymatic oxidation of the product LTB4. Indeed, 
concentrations of H2O2 similar to those released by phagocytes (≥ 10 µM) inactivate purified 
5-LO in the absence of reducing agents [195]. The native (ferrous) enzyme is approximately 
seven times more sensitive to inactivation by H2O2 than the ferric enzyme, suggesting that the 
mechanism of inactivation possibly involves a Fenton-type reaction. The ferrous enzyme 
would react with H2O2, resulting in the formation of hydroxyl radicals, which are strong 
oxidants. This reaction can be described as Fe2+ + H2O2 → Fe3+ + OH• + OH−. Although the 
iron could be in the active state Fe3+, LT synthesis by 5-LO could be blocked by this 
mechanism in situations where this accompanied by increased H2O2 formation (e.g. activation 
of the respiratory burst) [159]. 
Effects of Oxidative Stress on AA Levels 
Another mechanism by which H2O2 could potentially affect the synthesis of 5-LO products 
is through the availability of the substrate AA. As noted above, H2O2 could stimulate cPLA2 
phosphorylation through activation of ERK, resulting in increased AA release. H2O2 stimulates 
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free AA levels following stimulation of alveolar macrophages [196], but this effect was due to 
inhibition of AA esterification into lipid rather than to a direct effect on cPLA2. It was initially 
proposed that this effect was due to inhibition of arachidonoyl-CoA synthetase [197], but H2O2 
did not directly inhibit this enzyme in alveolar macrophages, and appeared to act by depleting 
ATP, which is required for the synthesis of arachidonoyl-CoA [196]. 
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II  AIM OF STUDY 
 
Before ordering a test decide what you will do if it is 1. positive, or 2. negative. 
If both answers are the same, don’t do the test. 
D. Greenberg (1880-1958) 
In contrast to the biological effects of 5-oxo-ETE, which have been studied in detail, the 
regulation of 5-oxo-ETE biosynthesis is not well understood. 5-oxo-ETE is formed by the 
oxidation of 5-HETE. This reaction is catalyzed by 5h-dh, a NADP+-dependent microsomal 
enzyme that is present in neutrophils, eosinophils, monocytes, lymphocytes, and platelets, and 
is highly selective for 5-HETE [22,68,70,198]. The aim of this study was to investigate the 
expression pattern of this enzyme and the regulation of its activity.  
II.1. Does Myeloid Differentiation Affect Expression of 5h-dh 
Activity? 
The expression of many enzymes involved in leukotriene synthesis is genetically regulated 
and confined to specific tissues and differentiation states. 5h-dh has so far been reported to be 
present in blood leukocytes as well as platelets. It is not known whether 5h-dh is present in 
myeloid progenitor cells or whether it is induced during their maturation to neutrophils or 
monocytes. To examine this question we have investigated the synthesis of 5-oxo-ETE from 
5-HETE by 5h-dh in HL-60 cells and U-937 [199] cells, which have been widely used in 
studies on the induction of eicosanoid-forming enzymes [200-209]. The enzyme was 
examined in whole cells as well as in the microsomal fractions and the effects of various 
differenting agents were examined. HL-60 cells are a promyelocytic cell line that has been 
used as a model for granulocyte / monocyte / macrophage differentiation [210]. They can be 
differentiated into monocyte-like cells by 1,25-dihydroxy-Vitamin D3 (dh-VitD3) [211], into 
macrophage-like cells by phorbol myristate acetate (PMA) [212] and into granulocytic cells 
by retinoic acid (RA) [213] or dimethyl sulfoxide (DMSO) [214]. U-937 cells, a human 
promonocytic cell line, are frequently used to study monocyte / macrophage differentiation 
[215]. This cell line can be differentiated into macrophage-like cells by treatment with PMA 
[215] or into monocyte-like cells by treatment with dh-VitD3 [216], RA [217] or DMSO 
[218]. Unlike HL-60 cells, U-937 cells cannot differentiate into granulocytes [219].  
II.2. Does Oxidative Stress Increase 5-oxo-ETE Synthesis? 
Despite the presence of very high 5h-dh activity in the microsomal fractions of 
inflammatory cells, unstimulated intact cells form only very small amounts of 5-oxo-ETE 
when incubated with 5-HETE. This may be due to limited availability of NADP+, which is 
present at very low levels in the cytosol, as cells maintain this cofactor in its reduced state 
(NADPH) as a protective mechanism against oxidative stress [136]. In neutrophils and 
monocytes, 5-oxo-ETE synthesis is dramatically increased by stimulation of the respiratory 
burst, which would increase the levels of NADP+ in the cytosol [68,71,74]. While PMNL and 
monocytes possess NADPH oxidase, which provides the cofactor for 5h-dh when stimulated, 
lymphocytes and platelets do not express this system. We wished to investigate whether other 
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systems that may influence the ratio of NADPH to NADP+ could regulate 5-oxo-ETE 
synthesis in those cells. 
We hypothesized that 5-oxo-ETE production is upregulated by oxidative stress and that 
this is dependent on the glutathione redox pathway facilitates this. H2O2, organic peroxides 
(such as tBuOOH), and lipid peroxides (e.g. 13-HpODE) can affect the cellular redox status, 
as a major pathway for their inactivation is their GSH-dependent reduction to H2O by 
glutathione peroxidases [136]. This results in the formation of GSSG, which is recycled to 
GSH by glutathione reductase, which concomitantly oxidizes NADPH to NADP+. The latter 
is in turn reduced back to NADPH by the pentose phosphate pathway (PPP), which uses 
glucose 6-phosphate as its initial substrate, and is a major defense mechanism against 
oxidative stress. We reasoned that by increasing NADP+ levels, oxidative stress could be a 
major regulator of 5-oxo-ETE synthesis. We tested this hypothesis in U-937 cells and then 
examined the relevance of our findings in regard to different blood cells, including 
neutrophils, monocytes, lymphocytes, and platelets. 
II.3. Can 5-Oxo-ETE by Produced by Structural Cells? 
Because of the high expression of 5h-dh in undifferentiated myeloid cell lines (HL-60 and 
U-937) in the first part of this study, we wondered whether non-myeloid cell types express 
this enzyme. Under non-pathological conditions, non-myeloid tissue cells contain little or no 
5-LO activity, but contain several leukotriene-metabolizing enzymes in a tissue specific 
distribution pattern. We reasoned that cells that are in close contact to 5-LO-containing 
leukocytes (e.g. neutrophils and macrophages) and are subject to oxidative stress in vivo 
should be prime suspects to investigate. We therefore investigated whether endothelial as well 
as epithelial cell lines have the ability to synthesize 5-oxo-ETE. 
As our initial experiments confirmed this hypothesis, we wished to characterize the 
enzyme responsible for this activity to determine whether its properties are similar to those of 
leukocyte 5h-dh. We also wanted to determine whether the regulation of 5-oxo-ETE synthesis 
by structural cells is similar to that found in inflammatory cells.  
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III  MATERIAL AND METHODS  
III.1. Materials 
5-HETE was prepared by total organic synthesis by J. Rokash (Florida Institute of 
Technology, Melbourne, FL, USA) [220]. 13S-hydroperoxy-9Z,11E-octadecadienoic acid (13-
HpODE) and 13S-hydroxy-9Z,11E-octadecadienoic acid (13-HODE) were prepared by 
oxidation of linoleic acid with soybean lipoxygenase Type 1B. The subsequent was prepared by 
reduction of 13-HpODE with triphenylphosphine (TPP) [221].  
3-Amino-1,2,4-triazole (3-AT), 1,2-bis[2-chloroethyl]-1-nitrosourea (BCNU; carmustine), 
buthionine sulfoximine (BSO), 3-(cyclohexylamino)-1-propane sulfonic acid (CAPS), 
dehydroepiandrosterone (DHEA), diamide, dimethyl sulfoxide (DMSO), H2O2, N-(2-
hydroxyethyl)-piperazine-N'-(2-hydroxypropanesulfonic acid) sodium salt (HEPSSO), 2-
morpholinoethanesulfonic acid (MES), N-ethylmaleimide (NEM), tert-butyl hydroperoxide 
(tBuOOH), phorbol 12-myristate 13-acetate (PMA), phenazine methosulfate (PMS), retinoic 
acid (RA), and TPP were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Dextran 
T-500 and Ficoll-Paque were obtained from the Amersham Bioscience Corp (Piscataway, NJ, 
USA). Auranofin was obtained from the ALEXIS Corporation (Lausen, Switzerland). 
Phenylmethanesulfonyl fluoride (PMSF), sodium azide (SA), and glucose were purchased from 
Fisher Scientific (Nepean, Ontario, Canada). RPMI 1640 and other products for cell culture 
were obtained from Invitrogen (Burlington, Ontario, Canada). 5S-hydroperoxy-6E,8Z,11Z,14Z-
eicosatetraenoic acid (5-HpETE), arachidonic acid (AA), A23187, and 9-oxo-15S-hydroxy-
prosta-5Z,8(12),13E-trien-1-oic acid (PGB2) were obtained from Cayman Chemicals (Ann 
Arbor, MI,USA).  
III.2. Blood Cell Preparation, Cell Lines, and Culture Conditions 
Unless otherwise indicated, cell purifications were done in phosphate-buffered saline (PBS-; 
137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, and 8.1 mM Na2HPO4 at a pH of 7.4), and 
incubations in PBS+ supplemented with calcium (1.8 mM) and magnesium (1 mM) (PBS+). 
III.2.1 U-937 Cells and HL-60 Cells 
U-937 and HL-60 cells, obtained from ATCC (Manassas, VA, USA), were cultured in 10% 
fetal bovine serum (FBS) in modified RPMI 1640 medium containing L-glutamine (2 mM), 
sodium bicarbonate (1.5 g/L), glucose (4.5 g/L), HEPES (25 mM), and sodium pyruvate (1.0 
mM). Cells were maintained at a density between 105 and 1.5×106 cells/ml. To induce 
differentiation, cells (2×105/ml) were cultured for up to 4 days with vehicle (0.1% DMSO), dh-
VitD3 (50 nM), DMSO (1.3%), or RA (300 nM). In case of PMA, cells (106 /ml) were 
incubated with PMA (18 nM) for various times. The higher initial cell concentration was 
required to ensure sufficient cell numbers, as addition of PMA led to growth arrest. The cells 
remained in suspension for the duration of all of the above treatments with the exception of the 
adherent U-937 cells cultured with PMA. In this case, the cells were resuspended by incubation 
with 2 mM EDTA in PBS- on ice for 20 min followed by scraping with a rubber policeman. 
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III.2.2 Epithelial Cell Lines 
A-549, BEAS-2B, T84, and HEp-2 cells were obtained from ATCC and cultured in 
10% FBS in DMEM/F12 medium containing L-glutamine (2 mM), sodium bicarbonate (1.5 
g/L), glucose (2.5 g/L), HEPES (10 mM), and sodium pyruvate (1.0 mM). Cells were sub-
cultured before reaching confluence and used before reaching passage 50. 
III.2.3 Human Aortic Endothelial Cells (HAEC) 
Human aortic endothelial cells (HAEC) were obtained from Clonetics (San Diego, CA, 
USA) and cultured in endothelial growth medium 2 (EGM-2) (with recommended growth 
factors, cytokines, and supplements) containing 2% FBS. Cells were subcultured when they 
reached ~75% confluence at a seeding density of 2,500 to 5,000 cells/cm2. Cells were used 
until passage 7. 
III.2.4 Preparation of Blood Cells 
Neutrophils and peripheral blood mononuclear cells (PBMC) were prepared by treatment of 
whole blood with Dextran T-500 for 45 min, followed by centrifugation over Ficoll-Paque. Red 
blood cells (RBC) in the neutrophil-containing pellet were removed by hypotonic lysis [22]. 
PBMC and neutrophils were then suspended in PBS-. 
Human monocytes were prepared as described in the literature [222] with some 
modifications. PBMC present at the interface after centrifugation of leukocytes over Ficoll-
Paque as described above were washed by centrifugation and resuspended in ice-cold 
RPMI 1640 (4°C). The washed cells (2 × 107 cells in 10 ml per dish) were then added to 
Corning tissue culture dishes (Fisher, Nepean, Ontario, Canada) that had been pretreated with 
1.5 ml autologous plasma for 20 min at 37°C. After incubation for 30 min at 37°C the loosely 
adherent lymphocytes were removed with gentle streams of the culture medium from a 10 ml 
pipette. The lymphocytes were aspirated and this wash-aspiration procedure was repeated twice 
more with RPMI at 37 oC and then with PBS- at 4° C. The monocyte-enriched adherent cells 
were detached from the plastic by incubation for 30 min with ice-cold 2 mM EDTA in PBS- in 
the cold room, followed by removal with a rubber policeman. This monocyte-enriched fraction 
(>85% CD14+) is subsequently referred to as monocytes. 
For preparation of platelets, whole blood (20 ml) was collected in medium (2.8 ml) 
containing citric acid (15.5 mM), sodium citrate (90 mM), NaH2PO4 (16 mM), dextrose 
(161 mM), and adenine (2 mM) [70]. After centrifugation at 200 x g for 15 min, the supernatant 
was diluted with an equal volume of medium containing 94 mM citrate and 140 mM dextrose, 
pH 6.5. After centrifugation at 1000 x g for 10 min, the pellet was resuspended in PBS- to give 
a platelet concentration of 3 × 108 cells/ml. 
III.3. Preparation of Microsomal Fractions 
Cells were washed by centrifugation, resuspended in 20 ml PBS- supplemented with 1 mM 
PMSF, and disrupted by sonication at a setting of 40 cycles/s (model 4710 ultrasonic 
homogenizer, Sonics and Materials, Danbury, DC) on ice for 5 × 6 s with 30 s intervals for 
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cooling [22]. The disruptate was successively centrifuged at 4 °C at 1,500 × g for 10 min, 
10,000 × g for 10 min, and 150,000 × g for 80 min and the final pellet was resuspended in PBS-
. Protein was measured with the Bio-Rad DC (detergent compatible) protein assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA) and adjusted to the indicated concentrations. 
III.4. Incubation conditions 
III.4.1 5-oxo-ETE Production by Microsomes and Cells in Suspension 
Unless otherwise indicated, incubations were performed in PBS+ in the absence of glucose. 
Suspensions (1 ml) of HL-60 cells, U-937 cells, lymphocytes, monocytes, PBMC neutrophils 
(2×106 cells/ml), platelets (108 cells/ml), or cell microsomes (50 to 500 µg protein/ml) were 
incubated with 5-HETE (1 µM) for 5 min unless otherwise indicated. To establish the maximal 
ability of cells to convert 5-HETE to 5-oxo-ETE, cells were preincubated with PMS (100 µM, 
if not stated otherwise) for 6 min prior to addition of the substrate 5-HETE. PMS stimulated 
5-oxo-ETE synthesis by non-enzymatically converting intracellular NADPH to NADP+ (Figure 
III.1) [75]. 
5h-dh
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5-oxo-ETE
CO2H
OH
CO2H
O
NADP+
NADPH
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Figure III.1  Measurement of 5h-dh in whole cells. 
PMS stimulates 5-oxo-ETE synthesis in intact cells 
through the non-enzymatic conversion of NADPH to 
NADP+ [75].  
To manipulate the effects of oxidative stress, cells or microsomes were preincubated with 
various substances, none of which affected 5h-dh activity directly, as indicated in Table IV.2, 
page 55. To study the effect of pH, microsomes were diluted in 50 mM MES (pH 4.0-6.0), 
50 mM HEPSSO (ph 6.8 – 9.0), or 50 mM CAPS (pH 9.0 – 11.4). 
III.4.2 5-oxo-ETE Production by Adherent Cells 
In order to screen epithelial cell lines (A549, BEAS-2B, T84 and HEp-2) for 5h-dh, they 
were grown in 6-well plates until they reached confluence. For further studies, epithelial cells 
(A549 and BEAS-2B) were plated approximately 24 h before incubation with 5-HETE in 6-
well plates at a cell density of 106 cells/well. Prior to the incubations, the culture medium of the 
epithelial cells was aspirated and the cells were washed once with PBS+. The incubations were 
then carried out in 1 ml PBS+ in the absence of glucose, if not stated otherwise. Endothelial 
cells were grown to confluence and were treated similarly, except that indicator free Hanks 
buffer (1 g glucose/ml) was used instead of PBS+. To estimate the cell number used in each 
experiments, selected wells were washed once with PBS- and then trypsinized and counted with 
a hematocytometer. In our hands 106 epithelial cells grew to 1.3±0.2 × 106 and 1.2±0.2 × 106 
cells (A549 and BEAS-2B, respectively) within 24h.  
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III.4.3 Detection of 5-LO activity 
To detect 5-LO activity, cells were incubated with AA (20 µM) and the Ca++ ionophore 
A23187 (5 µM) for the indicated times in PBS+. In certain experiments, cells were pretreated 
for 6 min with PMA (30 nM) or incubated in the presence of tBuOOH (100 µM). 
III.5. Eicosanoid Analysis by Precolumn Extraction/(RP)-HPLC 
All incubations were terminated by addition of methanol (0.65 mL) and cooling to 0°C. The 
concentration of methanol in each sample was adjusted to 30% by addition of water and either 
13-HODE or PGB2 were added as internal standards to correct for technical recovery that is not 
due to metabolism. Alternatively, to detect the more hydrophilic ω-oxidation products of LTB4, 
the final MeOH concentration was adjusted to 15%. Eicosanoids were analyzed by precolumn 
extraction/RP-HPLC [223] using a modified Waters Millenium system (Waters Associates, 
Milford, MA). The stationary phase was a C18 column (150 x 3.9 mm) of octadecylsilyl silica 
(4 µm particle size Novapak column, Waters). The mobile phase for the detection of 5h-dh 
activity was a linear gradient composed of solvents A (water/acetic acid (100:0.02)) and B 
(acetonitrile/acetic acid (100/0.02)) as follows: 0 min: 35% B; 10 min, 90% B. For the 
detection of 5-LO activity the mobile phase was a linear gradient composed of solvents A 
(water/acetic acid (100:0.02)), B (acetonitrile/ acetic acid (100/0.02)), and C (methanol/acetic 
acid (100/0.02)) as follows: 0 min: 65.5% A, 23.7% B, 10.8% C; 30 min, 11.1% A, 37.6% B, 
51.3% C. All solvents were of HPLC quality. Products were quantitated by comparing the areas 
of their peaks of UV absorbance at their λmax with that of the internal standard. The extinction 
coefficients used were: 5-HETE (235 nm; 27,000), 5-oxo-ETE (280 nm, 20,500), 5-oxo-20-
HETE (280 nm, 20,5000), LTB4 (270 nm, 39,500), PGB2 (280 nm, 28,680), 13-HODE (235 
nm, 23,000), and 13-HpODE (235 nm, 23,000). The identities of the products measured were 
confirmed by examination of their complete UV spectra.  
III.6. Data analysis 
For the experiments estimating the metabolism and loss of 5-HETE and 5-oxo-ETE, equal 
amounts of eicosanoids were incubated in cell-free buffer for 20 min and used as reference. % 
Remaining LTB4 was determined as loss of the original added compound. As 5-oxo-ETE and 
5-HETE are interconverted in human cells, the sum of 5-oxo-ETE and 5-HETE was compared 
with the originally added eicosanoid. Since AA has a low extinction coefficient, we used 
radiolabeled 14C-AA. This was mixed prior to the incubations with unlabeled AA to give a final 
concentration of 1 µM. AA was analyzed by HPLC and the radioactivity comigrating with cold 
AA was collected in tubes and analyzed using a β-counter.  
EC50 and IC50 values were estimated by fitting the data to the Hill-equation. In some 
instances this was done by visual approximation, when the fitting was not appropriate. The 
results are presented as means ± SE. Statistical significance was always assessed using one-way 
repeated measures ANOVA followed by the Bonferroni test. A P value of less than 0.05 was 
considered significant. “n” refers to the number of separate independent experiments 
performed. In the case of blood cells, a different non-asthmatic donor was used for each 
experiment. 
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IV  RESULTS 
IV.1. Effects of Myeloid Cell Differentiation on 5h-dh Activity 
IV.1.1 Undifferentiated U-937 and HL-60 cells contain 5h-dh 
U-937 and HL-60 cells were treated with vehicle (0.1% DMSO) for 3 days. To determine 
whether they contain 5h-dh activity, cells (2.5×106/ml) were preincubated with 100 µM PMS 
for 6 min, followed by incubation with 5-HETE (4 µM) for a further 20 min period. Under 
these circumstances, excessive amounts of substrate were provided while PMS converted 
NADPH into the cofactor of 5h-dh NADP+ (Figure III.1), thus overcoming the limiting factors 
of the reaction. Preliminary experiments indicated that this concentration of PMS maximally 
stimulated 5-oxo-ETE production by these cells (see also Figure IV.10, page 57). The products 
were then analyzed by reverse-phase-HPLC using PGB2 as the internal standard. Under these 
conditions, undifferentiated vehicle-treated U-937 cells synthesized 319 pmol 5-oxo-ETE/106 
cells (Figure IV.1 A), whereas HL-60 cells synthesized 341 pmol/106 cells (Figure IV.1C). 
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Figure IV.1  Chromatographic analysis of 5-oxo-ETE synthesis by myeloid cell lines 
U-937 cells were treated with either vehicle (A, 0.1% DMSO) or 18 nM PMA (B) for 3 days. 
Similarly, HL-60 cells were treated with either vehicle (C) or 50 nM dh-VitD3 (D). Cells (2.5×106 in 
1 ml) were preincubated with 100 µM PMS, which reduces NADPH non-enzymatically to NADP+, 
for 6 min prior to incubation with 4 µM 5-HETE for 20 min. The reaction was then terminated by 
addition of ice-cold MeOH and the amounts of 5-oxo-ETE were analyzed by reversed-phase 
HPLC using 225 ng PGB2 as an internal standard as described in Material and Methods.  
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IV.1.2 Regulation of 5h-dh Activity Expression in U-937 cells 
Effects of Differentiating Agents on 5-oxo-ETE Synthesis by U-937 cells 
U-937 cells were cultured in the presence of either vehicle or a variety of differentiating 
agents, including PMA (18 nM), dh-VitD3 (50 nM), RA (300 nM), and DMSO (1.3%). The 
cells began to adhere to the surface of the wells after 24 h in the presence of PMA, and were 
completely adherent by day 2. However, none of the other agents tested induced adherence of 
U-937 cells under the conditions employed. Treatment of cells with vehicle alone for three days 
had no effect on their ability to produce 5-oxo-ETE from 5-HETE (Figure IV.2). In contrast, 
PMA induced a significant (P < 0.001) 3-fold increase in 5-oxo-ETE production, from 292 ± 
31 to 848 ± 100 pmol/106 cells (Figure IV.2). DMSO (P < 0.01) and dh-VitD3 (P < 0.05) 
induced smaller significant increases in 5-oxo-ETE synthesis of approximately 2-fold 
compared to the vehicle. RA tended to increase 5-oxo-ETE production, but this effect was not 
statistically significant. For comparison, 5-oxo-ETE synthesis was also assessed in freshly 
isolated blood monocytes and neutrophils under the identical incubation conditions used for 
U-937 cells. Undifferentiated U-937 cells produced slightly smaller amounts of 5-oxo-ETE 
than monocytes (388 ± 15 pmol/106 cells; NS) and neutrophils (358 ± 150 pmol/106 cells; NS), 
whereas PMA-differentiated U-937 cells produced significantly greater amounts. 
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Figure IV.2  Influence of differencing agents 
on 5h-dh activity in U-U937 cells. 
U-937 cells were cultured for 3 days in the 
presence 18 nM PMA, 50 nM dh-dh-VitD3 (VD), 
0.3 µM all-trans RA or 1.3% DMSO (Vec). The 
cells were harvested and resuspended in PBS+ 
as described in Material and Methods. 2.5×106 
cells were preincubated with 0.1 mM PMS prior 
to addition of 4 µM 5-HETE for 20 min. The 
amounts of 5-oxo-ETE produced by control 
U-937 cells at day 0 (Con), peripheral blood 
monocytes (Mono) and neutrophils (PMNL) are 
shown for comparison. All values are ± SE 
*, p ≤ 0.05; **, p ≤ 0.01; *** p ≤ 0.001 when 
compared to vehicle treated cells (n ≥ 4). 
Time Course of PMA Induction of 5-oxo-ETE Synthesis in U-937 cells 
As PMA induced the greatest increase in 5-oxo-ETE synthesis, we performed a time course 
for this response. A significant effect on 5-oxo-ETE synthesis was observed within two days, 
when the rate of production was double that of control vehicle-treated cells (P < 0.05, Figure 
IV.3A). The response to PMA reached a plateau within three to four days, at which time 
5-oxo-ETE was synthesized at about three times the rate of vehicle-treated cells.  
Effect of PMA Treatment on Specific 5h-dh Activity in Microsomes 
To assess 5h-dh activity in U-937 cells more directly we examined the conversion of 
5-HETE to 5-oxo-ETE by microsomal fractions. Microsomes (50 µg protein/ml) from cells 
treated for four days with either PMA or vehicle were incubated with different concentrations 
of 5-HETE in the presence of NADP+ (0.1 mM). The amounts of 5-oxo-ETE formed were then 
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determined by HPLC. Lineweaver-Burk analysis was used to determine the KM and Vmax for 
this reaction. Microsomes from untreated and PMA differentiated cells had similar KM values 
of 568 ± 172 nM and 670 ± 182 nM, respectively. PMA treatment resulted in a significant 
increase in the Vmax (Figure IV.3 B) from 401 ± 117 to 1289 ± 192 pmol 5-oxo/(min×mg 
protein) (P < 0.001). Table IV.1 shows a comparison of the KM and Vmax values for microsomal 
5h-dh activity in U-937 cells and peripheral blood neutrophils. The binding affinity of U-937 
cell derived 5h-dh tended to be higher than that of neutrophilic 5h-dh (399 ± 137 nM), but the 
differences were not statistically significant. The Vmax of neutrophil derived 5h-dh was between 
that of undifferentiated and PMA-treated U-937 cells (540 ± 295 pmol 5-oxo/(min×mg 
protein)). 
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Figure IV.3  Effect of PMA on 5h-dh activity in U-937 cells. 
A, U937 cells were treated with either vehicle (Control; ○) or 18 nM PMA (●) for up to four 
days. At the indicated times the cells were harvested and 5-oxo-ETE formation was 
determined as described in the legend to Figure IV.1. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 
when compared to corresponding vehicle treated cells (n ≥ 4;). B, Lineweaver-Burk Plot. 
Microsomal fractions obtained from either vehicle-treated (○), or cells differentiated with PMA 
(18 nM) over 4 days (●), were incubated with 0.1 mM NADP+ and various amounts of 
5 -HETE (0.2 − 6 µM) in PBS. After 5 min the reactions were terminated by addition of an 
equal volume of ice-cold MeOH and the samples were analyzed as described in III.5, page 45. 
Table IV.1  Lineweaver-Burk analysis of 5h-dh in neutrophils and U-937 cells 
Microsomes (50 µg protein/ml) derived from neutrophils and U-937 cell treated either with vehicle 
or PMA for 4 days were incubated with increasing amounts of 5-HETE and 100 µM NADP+ for 
5 min. The KM and the Vmax for 5-oxo-ETE formation were then analyzed by linear regression as 
shown in Figure IV.3 B. The calculated values for Vmax and KM are shown ± SE with the number of 
experiments in parentheses. The amounts of microsomal protein per cell is shown as well. * Vmax 
is significantly (P<0.01) higher in PMA treated U-937 cells than in vehicle control (n).  
 KM      Vmax Microsomal Protein
 (nM) ⎟⎟⎠
⎞
⎜⎜⎝
⎛
× protein mg min 
pmol (µg / 10 cells)6 
U-937 ctrl 568 ± 172 401 ± 117   (5) 37.6 ± 15.8   (4) 
U-937 PMA 670 ± 182 1289 ± 192** (5) 33.9 ±   8.4   (4) 
Neutrophils 399 ± 137 540 ± 295   (4) 7.0 ±   0.9   (5) 
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IV.1.3 Examination of 5h-dh in HL-60 cells 
Effects of Differentiating Agents on the Synthesis of 5-oxo-ETE by HL-60 cells 
The effects of treatment of HL-60 cells with the above differentiating agents for 3 days on 
5-oxo-ETE synthesis were investigated after 3 days. The vehicle alone (0.1% DMSO) had no 
effect on 5-oxo-ETE synthesis by HL-60 cells, which was similar to that observed for both 
monocytes and neutrophils (Figure IV.4). The only agent that significantly stimulated 5-oxo-
ETE synthesis by HL-60 cells was dh-VitD3, which significantly increased the amount of this 
eicosanoid from 345 ± 50 to 715 ± 226 pmol 5-oxo/106 cells (P < 0.001). PMA had a modest 
effect on 5-oxo-ETE synthesis by these cells, but this was not statistically significant (532 ± 73 
pmol 5-oxo/106 cells; NS). Neither RA nor DMSO had any effect. In contrast to U-937 cells, 
PMA did not induce adherence of HL-60 cells, but did result in the death of 20-50% of the cells 
within four days and inhibited cell proliferation within one day. 
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Figure IV.4  Influence of differencing 
agents on 5h-dh activity in HL-60 cells. 
HL-60 cells were cultured for 3 days in the 
presence of vehicle (0.1% DMSO), 18 nM 
PMA, 50 nM dh-dh-VitD3 (VD), 0.3 µM all-
trans RA, or 1.3% DMSO. The cells were 
harvested and resuspended in PBS+ as 
described in Material and Methods. 2.5×106 
cells were preincubated with 0.1 mM PMS 
prior to addition of 4 µM 5-HETE for 20 min. 
The amounts of 5-oxo-ETE produced by 
control HL-60 cells at day 0 (Con), 
peripheral blood monocytes, and neutrophils 
are shown for comparison. ***, P ≤ 0.001 
when compared to vehicle treated cells 
(n ≥ 4). 
 
Previous studies [208,224] showed that maximal neutrophilic differentiation of HL-60 cells 
with DMSO is reached after extended culture for up to 7 days. In our hands 1.3% DMSO 
induced considerable loss of viability when cells were cultured in 10% FBS. Over 40% were 
dead by day 4 as determined by their ability to exclude trypan blue. To investigate the potential 
effect of DMSO over longer periods, we grew HL-60 cells in 20% FBS in the presence or 
absence of 1.3% DMSO for up to 6 days [208,224]. After this period, control cells and DMSO-
treated cells produced 363 ± 55 and 321 ± 25 pmol 5-oxo-ETE/106 cells, respectively (n=3; 
NS). 
Time Course for Induction of 5-oxo-ETE Synthesis in HL-60 Cells by dh-VitD3. 
HL-60 cells were cultured in the presence of vehicle or dh-VitD3 for various times. There 
were no changes in 5-oxo-ETE synthesis by vehicle-treated cells over a period of four days. In 
contrast, dh-VitD3 significantly increased the ability of these cells to synthesize 5-oxo-ETE by 
day two (P < 0.05) (Figure IV.5). Maximal rates of 5-oxo-ETE production were observed after 
three days of treatment with PMA (P < 0.01).  
RESULTS   50 
Time (days)
0 1 2 3 4
5-
ox
o-
ET
E 
(p
m
ol
/1
06
 c
el
ls
)
300
400
500
600
700
dhVitD3
Control
HL-60 cells
**
**
*
 
Figure IV.5  Time course of 5h-dh activity 
after dh-VitD3 differentiation. 
HL-60 cells were treated with 50 nM dh-VitD3 
(●) or vehicle (○) for up to four days. At the 
indicated times the cells were harvested as 
described in material and methods. The cells 
were then incubated with PMS and 5-HETE and 
the amount of 5-oxo-ETE produced was 
analyzed as described above. *, P ≤ 0.05; 
**, P ≤ 0.01 when compared to the 
corresponding vehicle treatment (n ≥ 3). 
 
IV.1.4 Interconversion of 5-HETE and 5-oxo-ETE by U-937 Cells 
Both, neutrophils and platelets have been shown to convert 5-oxo-ETE and to 5-HETE, 
potentially due to the activity of 5h-dh, although a distinct keto-reductase has not been 
excluded [22,70]. We wanted to determine whether the forward (5-HETE ? 5-oxo-ETE) or the 
backward (5-oxo-ETE ? 5-HETE) reaction is favored in unstimulated U-937 cells. We 
incubated 2×106 U-937 cells with 1 µM 5-HETE or 5-oxo-ETE for various times and measured 
the product formation by HPLC. In this case PMS was not added, so that there would be a large 
excess of cytosolic NADPH over NADP+, thus favoring the reverse reaction. Figure IV.6 A 
shows the amounts of 5-oxo-ETE and 5-HETE being formed under these conditions. Although 
the rate of the backward reaction was higher at 3, 6, and 12 min, there was no significant 
difference in the forward and backward reactions. At 12 min, 24 ± 6 pmol 5-HETE /106 cells 
and 19 ± 1 pmol 5-oxo-ETE/106 cells were formed. 
We then examined the interconversion of 5-HETE and 5-oxo-ETE more directly. We 
incubated microsomes from undifferentiated U-937 cells with either 5-oxo-ETE or 5-HETE 
and the corresponding cofactor (NADPH or NADP+, respectively) for 15 min in 50 mM MES, 
50 mM HEPSSO, or 50 mM CAPS (Figure IV.6). The pH ranged from pH 4 - 11.4. For the pH 
values at which the buffer was changed, separate measurements were made using each of the 
two buffers. The forward and reverse reactions followed distinct pH dependencies. The pH 
maximum of the forward reaction was pH 10 (322 pmol 5-oxo-ETE/(min×mg)) and that of the 
backward reaction was pH 6 (P = 100 pmol 5-HETE/(min×mg)). The conversion rates of the 
forward and reverse reactions intercepted between pH 6 and 6.8. At the physiological pH 
of 7.45, the rate of the forward reaction of microsomal 5h-dh is double the rate of the reverse 
reaction. Both, the forward and the reverse reaction of microsomal 5h-dh are inactivated at 
extreme pHs (pH ≤ 4.0 and pH ≥ 11.4). NADP+ alone was not capable of oxidize 5-HETE in 
the absence of microsomes at pH 4, pH 6, pH 7.4, and pH 10. 
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Figure IV.6  Interconversion of 5-oxo-ETE and 5-HETE by U-937 cells 
A shows the time course for the formation of 5-oxo-ETE from 1 µM 5-HETE (•), and of 5-HETE 
from 1 µM 5-oxo-ETE (∆) following incubation of 2×106 U-937 cells in PBS+ (n=4).  
B shows the pH-dependence of microsomal 5h-dh for the forward and the reverse reaction. 
100 µg protein were incubated in 50 mM MES (▲,∆), HEPSSO (•,○), or CAPS (■,□) for 15 min 
with either 1 µM 5-HETE and 100 µM NADP+ (filled symbol) or 1 µM 5-oxo-ETE and 100 µM 
NADPH (open symbols). The results are representative of three such experiments. 
IV.1.5 Metabolism of 5-oxo-ETE, 5-HETE, and AA by esterification 
We detected a significant loss of 5-oxo-ETE and 5-HETE when they were incubated with 
U-937 cells. We originally hypothesized that 5-oxo-ETE is converted by LTC4-S to FOG7 or by 
another GST to its stereoisomer [91,225], because U-937 cells contain significant amounts of 
LTC4-S [201] and have been previously utilized to purify this enzyme [226]. Since FOG7 does 
not have a UV chromophore, we conducted experiments with radioactively labeled 5-oxo-ETE. 
However, initial experiments with radiolabeled 5-oxo-ETE using HPLC protocols, which were 
optimized to analyze glutathionylated LTs, showed no product peaks other than 5-oxo-ETE or 
5-HETE (data not shown). 
The absence of radioactive product peaks in the chromatograms sparked a series of 
experiments to investigate whether 5-oxo-ETE and 5-HETE are esterified to lipids by a CoA-
dependent pathway, as the products would not have been detected under the condition we used. 
Figure IV.7 shows the time course for the recovery of 5-HETE, 5-oxo-ETE, LTB4 and AA 
following incubation with U-937 cells. The recoveries of 5-HETE and 5-oxo-ETE were 
measured as the sum of both eicosanoids, due to the fact they are interconverted by these cells 
(see Figure IV.6). Recovery of 14C-AA was measured was analyzed by isocratic RP-HPLC. 
Radioactivity in the fractions collected every minute was detected with a β counter. The 
recovery of AA and the eicosanoids tested were adjusted to the amounts recovered from cell-
free incubations (20 min).  
Under our conditions the rate of 5-oxo-ETE loss was significantly larger than the rate of 
5-HETE (Figure IV.7) (P < 0.005 at 5 min) suggesting that the underlying mechanism prefers 
5-oxo-ETE as a substrate over 5-HETE. Although AA had the tendency to be lost more rapidly 
than 5-oxo-ETE, further experiments are needed to gain statistical significance. In contrast, 
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LTB4 was not metabolized in a similar manner. At no time we detected a significant decrease in 
the amount of LTB4 compared to cell free incubations.  
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Figure IV.7  Recovery of LTB4, 5-oxo-ETE, and 5-HETE from U-937 cells. 
A 2×106 U-937 cells were incubated with 1 µM 5-HETE (•,n=4), 5-oxo-ETE (▲,n=4), LTB4 
(∇,n=4), or AA (?,n=2) for the indicated times. The sum of 5-oxo-ETE and 5-HETE recovered is 
expressed as the percentage of the original eicosanoid added to buffer in the absence of cells 
(n=4). LTB4 and AA are expressed as the amounts of fatty acid recoverd from buffer alone. See 
Material and Methods for more details. §, P < 0.05; §§§, P < 0.001 when compared to recovery of 
5-oxo-ETE. B U-937 cells were treated for 30 min in the absence (ctrl), in the presence of vehicle 
(DMSO) or Triacsin C (20 µM) prior to addition of substrate. Arachidonic acid (AA, 40 µM) was 
added at the same time as the substrate: 5-oxo-ETE (1 µM, open bars, n=4), 5-HETE (1µM, solid 
bars, n=4) or AA (1 µM, striped gray bars, n=2). The incubations were terminated 20 min after 
substrate addition and the recovery was determined as described above (n=4). §, P < 0.05; §§§, P 
< 0.001 when compared to recovery of 5-oxo-ETE; *, P < 0.05; **, P < 0.001 compared to vehicle 
treated (DMSO) cells. 
Based on the above results we hypothesized that 5-HETE and 5-oxo-ETE are taken up by 
the cells, bound to Coenzyme A (CoA), and then esterified into either phospholipids or 
triglycerides, as described for 5-HETE in human neutrophils [59]. To test this hypothesis, we 
attempted to block the uptake of 5-oxo-ETE and 5-HETE by preincubation of the cells for 30 
min with triacsin C, an inhibitor of nonspecific long chain acyl-CoA synthetases and preference 
for arachidonyl-CoA synthetase in vitro [101]. Triacsin C increased the recovery of 5-HETE 
from 48 ± 4% (vehicle treated cells) to 93 ± 5% and that of 5-oxo-ETE from 23 ± 5% to 88 ± 
4% (n=4, P < 0.001) after incubation with U-937 cells for 20 min (Figure IV.7). To further 
substantiate the potential involvement of lipid esterification in the loss of 5-HETE and 
5-oxo-ETE we also attempted to block this process by addition of 40µM AA, which should 
saturate the acylation process. Similar to triacsin C, the addition of AA increased the amount of 
5-HETE recovered to 93 ± 5% and that of 5-oxo-ETE to 92 ± 6% (n=4, P < 0.001). Analogous 
results were obtained when AA was replaced by DHA, a 22 carbon ω3-PUFA. The addition of 
DHA raised the recovery of 5-HETE and 5-oxo-ETE to 102 ± 4% and 95 ± 4%, respectively 
(n=2). We show here vehicle and untreated control, because initial experiments indicated that 
DMSO treatment may enhance the recovery of 5-oxo-ETE. However, these differences were 
not statistically significant.  
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Preliminary studies were undertaken to compare the recovery of AA with that of 5-oxo-ETE 
or 5-HETE. AA appears to be taken up more rapidly than 5-oxo-ETE (Figure IV.7A), but more 
experiments are needed in order to perform statistical analysis. To determine whether AA is 
metabolized in a similar manner as 5-HETE or 5-oxo-ETE, U-937 cells were pretreated with 
triacsin C or co-incubated with successive amounts of unlabeled AA. As shown in Figure 
IV.7B, the treatment with triacsin C and AA had similar effects, enhancing the recovery of AA 
from 11 ± 1% in vehicle treated cells to 39 ± 4% and 52 ± 2%, respectively. 
IV.1.6 5-LO and ω-Oxidation Activity in U-937 and HL-60 cells 
5-oxo-ETE and 5-HETE are not Converted by ω-Oxidation in U-937 and HL-60 cells 
Neutrophils convert 5-HETE [72] and 5-oxo-ETE [34] to their 20-hydroxy metabolites via 
LTB4 20-hydroxylase using NADPH as cofactor and it is not know whether U-937 express 
CYP4F3 or CYP4F2 (see also page 24). As PMS inhibits this enzyme [74], it could potentially 
have masked 20-hydroxylase activity in the present studies. However, we were unable to detect 
any ω-oxidation products following incubation of 5-HETE or 5-oxo-ETE with either intact U-
937 or HL-60 cells in the absence of PMS. Differentiation of U-937 cells with PMA did not 
lead to detectable ω-oxidation of 5-HETE or 5-oxo-ETE. Similarly, differentiation of HL-60 
cells with dh-VitD3 for 3 days or with DMSO for up to 6 days did not lead to the formation of 
detectable ω-oxidation products. Under similar conditions, human peripheral blood neutrophils 
(2×106 PMNL/ml) converted 1 µM 5-HETE within 5 min to 72 ± 6 nM 5,20-diHETE (Figure 
IV.12, page 59).  
U-937 and HL-60 Cells do not contain detectable5-LO Activity 
To investigate whether these cell lines are capable of forming 5-oxo-ETE from exogenous 
AA, we incubated 5×106 HL-60 or U-937 cells with 20 µM AA, 5 mM Ca++ ionophor A23187 
and 30 nM PMA for 20 min and looked for potential 5-LO products (LTB4, 5-HETE, and 
5-oxo-ETE). In our hands, HL-60 and U-937 cells did not have detectable levels of 5-LO 
activity when cultured under standard conditions (10% FBS in RPMI 1640), in agreement with 
a previous report [227]. Neither were we able to detect any 5-LO products in U-937 cells 
differentiated with PMA, or in HL-60 cells treated with dh-VitD3 or DMSO for 3 days. We also 
examined AA metabolism in HL-60 cells differentiated for five or six days in RPMI 1640 with 
20% FBS and 1.3% DMSO. Again, 5-LO products were below the detection limit of our 
system. In comparison, human PMNL (2×106 cells/ml) regularly produced large amounts of 
5-LO products (defined as the sum of LTB4, LTA4 hydrolysis products, 5-HETE, 
5,15-diHETE, 5-oxo-ETE, and the corresponding ω-oxidation products) in the µM-range when 
stimulated under the same conditions. 
 
 
 
For every complex problem, there is a solution that is simple, neat, and wrong.  
H. L. Mencken 
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IV.2. Regulation of 5-oxo-ETE Synthesis by Oxidative Stress 
IV.2.1 Oxidative Stress Enhances the Synthesis of 5-Oxo-ETE 
H2O2 enhances Formation of 5-oxo-ETE from 5-HETE in U-937 Cells 
As U-937 cells possess high 5h-dh activity, they were used as a model to investigate the 
effects of oxidative stress induced on 5-oxo-ETE synthesis. Oxidative stress was induced by 
treatment with either H2O2, tBuOOH, or 13-HpODE. Following incubation of these cells with 
5-HETE (1 µM) in the presence or absence of H2O2 (100 µM), the amounts of 5-oxo-ETE were 
measured by HPLC using 13-HODE as an internal standard. In the absence of H2O2 very little 
5-oxo-ETE was detected (Figure IV.8 A), whereas large amount were formed in its presence 
(Figure IV.8 B). 
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Figure IV.8  Hydrogen peroxide stimulates the formation of 5-oxo-ETE from 5-HETE. 
Chromatograms of the products formed during incubation of U-937 cells (2 x 106 cells/ml) with 5-
HETE (1 µM) for 5 min in the presence of either vehicle (A) or H2O2 (B). Precolumn 
extraction/RP-HPLC was performed as described in Materials and Methods. Abbreviations: 13h, 
13-HODE (internal standard); 5h, 5-HETE; 5o, 5-oxo-ETE. 
Time Course of H2O2 and tBuOOH induced 5-oxo-ETE Synthesis 
The time courses for the effects of H2O2 (100 µM) and tBuOOH (100 µM) on 5-oxo-ETE 
formation are shown in Figure IV.9 A. Both hydroperoxides strongly stimulated 5-oxo-ETE 
synthesis to a similar extent over the first 5 min. However, the amount of 5-oxo-ETE formed in 
the presence of H2O2 subsequently declined, whereas it continued to increase in the presence of 
tBuOOH and reached maximal levels within 10 to 15 min. To determine whether this transient 
effect of H2O2 could be due to its metabolism, incubations were performed in the presence of 
sodium azide, which inhibits both catalase and myeloperoxidase [117], two key enzymes 
involved in H2O2 metabolism. Azide did not significantly alter the response to H2O2 during the 
first 5 min, but thereafter strongly enhanced its effect on 5-oxo-ETE synthesis (Figure IV.9 A). 
Due to the short-lived effect of H2O2, all subsequent incubations with 5-HETE were performed 
for a period of 5 min. No detectable oxidation of 5-HETE occurred when it was incubated with 
H2O2 or tBuOOH in the absence of cells (data not shown). 
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Table IV.2. Effects of various agents on microsomal 5h-dh activity. 
The right column shows the effects of various agents on 5h-dh activity in microsomal fractions 
(150 µg protein/ml) from U-937 cells, following incubation with 5-HETE (1 µM) and NADP+ (100 
µM) for 5 min. The concentrations and preincubation times shown in the left column were used for 
incubations with both microsomes and intact cells. The amounts of 5-oxo-ETE are expressed as 
percentages of control values (811± 115 pmol/mg protein) and are the average ± SE of three 
separate experiments. None of the agents significantly affected 5h-dh activity. 
Compound Action
5-oxo-ETE  
(% Control) 
3-AT (5 mM, 30 min) Inhibits catalase [228] 106.6 ± 7.9 
Auranofin (10 µM, 30 min) Inhibits thioredoxin reductase [135] §§ 
Azide (1 mM, 30 min) Inhibits heme enzymes (myeloperoxidase, catalase) [117] 110.5 ± 6.3 
BCNU (100 µM, 30 min) Inhibits glutathione and thioredoxin reductases [86] 106.8 ± 4.7 
BSO (1 mM, 24 h) Inhibits γ-glutamylcysteine synthetase (depletes GSH) [229]   § 
DHEA (100 µM, 30 min) Inhibits Gluc-6-P dehydrogenase (Blocks PPP) [137] 114.5 ± 0.2 
Diamide (250 µM) Converts GSH ? GSSG [230] 84.8 ± 8.6 
DMSO (1%, 30 min) Vehicle 110.3 ± 5.1 
Glucose (1 mg/ml, 30 min) Gluc ? Gluc-6-P ? PPP 103.9 ± 7.9 
H2O2 (100 µM) Induces oxidative stress 93.2 ± 1.5 
NEM (100 µM, 10 min) Alkylates SH groups [231] 92.4 ± 12.1 
PMA (30 nM, 6 min) Stimulates PKC & the respiratory burst [232] 102.1 ± 1.1 
PMS (100 µM, 6 min) Converts NADPH ? NADP+ [75] 88.2 ± 3.1 
tBuOOH (100 µM) Induces oxidative stress 84.9 ± 5.1 
§  Did not affect PMS-stimulated 5-oxo-ETE synthesis in U-937 cells. 
§§  Did not affect H2O2-stimulated 5-oxo-ETE synthesis in U-937 cells. 
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Figure IV.9  Hydroperoxides stimulate the formation of 5-oxo-ETE from 5-HETE. 
A: Time courses for the formation of 5-oxo-ETE following incubation of 1 µM 5-HETE with U-937 
cells in the presence of vehicle (Control; ▲; n = 4), 100 µM H2O2 (•; n = 7), 100 µM H2O2 and 1 
mM sodium azide (H2O2 /Az; ○; n =3), and 100 µM tBuOOH (∇; n = 4). ***, P < 0.001 when 
compared to H2O2 without azide. B: Concentration-response curves for the effects of H2O2 (•; n = 
5), tBuOOH (tBu; ∇; n = 3), 13-HpODE (13hp; ∆; n = 3), and PMA (▼; n = 3) on the formation of 
5-oxo-ETE following incubation of U-937 cells with 1 µM 5-HETE  for 5 min. 5-Oxo-ETE was 
measured as shown in Figure IV.8A. All values are means ± SE. 
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The effects of various concentrations of different hydroperoxides on 5-oxo-ETE formation 
by U-937 cells are shown in Figure IV.9B. tBuOOH (EC50, 3.5 ± 0.9 µM) is the most potent 
stimulator of 5-oxo-ETE formation, followed by H2O2 (EC50, 12.1 ± 2.6 µM). Both 
hydroperoxides elicited an approximately 7.5-fold increase in 5-oxo-ETE synthesis when 
compared to controls. The linoleic acid metabolite 13-HpODE also stimulated 5-oxo-ETE 
formation, but was somewhat less potent. Because of the limited availability of this substance, 
we were unable to determine the maximal response. In contrast to hydroperoxides, PMA, which 
is a potent stimulator of 5-oxo-ETE formation by neutrophils [74], had no detectable effect on 
its formation by U-937 cells after 5 min (Figure IV.9B). 
IV.2.2 The GSH Redox Cycle Mediates the Effect of Oxidant Stress on 5-Oxo-
ETE Formation 
An important means of cellular inactivation of hydroperoxides is their GSH-dependent 
reduction by glutathione peroxidase, followed by the reduction of the resulting GSSG back to 
GSH by glutathione reductase, which is accompanied by the formation of NADP+ (for 
overview see Figure V.1, page 76). To determine whether the stimulatory effect of 
hydroperoxides on 5-oxo-ETE formation could be mediated by the glutathione redox cycle, we 
tested the effects of various reagents that affect this cycle. 
The glutathione reductase inhibitor BCNU (carmustine) [233] completely blocked the 
stimulatory effect of H2O2 on 5-oxo-ETE formation (Figure IV.10A) and had a similar effect 
on the response to tBuOOH (data not shown). For comparison, baseline conversion of 5-HETE 
to 5-oxo-ETE (± SE) in the absence of H2O2 or inhibitors is shown by the horizontal lines in 
Figure IV.10A. The effect of BCNU (30 µM) on the concentration-response to H2O2 is shown 
in Figure IV.10B. In contrast to its strong inhibitory effect on H2O2-induced 5-oxo-ETE 
formation, BCNU had little effect on the response to PMS (Figure IV.10B, inset), which acts 
by a different mechanism as it non-enzymatically converts intracellular NADPH to NADP+ 
[76]. Nor did it affect the synthesis of 5-oxo-ETE by microsomal fractions from U-937 cells 
(Table IV.2). BCNU also inhibits thioredoxin reductase [233], which could also potentially 
explain its inhibitory effect on the response to H2O2. To determine whether thioredoxin redox 
cycling is involved in this response we investigated the effects of the thioredoxin reductase 
inhibitor auranofin on H2O2-induced 5-oxo-ETE formation. Auranofin, which is a very potent 
inhibitor of this enzyme (IC50, 4 nM) [135], had no effect on the formation of 5-oxo-ETE in 
response to H2O2 at concentrations as high as 10 µM (Table IV.3). This inhibitor was also 
without effect on PMS-induced 5-oxo-ETE formation.  
To provide further evidence for the role of GSH in response to H2O2 we used two 
approaches to deplete cellular GSH. NEM, which is an extremely efficient alkylator of SH 
groups, thus preventing the formation of GSSG, completely suppressed H2O2-induced 
5-oxo-ETE synthesis to levels below baseline (Figure IV.10A). Similar to BCNU, NEM did not 
have a direct effect on 5h-dh (Table IV.2). The response to H2O2 was also inhibited by about 
50% following culture of U-937 cells for 24 h in the presence of BSO (Figure IV.10C), which 
depletes cells of GSH by inhibiting γ-glutamylcysteine synthetase [229]. In contrast, BSO had 
no effect on the stimulatory effect of PMS on 5-oxo-ETE formation. 
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Figure IV.10  The effects of H2O2 on 5-oxo-ETE formation are blocked by inhibitors of the 
GSH redox cycle and stimulated by oxidation of GSH. 
A: Effects of different concentrations of BCNU (○; n = 4) and NEM (▲; n = 4) on the amount of 5-
oxo-ETE formed during incubation of 5-HETE (1 µM) with U-937 cells in the presence of H2O2 
(100 µM) for 5 min. The solid and dashed horizontal lines indicate the amount ± SE of 5-oxo-ETE 
formed from 5-HETE in the absence of H2O2 or any other agents. B: Concentration-response 
curves for effects of H2O2 on 5-oxo-ETE formation in the presence of either BCNU (○; 30 µM; n = 
3) or vehicle (●; Con; n = 3). The inset shows the concentration-response curves for effects of 
PMS on 5-oxo-ETE formation in the presence of either BCNU (○; 30 µM; n = 3) or vehicle (●; n = 
3). C: Effects on 5-oxo-ETE synthesis of depletion of GSH in U-937 cells by treatment with 
vehicle (open bars) or BSO (filled bars) for 24 h (n = 3). All values are means ± SE. ***, P < 0.001 
when compared to pretreatment with vehicle followed by H2O2. D: Effect of diamide on 5-oxo-ETE 
formation. U-937 cells (2 x 106 cell/ml) were incubated for 5 min with 5-HETE (1 µM) in the 
presence or absence of different concentrations of diamide. The inset shows the time courses for 
the formation of 5-oxo-ETE in the presence (DA; ●) or absence (Con; ○) of diamide (250 µM). All 
values are means ± SE of 4 separate experiments. 
We also examined the effects of diamide, which acts by non-enzymatically oxidizing 
intracellular GSH to GSSG [230] (Figure IV.10 D). Diamide (EC50, 15.5 ± 2.5 µM) strongly 
stimulated the formation of 5-oxo-ETE to an extent similar to that observed with H2O2. The 
time course for 5-oxo-ETE synthesis in the presence of diamide, shown in the inset to Figure 
IV.10D, is very similar to that observed with tBuOOH (Figure IV.9 B), except that the response 
appears to be somewhat more sustainable. In contrast, diamide had no effect on the conversion 
of 5-HETE to 5-oxo-ETE by U-937 cell microsomes (Table IV.2). 
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Table IV.3  Effects of inhibition of thioredoxin reductase on 5-oxo-ETE formation by U-937 
cells. 
U-937 cells (2 x 106 cell/ml) were preincubated with auranofin for 30 min at 37oC followed by 
incubated for a further 5 min with 5-HETE (1 µM) and H2O2 (100 µM). The products were 
analyzed by precolumn extraction/HPLC as described in Materials and Methods. The results are 
means ± SE (n = 3). 
5-Oxo-ETE (pmol/ml) 
Treatment 
Control H2O2 PMS 
Vehicle 23 ± 2 142 ±  9 137 ± 21 
Auranofin (1 µM) 21 ± 1 152 ± 11 140 ± 12 
Auranofin (10 µM) 20 ± 3 133 ±  6 137 ± 10 
IV.2.3 Activation of the Pentose Phosphate Pathway Inhibits 5-Oxo-ETE 
Formation 
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Figure IV.11  Glucose inhibits H2O2 induced 5-oxo-ETE formation through the PPP. 
A: U-937 cells were incubated with 5-HETE (1 µM) and H2O2 (100 µM) for 5 min in PBS+ 
containing different concentrations of either glucose (●) or galactose (○). The values are 
expressed as percentages of the amounts of 5-oxo-ETE formed in control incubations (183 ± 14 
pmol/ml) in the absence of any added hexose and are means ± SE of data from 5 separate 
experiments. B: Reversal of the inhibitory effect of glucose by the glucose 6-phosphate 
dehydrogenase inhibitor DHEA. U-937 cells were preincubated with different concentrations of 
DHEA in PBS+ in the presence (●) or absence (○) of glucose (5.6 mM) for 30 min, followed by 
incubation for a further 5 min with H2O2 (100 µM) and 5-HETE (1 µM) (n = 3). *, P < 0.05; **, P < 
0.01 when compared to vehicle in the presence of glucose. 
The PPP is the major mechanism whereby cells maintain a high ratio of NADPH to NADP+. 
To determine whether this pathway could affect the formation of 5-oxo-ETE by reducing 
NADP+ to NADPH (see Figure V.1, page 76) we investigated the effects of glucose, which is 
metabolized by the PPP following its phosphorylation to glucose 6-phosphate, compared to 
other hexose sugars such as galactose, which are not a substrate for this pathway. Glucose 
(IC50, 0.42 ± 0.08 mM) strongly inhibited the formation of 5-oxo-ETE in the presence of H2O2 
whereas galactose had no effect (Figure IV.11A). To substantiate the role of the PPP in the 
inhibitory effect of glucose, we examined the effect of DHEA, which is an inhibitor of glucose 
6-phosphate dehydrogenase, the initial enzyme in this pathway [137]. The inhibitory effect of 
5.6 mM glucose on H2O2-induced 5-oxo-ETE formation was almost completely reversed by 
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DHEA (EC50, 68 ± 16 µM) (Figure IV.11B). In contrast, DHEA had no effect on H2O2-induced 
5-oxo-ETE synthesis by U-937 cells in glucose-free medium (Figure IV.11B) and did not affect 
oxidation of 5-HETE in the presence of microsomal fractions from these cells (Table IV.2). 
IV.2.4 Effects of Oxidative Stress on 5-oxo-ETE Synthesis by Peripheral 
Leukocytes 
To determine whether 5-oxo-ETE synthesis by peripheral leukocytes can also be regulated 
by oxidative stress, we investigated the effects of increasing concentrations of H2O2 on its 
formation by lymphocytes, monocytes, and neutrophils under conditions similar to those 
employed with U-937 cells. Although baseline synthesis of 5-oxo-ETE by all three types of 
cells was similar (~15 pmol/ml; Figure IV.12), there were considerable differences in the 
responses of these cells to H2O2. Lymphocytes strongly responded to concentrations of H2O2 as 
low as 1 µM (EC50, 4.1 ± 0.9 µM). H2O2 also strongly stimulated 5-oxo-ETE formation by 
monocytes, but was somewhat less potent (EC50, 28.8 ± 6.9 µM). The maximal response to 
H2O2 was slightly greater for monocytes than for lymphocytes (142 ± 18 vs 108 ± 8 pmol 5-
oxo-ETE/ml; P <0.05). 
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Figure IV.12   Effects of H2O2 on 5-oxo-ETE 
synthesis by leukocytes. 
5-HETE (1 µM) was incubated for 5 min with 
suspensions (2 x 106 cells/ml) of lymphocytes 
(○; Lymph; n = 7), monocytes (●; Mono; n = 5), 
or neutrophils (▲, D; Neutr; n = 6), prepared 
from whole blood as described in Materials and 
Methods, in the presence or absence of 
different concentrations of H2O2. The amounts 
of 5-oxo-ETE (5o, ▲, ○, ●) and, in the case of 
neutrophils, 5,20-diHETE (5,20dh; D) were 
measured by HPLC. All values are means ± 
SE. The effect of H2O2 on 5-oxo-ETE formation 
was statistically significant at all concentrations 
tested for lymphocytes (P < 0.001), at 10 µM  
(P < 0.05) and higher (P < 0.001) for 
monocytes, and only at a concentration of 316 
µM (P < 0.01) for neutrophils. 
 
In contrast to monocytes and lymphocytes, H2O2 had only a very modest effect on 
neutrophils, increasing 5-oxo-ETE synthesis from 16 ± 4 pmol/ml in untreated cells to a 
maximum of 34 ± 8 pmol/ml in cells treated with 316 µM H2O2 (P < 0.01) (Figure IV.12). 
Moreover, the dose response curves for the effect of H2O2 on neutrophils from individual 
donors were rather variable (EC50, 201 ± 90 µM). To determine whether the relative 
unresponsiveness of these cells to H2O2 was due to its rapid metabolism by catalase or 
myeloperoxidase (Figure V.1, page 76), incubations were performed in the presence of either 3-
AT (5 mM), which inhibits catalase, or azide (1 mM), which inhibits both enzymes. However, 
neither of these agents, either alone or in combination, significantly affected the response of 
neutrophils to H2O2 (data not shown). Because they possess high levels of the NADPH-
dependent enzyme LTB4 20-hydroxylase, neutrophils also convert 5-HETE to 5,20-diHETE 
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[72], and this was the major product under the conditions of our assays, amounting to ~70 
pmol/ml (Figure IV.12). However, the formation of this substance was not affected by H2O2. 
Furthermore the amount of 5,20-diHETE formed was not sufficient to deplete the substrate, 
because under the conditions we used (low cell concentration and short incubation time) only a 
relatively small proportion (≤ 15%) of the 5-HETE was metabolized. Powell and colleagues 
had previously showen that 5,20-diHETE could be further metabolized by neutrophils (after a 
lag period) to 5-oxo-20-HETE [74], but little or none of this product was detected in the present 
study because of the relatively short 5-min incubation time employed. 
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Figure IV.13  Regulation of 5-oxo-ETE synthesis by blood cells. 
Neutrophils (A), monocytes (B), lymphocytes (C), platelets (D), and U-937 cells (E) were 
incubated for 5 min with 5-HETE (1 µM) in the presence of vehicle (Veh), H2O2 (100 µM), 
tBuOOH (tBu; 100 µM), diamide (DA; 250 µM), PMA (100 nM), or PMS (1 mM for leukocytes and 
platelets; 100 µM for U-937 cells) in either glucose-free PBS+ (solid bars) or PBS+ containing 5.6 
mM glucose (open bars). The cell concentrations were 2 x 106/ml for leukocytes and 108/ml for 
platelets. The values are means ± SE of data from 6 separate experiments, except for platelets (n 
= 4). *, P< 0.05; **, P < 0.01; ***, P < 0.001 when compared to vehicle (in the absence of glucose. 
§, P < 0.05; §§, P < 0.01 when compared to the corresponding treatment in the absence of 
glucose. 
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IV.2.5 Cell specific regulation of 5-oxo-ETE Formation by Blood Cells 
Powell and co-workers showed previously that PMA strongly stimulates the formation of 5-
oxo-ETE by neutrophils by activating NADPH oxidase [74] and the present study indicates that 
both oxidative stress and the PPP also strongly affect the biosynthesis of this substance. To 
investigate the abilities of oxidative stress, NADPH oxidase, and the PPP to regulate 5-oxo-
ETE synthesis by blood cells, 5-HETE (1 µM) was incubated with neutrophils (Figure 
IV.13A), monocytes (Figure IV.13B), lymphocytes (Figure IV.13C), and platelets (Figure 
IV.13D) for 5 min in the presence of either H2O2 (100 µM), tBuOOH (100 µM), or PMA (100 
nM) with or without 5.6 mM glucose. For comparison, data for U-937 cells obtained under 
identical conditions are also shown (Figure IV.13E). To estimate the maximal capacities of 
these cells to produce 5-oxo-ETE, incubations were also performed in the presence of 1 mM 
PMS, which, in all cases, induced a strong response. H2O2 and tBuOOH strongly stimulated 5-
oxo-ETE formation by monocytes, lymphocytes, and platelets, but had only very modest 
effects on neutrophils as noted above. Diamide had effects on 5-oxo-ETE synthesis very similar 
to H2O2 in all of the cell types investigated. 
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Figure IV.14  Effect of H2O2 on the formation of oxoeicosanoids from 5-HETE, 5-HpETE, 
and 13-HpODE by PBMC. 
PBMC (2 x 106 cells in 1 ml), prepared by centrifugation of mixed leukocytes over Ficoll-Paque, 
were incubated with 5-HETE (1 µM), 5-HpETE (1 µM) or 13-HpODE (1 µM) for 5 min at 37 oC and 
the products were analyzed by RP-HPLC. A shows both the amounts of 5-oxo-ETE formed from 
either 5-HETE (5h ? 5o) or 5-HpETE (5hp ? 5o) and the amount of 13-oxo-ETE formed from 13-
HpODE (13hp ? 13o) in the presence or absence of H2O2. All incubations were terminated by the 
addition of triphenylphosphine in 0.4 ml methanol (final concentration, 40 µM) to reduce any 
unreacted hydroperoxy substrate. B shows the amounts of 5-HpETE (5hp), 5-HETE (5h), and 5-
oxo-ETE (5o) detected after incubation of 5-HpETE (1 µM) with PBMC (2 x 106 cells in 1 ml) for 5 
min at 37 oC. In this case triphenylphosphine was omitted to permit estimation of unreacted 5-
HpETE. All values are means ± SE (n = 5). 
In contrast to H2O2, PMA (100 nM) strongly stimulated 5-oxo-ETE formation by 
neutrophils and monocytes, but did not affect its formation by either lymphocytes or platelets. 
In neutrophils, PMA inhibited the formation of 5,20-diHETE by 60% (P < 0.005), so that in its 
presence, 5-oxo-ETE was the major 5-HETE metabolite detected (data not shown), in 
agreement with previous findings by Powell and colleagues [74]. 
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The response to glucose also varied substantially among different cell types. Glucose 
inhibited both H2O2- and PMA- stimulated 5-oxo-ETE formation by neutrophils and 
monocytes, although not to the extent observed with U-937 cells. In contrast, glucose had no 
effect on H2O2-elicited 5-oxo-ETE synthesis by either lymphocytes or platelets. Moreover 
glucose did not affect the ω-oxidation of 5-HETE in neutrophils (data not shown). 
IV.2.6 Effects of Oxidative Stress On Metabolism of 5-HETE and 5-HpETE by 
PBMC 
5-Oxo-ETE can be synthesized both enzymatically from 5-HETE through the action of 5h-
dh [22] as well as by dehydration of 5-HpETE by a heat stable cytosolic factor in mouse 
macrophages [79]. We examined the effect of H2O2 on the formation of 5-oxo-ETE by PBMC 
from both of these substrates. In the absence of H2O2, about four times as much 5-oxo-ETE was 
formed from 5-HpETE than from 5-HETE following incubation for 5 min at 37°C (Figure 
IV.14A). H2O2 markedly stimulated the formation of 5-oxo-ETE from both substrates, resulting 
in the formation of approximately equal amounts after 5 min. In contrast, 13-HpODE was only 
converted to relatively small amounts of 13-oxo-ODE, and although this increased in the 
presence of H2O2, it was oxidized to a much lesser extent than 5-HpETE. In the above 
experiments, triphenylphosphine was added at the end of the incubation to reduce any 
remaining hydroperoxy-fatty acid and thereby block any further formation of the corresponding 
oxo-fatty acid. To determine the extent to which 5-HpETE was reduced to 5-HETE during the 
incubation, triphenylphosphine was omitted and the products analyzed by HPLC. In control 
incubations with vehicle, nearly all of the 5-HpETE was converted to 5-HETE (Figure IV.14 
6B). However, in the presence of H2O2, 5-HETE formation was reduced by about 40% and the 
amounts of 5-oxo-ETE and unreacted 5-HpETE were greater. 
IV.2.7 Effects of Oxidative Stress on Formation of 5-Lipoxygenase Products by 
PBMC 
The experiments described above were performed using either 5-HETE or 5-HpETE as the 
substrate. To determine whether oxidative stress could also stimulate the formation of 5-oxo-
ETE when the substrate is provided by 5-lipoxygenase rather than being added directly, we 
investigated the effects of tBuOOH on the formation of 5-lipoxygenase products by PBMC 
stimulated with A23187 (5 µM) in the presence of arachidonic acid (20 µM). Under these 
conditions, the formation of 5-lipoxygenase products is dependent on the synthesis of 5-HETE 
and LTA4 by monocytes, and their conversion to 5-oxo-ETE and LTB4 by both monocytes and 
lymphocytes. The major 5-lipoxygenase product formed after stimulation of PBMC with 
A23187 and arachidonic acid was 5-HETE (Figure IV.15). However, tBuOOH (100 µM), 
stimulated the formation of 5-oxo-ETE by about 3-fold (P < 0.01), and reduced the amount of 
5-HETE detected (P < 0.05). In contrast, tBuOOH had little effect on the formation of LTB4 by 
PBMC.  
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Figure IV.15  Effects of tBuOOH on the synthesis 
of 5-LO products by PBMC. 
PBMC (2 x 107 cells/ml), prepared by 
centrifugation of mixed leukocytes over Ficoll-
Paque, were incubated with A23187 (5 µM) and 
arachidonic acid (20 µM) in the presence (filled 
bars) or absence (open bars) of tBuOOH (100 µM). 
The amounts of 5-HETE, 5-oxo-ETE (5o-ETE), and 
LTB4 formed after 5 min were determined by HPLC. 
The values are means ± SE (n = 5). *, P < 0.05; **, P 
< 0.01 when compared to control without tBuOOH. 
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IV.3. Synthesis of 5-oxo-ETE Production by non-myeloid Cells 
IV.3.1 Expression and Regulation of 5h-dh in Epithelial Cells 
Screening of Epithelial Cell Lines for 5h-dh Activity 
To investigate whether the epithelium is capable of producing 5-oxo-ETE from 5-HETE, we 
screened 4 different epithelial cell lines (HEp-2, T84, A549 and BEAS-2B) for 5h-dh. As with 
myeloid cells (see Figure IV.2 and Figure IV.4), the cell lines were incubated with 100 µM 
PMS for 6 min followed by 4 µM 5-HETE for an additional 20 min. Figure IV.16 shows the 
normalized amounts of 5-oxo-ETE released from the epithelial cell lines tested in comparison 
to blood neutrophils and monocytes. All epithelial cell lines tested are capable of transforming 
5-HETE to 5-oxo-ETE in amounts comparable to blood cells. A549 cells synthezised 390 ± 36 
and BEAS-2B cells 197 ± 67 pmol 5-oxo-ETE per 106 cells under these circumstances. HEp-2 
cells were originally thought to be derived from an epidermoid carcinoma of the larynx, but 
was later found to have been established via HeLa cell contamination (see ATTC information). 
Due to our focus on lung diseases and the origin of HEp-2 cells and T84 cells, the latter were 
derived from a lung metastasis of a colon carcinoma and maintained the original histological 
characteristics of the colon carcinoma, we continued our studies with A549 cells and BEAS-2B 
cells. 
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Figure IV.16  Expression of 5h-dh in 
epithelial Cell lines. 
Epithelial cells were cultured to confluence 
in 6-well plates. Cells were washed twice 
with PBS+ and then incubated for 6 min 
with 100 µM PMS. The cells were then 
incubated for another 20 min with 4 µM 5-
HETE. Parallel cultured cells were 
detached with trypsin and counted. Results 
obtained with monocytes and PMNL are 
shown as comparison. n ≥ 4, except for 
T84 and HEp-2cells (n=2). 
 
Characterization of Epithelial 5h-dh 
We investigated characteristics of the enzyme in A549 cells responsible for the formation of 
5-oxo-ETE in more detail to determine whether it is similar to myeloid cell 5hdh. To examine 
the substrate specificity, cofactor requirements, and subcellular localization, we incubated 
cytosol, granules, and microsomes with 4µM 5-HETE, 12-HETE, and 15-HETE respectively, 
in the presence of 100 µM NADP+ or NAD+. As shown in Figure IV.17, 5-HETE is 
metabolized by the microsomal fraction to 1.03 ± 0.32 pmol 5-oxo-ETE/(min×µg protein) in 
the presence of NADP+. Under similar conditions, but with NAD+ acting as the electron 
acceptor, only 0.06 ± 0.02 pmol 5-oxo-ETE/(min×µg protein) were formed. The enzymatic 
activity to produce 5-oxo-ETE is mainly located in the microsomal fraction, since only half the 
specific activity is found in the granules and only trace amounts in the cytosol (0.54 ± 0.1 and 
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0.02 ± 0.01 pmol 5-oxo-ETE/(min×µg protein), respectively). The enzyme responsible for 
5-HETE metabolism in the microsomal fraction is highly substrate specific. Only 0.06 ± 0.05 
pmol 12-oxo-ETE/(min×µg protein) and 0.03 ± 0.01 pmol 15-oxo-ETE/(min×µg protein) were 
formed from 12-HETE and 15-HETE, respectively by microsomes in the presence of NADP+. 
To further investigate the substrate specificity of the epithelial microsomal 5h-dh, we examined 
the conversion of 5R-HETE, the stereoisomer of 5S-HETE. 5R-HETE is not a good substrate 
for this enzyme, because only 0.04 ± 0.01 pmol 5-oxo-ETE/(min×µg protein) were formed 
(Figure IV.17). It is noticeable that more 15-HETE than 5-HETE is oxidized in the cytosolic 
fraction to the corresponding oxo-ETE (0.08 ± 0.03 pmol 15-oxo-ETE /(min×µg protein)) in 
the presence of NADP+. We also incubated the cytosolic fraction with PGF2α, which was 
oxidized to its keto-derivative. The cytosolic 15-dehydrogenase activity of A549 cells is 
therefore presumably 15h-PG-dh. Under the conditions we employed, the specific activity of 
microsomal 5h-dh is over 12 times higher than that of cytosolic 15h-PG-dh in A549 cells. 
5-HETE 12-HETE 15-HETE
0.0
0.3
0.6
0.9
1.2
5-HETE 12-HETE 15-HETE
5-
ox
o-
ET
E 
[p
m
ol
 /(
µg
 × 
m
in
)] 
0.0
0.3
0.6
0.9
1.2
5-HETE 12-HETE 15-HETE
0.0
0.3
0.6
0.9
1.2
5(S
)-H
ET
E
5(R
)-H
ET
E
0.0
0.3
0.6
0.9
1.2  A       Microsomes
  B       Granules
  C       Cytosol
 
Figure IV.17  Subcellular localization and substrate specificity of 5h-dh in A549 cells. 
Subcellular fractions of A549 cells were prepared as described in material and methods. The 
different fractions were incubated with 4 µM 5-HETE, 12-HETE, or 15-HETE for 20 min in the 
presence of either 100 µM NADP+ (filled bars) or 100 µM NAD+ (open bars). A shows the 
normalized amounts of the oxo-products formed by microsomes (50 µg protein). The inset shows 
amounts of 5-oxo-ETE formed from 5S-HETE and 5R-HETE (n=2). B shows the products formed 
by granules (150 µg protein). In C the products formed by the cytosol (400-500 µg protein) are 
shown. (n ≥ 3). 
To further compare epithelial and leukocyte 5h-dh, we examined the steady state kinetics of 
their activities using the Lineweaver-Burk plot. Similar to U-937 cells and PMNL, we 
incubated A549 cell derived microsomes (50 µg protein/ml) with 100 µM NADP+ and various 
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amounts of 5-HETE for 5min. As shown in Figure IV.18, the reaction follows Michaelis-
Menten kinetics. Linear regression of the Lineweaver-Burk plots revealed a Vmax of 1.6 ±0.5 
pmol 5-oxo-ETE /(min×µg) and a KM of 0.89 ± 0.15 µM (n=5). In comparison, neutrophils and 
U-937 have a lower Vmax (0.4 ± 0.12 and 0.5 ± 0.3 pmol 5-oxo-ETE /(min×µg), respectively) 
and a slightly lower KM (0.57 ± 0.17 and 0.4 ± 0.14 µM, respectively). For more details see also 
Table IV.1, page 48. 
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Figure IV.18  Steady State analysis of 5h-dh in A549 cells microsomes. 
Microsomal protein (50 µg) derived from A549 cells were incubated with increasing amounts of 
5-HETE and 100 µM NADP+ for 5 min. A: Specific 5h-dh activity of a representative experiment 
(n=5) is shown as a function of the substrate concentration. B: The corresponding Lineweaver-
Burk plot, the double reciprocal presentation, of the same data as in A. Linear regression of all 
experiments with A549 cell derived microsomes yields a Vmax=1.6 ± 0.5 pmol/(min × µg protein) 
and a KM = 0.89 ± 0.15 µM. 
5-oxo-ETE Production in Epithelial Cells is Upregulated by Oxidative Stress 
To determine whether 5-oxo-ETE synthesis by epithelial cells can be regulated by oxidative 
stress, we investigated the effects of increasing concentrations of H2O2 and tBuOOH on its 
formation by A-549 and BEAS-2B cells. To ensure reproducibility, cells were incubated with 
4 µM 5-HETE for 10 min in the presence of peroxides. We had to use high concentration of 
5-HETE for the experiment, because considerable amounts of both, 5-oxo-ETE and 5-HETE 
were taken up by epithelial cells presumably into cellular lipids (see also Figure IV.20, page 
68). Although baseline synthesis of 5-oxo-ETE by A-549 and BEAS-2B cells was different 
(36± 7 and 17 ± 2 pmol 5-oxo-ETE/106 cells; Figure IV.19 A and C), there were no 
considerable differences in the relative responses of these cells to H2O2 and tBuOOH. A-549 
and BEAS-2B cells strongly responded to concentrations of H2O2 as low as 10 µM (EC50, 14 ± 
4 and 9 ± 3 µM, respectively). Although tBuOOH strongly stimulated 5-oxo-ETE formation by 
A-549 and BEAS-2B cells, it was somewhat less potent (EC50, 33 ± 12 µM) than H2O2 
(18 ± 5 µM). tBuOOH appeared to be more efficacious, but these differences were not 
statistically significant. 
To investigate the roles of the GSH redox cycle and the PPP in regulating 5-oxo-ETE 
synthesis by epithelial cells, 5-HETE (4 µM) was incubated with A-549 cells (Figure IV.19 B) 
and BEAS-2B cells (Figure IV.19 D) for 10 min in the presence of either H2O2 (100 µM) or 
diamide (250 µM) with or without 5.6 mM glucose. Diamide  stimulated 5-oxo-ETE formation 
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by A-549 cells (P < 0.001) to a similar extent as H2O2, but appeared to be more efficacious in 
BEAS-2B cells. Glucose significantly inhibited the 5-oxo-ETE formation stimulated by both 
H2O2 (P < 0.001) and diamide (P < 0.005) by A-549 cells, although not to the extent observed 
with U-937 cells. Interestingly, DHEA (100 µM) failed to overcome the inhibitory effect of 
glucose on H2O2-stimulated 5-oxo-ETE formation in A-549. Similar results were obtained 
when BEAS-2B cells were incubated under identical conditions, but further experiments are 
needed to gain statistical significance. In contrast to H2O2 or diamide, PMA (100 nM) had no 
effect on 5-oxo-ETE formation by either A549 or BEAS-2B cells (data not shown). 
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Figure IV.19  Effect of oxidative stress on 5h-dh activity in Epithelial cells. 
A-549 (A,B) or BEAS-2B (C,D) cells were plated for 18 h in 6-well plates at a concentration of 
0.5×106 /ml (106/well). A-549 (A, n ≥ 3) or BEAS-2B (C, n = 3) cells were incubated with 4 µM 
5-HETE in the presence or absence of different concentrations of H2O2 (●), or tBuOOH (○) for 
10 min. A549 (B), and BEAS-2B (D) cells were incubated for 10 min with 5-HETE (4 µM) in the 
presence of vehicle (ctrl), H2O2 (100 µM), or diamide (DA; 250 µM) in either glucose-free PBS+ 
(solid bars) or PBS+ containing 5.6 mM glucose (open bars). The effect of DHEA (100 µM) on 
H2O2 induced 5-oxo-ETE formation is shown on the right. The amount of 5-oxo-ETE released was 
normalized to the number of cells counted in parallel (1.3 ± 0.2 and 1.2 ± 0.2 × 106 for A-549 and 
BEAS-2B cells, respectively). ***, P < 0.001 when compared to vehicle (in the absence of 
glucose). §§, P < 0.005, §§§, P < 0.001  when compared to the corresponding treatment in the 
absence of glucose (n-values are shown in graph). Note that data shown in C and D are from 
different experiments. 
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Uptake of 5-oxo-ETE and 5-HETE by A549 cells 
Preliminary studies showed that unstimulated A-549 cells produce only small amounts of 
5-oxo-ETE (< 5 pmol/106 cells in 10 min) when incubated with 1 µM 5-HETE. The relative 
increase in 5-oxo-ETE synthesis in response to H2O2, expressed as a percentage of control, was 
similar at 1 µM and 4 µM substrate concentrations, but the reproducibility and the recovery of 
the 5-oxo-ETE and 5-HETE were rather poor. We hypothesized that poor recovery is due to a 
rapid uptake of 5-oxo-ETE or 5-HETE due to incorporation of 5-oxo-ETE and 5-HETE into 
cellular lipids.  
Figure IV.20A shows the recovery of 1 µM 5-oxo-ETE and 1 µM 5-HETE from adherent 
A549 cells (1.3 ± 0.2× 106 cells/well). In contrast to U-937 cells, there is no significant 
difference in the rate of disappearance of these two eicosanoids during the incubations. After 
12 min, less then 50% between the originally added eicosanoids were recovered from the cells. 
As shown in Figure IV.20B, treatment with vehicle (0.5% DMSO) appeared to lower the 
recovery of 5-oxo-ETE, but this effect was not significant. Pretreatment with triacsin C 
enhanced the recovery of 5-oxo-ETE from 28 ± 6% to 65 ± 4% (n=4, P<0.05) and treatment 
with excess AA (40 µM) had a similar effect (65 ± 6%, n=4, P<0.05). Similar results were 
obtained with 5-HETE (n ≥ 3), except that the recovery was slightly higher than that of 
5-oxo-ETE in the presence of vehicle or agonists (Figure IV.20B). However, these differences 
were not of statistical significance. 
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Figure IV.20  Recovery of 5-oxo-ETE and 5-HETE from A549 cells. 
A. Time course of the recovery of 5-oxo-ETE and 5-HETE after incubation of adherent A549 cells 
(1.3 ± 0.2×106) with 1µM 5-oxo-ETE (▲,n=3) and 1µM 5-HETE (•,n=3). Cells were incubated for 
the indicated times in PBS+. The recovery is expressed as described in Figure IV.7, page 52. B 
A549 cells were treated for 30 min with vehicle (DMSO) or Triacsin C (20 µM). Arachidonic acid 
(AA, 40 µM) was added at the same time as 5-oxo-ETE (1 µM, open bars, n=3) and 5-HETE 
(1µM, solid bars, n=3). The incubations were terminated after 20 min and the recoveries were 
determined as described above. * P < 0.05 compared to vehicle treated cells. 
IV.3.2 Synthesis of 5-oxo-ETE by Endothelial Cells 
Endothelial cells have been implicated in the formation of cys-LTs through the transcellular 
conversion of leukocyte-derived LTA4 at sites of vascular inflammation and injury [234,235]. 
We hypothesized that endothelial cells, similar to the epithelial cell lines tested, posses 5h-dh 
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activity and convert 5-HETE to 5-oxo-ETE. To test this hypothesis we used HAEC). We 
incubated confluent HAEC for 20 min with 1 µM 5-HETE in Hanks buffer. Under these 
conditions, HAEC produced 24 ± 4 pmol 5-oxo-ETE/106 cells. The addition of PMS strongly 
enhanced the release of this eicosanoid to 360 ±35 pmol /106 cells b(Figure IV.22). We had to 
use Hanks buffer for this set of experiments, because HAEC, as primary cells, cannot be 
incubated in PBS+ as they detach after approximately 30 min of culture in PBS+. This could 
cause cellular stress and in turn affect the results of the experiment. 
We hypothesized that oxidative stress enhances the formation of 5-oxo-ETE by HAEC in a 
similar fashion as described above for the epithelial cells and leukocytes. Indeed, addition of 
316 µM H2O2 dramatically enhanced the formation of 5-oxo-ETE in HAEC cells after 5 min to 
99 ± 23 compared to 18 ± 8 pmol/106 cells in unstimulated cells (Figure IV.21A). In contrast to 
U-937 cells, this effect was not transient and 5-oxo-ETE levels were maintained for at least 
40 min. Diamide induced 5-oxo-ETE formation in a similar fashion as did H2O2, thus further 
substantiating the premise that oxidative stress enhances 5-oxo-ETE formation in HAEC 
through the GSH redox cycle. Since Hanks buffer contains 5.6 mM glucose, we hypothesized 
that this could have reduced the response to H2O2, because the PPP may inhibit this process by 
reducing NADP+ to NADPH. To test this hypothesis, we preincubated HAEC for 30 min with 
100 µM DHEA to block G6P-dh prior to the addition of H2O2- and 5-HETE. As shown in 
Figure IV.21, DHEA greatly enhanced the effect of H2O2 on 5-oxo-ETE formation in HAEC. 
The time course of 5-oxo-ETE formation did not reach a plateau by 40 min and its rate of 
formation did not decrease substantially over the period of time. This suggests that H2O2 
persists much longer in the presence of HAEC compared to the cell lines investigated. 
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Figure IV.21  Effect of peroxides and diamide on 5h-dh activity in endothelial cells. 
A: Time courses for the formation of 5-oxo-ETE following incubation of 1 µM 5-HETE with 
confluent primary human aorta endothelial cells in the presence of vehicle (Control; ▲; n = 2), 
316 µM H2O2 (•; n = 3), 316 µM H2O2 and 100 µM DHEA (H2O2 /DHEA; ∇; n =3), and 250 µM 
Diamide (○; n = 2). B: Concentration-response curves for the effects of H2O2 (•; n ≥ 5), and 
tBuOOH (tBu; ∇; n ≥ 3) on the formation of 5-oxo-ETE following incubation of HAEC with 1 µM 5-
HETE for 20 min. Incubations of HAEC were performed in Hanks buffer containing 5.6 mM 
glucose. All values are means ± SE. 
The effects of various concentrations of H2O2 and tBuOOH on 5-oxo-ETE formation by 
HAEC are shown in Figure IV.21B. Both peroxides induced an increase in 5-oxo-ETE 
synthesis at concentrations as low as 3 µM; however in both cases this increase was only 
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significant at a concentration of 31.6 µM. tBuOOH (EC50, 22.4 ± 5.0 µM, n=3) was a slightly 
less potent stimulator (NS) of 5-oxo-ETE formation than H2O2 (EC50, 14.0 ± 2.7 µM, n=5). 
TBuOOH was somewhat more efficacious than H2O2 in inducing an over 10.5-fold increase in 
5-oxo-ETE formation, compared to 7.5-fold for H2O2 at concentrations of 316 µM. 
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Figure IV.22  Regulation of 5h-dh activity 
in primary HAEC. 
Effects of PMS (100 µM, n=4), diamide (DA, 
250 µM, n=5), and H2O2 (100 µM, n=6) on 
the formation of 5-oxo-ETE by HAEC 
following incubations for 20 min with 1 µM 
5-HETE. Prior to addition of 100 µM H2O2 
and 5-HETE, HAEC were preincubated with 
DHEA (100 µM, n=5), 3AT (5 mM, n=5), or 
BCNU (30 µM, n=5). ***, P < 0.001 when 
compared to control (no H2O2 stimulation, 
n=6); §§§, P < 0.001; §, P < 0.05 when 
compared with H2O2 alone. 
 
We followed similar approaches as described above to further investigate the regulatory 
mechanisms of 5-oxo-ETE synthesis in HAEC. Diamide (250 µM, n=5) induced a similar 
increase in 5-oxo-ETE formation by HAEC as did H2O2 (316 µM, n=6), from 24 ± 4 pmol/106 
cells (vehicle) to 162 ± 29 (DA) and 158 ± 24 pmol 5-oxo-ETE/106 cells (H2O2). The 
stimulatory effect of H2O2 was almost completely blocked by pretreatment with BCNU to 42 ± 
8 pmol/106 cells (n = 5, P < 0.05). Treatment with 3-AT (5 mM) induced a slight increase of 
5-oxo-ETE formation to 219 ± 41 pmol/106 cells (NS), suggesting that metabolism of H2O2 by 
catalase is not a major factor. As described above, DHEA (354 ± 35 pmol/106 cells) 
significantly enhanced the levels of 5-oxo-ETE synthesized to amounts comparable with those 
induced by PMS (369 ± 27 pmol/106 cells), which non-enzymatically oxidizes NADPH to 
NADP+. 
 
 
 
 
 
 
The great tragedy of science - the slaying of a beautiful hypothesis by an ugly fact.  
Thomas Huxley 
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V  DISCUSSION 
V.1. Differentiation of Myeloid Cells Enhances 5h-dh Activity 
It has previously been shown that circulating leukocytes, including neutrophils, eosinophils, 
monocytes, and lymphocytes, all possess 5h-dh activity and convert 5-HETE to 5-oxo-ETE 
[7,22,68]. The objective of the present study was to determine whether cell lines representing 
pluripotent hematopoietic cells, the precursors of mature blood cells, also have this capability 
and whether 5h-dh activity could be induced in these cells during differentiation. The 
availability of a cell line with stable expression of 5h-dh activity would be very useful for 
studies on the regulation of 5-oxo-ETE biosynthesis. We focused on U-937 cells and HL-60 
cells, because they have been frequently used for studies on other components of the eicosanoid 
pathway and they are of human origin. 
We found that both, U-937 cells and HL-60 cells, have high levels of 5h-dh activity, 
comparable to those found in neutrophils and monocytes. This is the first report of the presence 
of this enzyme in immature cells. We also found that 5h-dh activity could be induced by 
differentiation of both cell types towards monocytes or macrophages. The greatest degree of 
induction was observed when U-937 cells were treated with PMA, which transformed these 
cells to adherent macrophage-like cells and increased their capacity to synthesize 5-oxo-ETE 
by 3-fold. Retinoic acid and dh-Vit D3, which are known to differentiate U-937 cells into 
monocyte-like cells [216,236], did not cause these cells to become adherent and elicited smaller 
increases in 5-oxo-ETE formation. In the case of HL-60 cells, only dh-VitD3, which induces 
monocytic differentiation, elicited a significant increase in 5-oxo-ETE synthesis. Agents that 
induced differentiation towards neutrophils (DMSO and retinoic acid) had no effect on 5-oxo-
ETE synthesis by these cells. 
We evaluated 5h-dh activity by measuring the conversion of 5-HETE to 5-oxo-ETE by 
intact cells in the presence of PMS. This is a relatively simple assay that avoids the problem of 
5-oxo-ETE synthesis being limited by the availability of the 5h-dh cofactor NADP+, which is 
normally present only at low levels in the cytosol. PMS non-enzymatically oxidizes 
intracellular NADPH, which is present at relatively high concentrations, to NADP+. Under 
these circumstances 5h-dh activity should only be limited by the amounts of enzyme and 
substrate present. In contrast to its effect on 5-oxo-ETE synthesis by intact cells, PMS does not 
affect 5h-dh activity directly, as we found it has no effect on microsomal enzyme activity 
(Table IV.2, page 55). The concentration of PMS used in the present study (100 µM) was found 
to maximally stimulate 5-oxo-ETE formation in myeloid cells. The results obtained using this 
whole cell assay were validated by examining the effects of differentiation of U-937 cells with 
PMA on microsomal 5h-dh activity, which revealed a similar 3-fold induction of enzyme 
activity. 
To ensure that our results could not be affected by the presence of other enzymes involved 
in the biosynthesis and metabolism of 5-HETE and 5-oxo-ETE, we determined whether U-937 
cells and HL-60 cells displayed either 5-LO or LTB4 20-hydroxylase activities. 5-LO is 
required for the synthesis of 5-HETE, whereas LTB4 20-hydroxylase is the main pathway for 
the metabolism of both 5-HETE [72] and 5-oxo-ETE [34] in neutrophils, converting both 
substances to their 20-hydroxy derivatives. There was no evidence for the formation of 
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products resulting from either of these enzymes in either of the monocytic cell lines, both 
before and after differentiation with PMA (U-937 cells), DMSO (HL-60 cells), or dh-VitD3 
(HL-60 cells). The absence of 5-LO in U-937 cells is consistent with earlier studies 
demonstrating that this enzyme is not expressed in these cells due to a high degree of 
methylation in the promoter region of its gene, even after differentiation towards monocytes 
[203]. Modest levels of 5-LO activity have previously been reported in DMSO-differentiated 
HL-60 cells, but it was necessary to use cell concentrations about 10 times higher than those 
used in the present study and they had to be primed with GM-CSF to demonstrate this [208].  
However, we did not use GM-CSF in the present studies. In human neutrophils LTB4 is 
hydroxylated by CYP4F3A [85]. In agreement with our data, Mizukami and colleagues showed 
that LTB4-hydroxylase is not expressed in HL-60 cells [237]. Differentiation of this cell line 
with DMSO only lead to a marginal induction of LTB4 hydroxylase activity in comparison to 
human peripheral blood neutrophils [237]. Since we used 5-HETE, which is a poorer substrate 
than LTB4 [201], we may have failed to detect a low expression of this enzyme under the 
conditions tested. 
HL-60 cells have been employed in studies on the induction of a variety of other enzymes 
and receptors involved in eicosanoid pathways. The first receptor for a 5-LO product to be 
cloned took advantage of retinoic acid-induced induction of the BLT1 receptor in these cells 
[238]. The differentiation pathway-dependent expression of eicosanoid metabolizing enzymes 
has been studied in HL-60 cells. HL-60 cells undergo neutrophilic differentiation when 
cultured with DMSO and eosinophilic differentiation when cultured in butyric acid or retinoic 
acid. In contrast to LTC4-S, LTA4 hydrolase, the enzyme responsible for the formation of 
LTB4, is induced in HL-60 cells following treatment with DMSO for up to 7 days. In contrast, 
LTC4-S, but not LTA4 hydrolase, is induced by treatment of a subclone of HL-60 cells, which 
readily undergoes eosinophilic differentiation, with butyric acid [204]. A key enzyme in the 
biological inactivation of prostaglandins, 15h-PG-dh, is induced by treatment of HL-60 cells 
with either PMA or DMSO [239]. This enzyme is quite different from 5h-dh, as it resides in the 
cytosol, requires NAD+ as a cofactor, and selectively oxidizes the ω6 hydroxyl group of various 
eicosanoids [205]. Moreover, 15h-PG-dh is induced during neutrophilic differentiation of HL-
60 cells with DMSO, which does not significantly affect 5h-dh activity in these cells. 
Undifferentiated U-937 cells contain higher levels of LTC4-S than circulating human 
monocytes [201], and this enzyme can be upregulated by treatment with DMSO, but not with 
PMA [201]. This is different from what we observed with 5h-dh in U-937 cells, indicating that 
different regulatory mechanisms for these two enzymes exist. In our hands, in U-937 cells 
5h-dh is induced by PMA and not by DMSO. Since LTC4-S and 5h-dh have been studied in 
microsomal fractions from U-937 cells, their activities can be directly compared. The KM of 
LTC4-S for LTA4 (5.6 µM) [201] is about 10 times higher than that of 5h-dh for 5-HETE, 
indicating that the latter enzyme has considerably higher affinity for its substrate. The specific 
activity of 5h-dh in undifferentiated U-937 cell microsomes is about ten times higher than that 
of LTC4-S [201]. The regulatory mechanisms of LTC4-S and 5h-dh activity expression does 
also considerably differ in HL-60 cells. LTC4-S is upregulated in HL-60 cells by differentiation 
with PMA as well as with DMSO. However, after differentiation the level of LTC4-S activity is 
only comparable to that of undifferentiated U-937 cells [201]. In contrast, neither PMA nor 
DMSO induced 5h-dh in HL-60 cells. 
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Preliminary studies showed that the 5h-dh mediated reaction is highly pH sensitive. The 
forward reaction is favored above pH 5.5. The kinetics increase dramatically at pH 9.5 with a 
maximum at pH 10.5 and the forward reaction is favored at the physiological pH 7.4. This is 
remarkably similar to the reported pH dependence of 15h-PG-dh type I [240]. In opposite to 
15h-PG-dh, microsomal 5h-dh is not affected by thiol depleting agents such as NEM (Table 
IV.2; [240]). Both, the forward as well as the reverse reaction of 5h-dh are inhibited at pH < 4.5 
and pH > 11.3. 
5-oxo-ETE synthesis by neutrophils in the presence of 100 µM PMS was considerably more 
variable than by monocytes (Figure IV.2, page 47). This appears to be because, unlike other 
leukocytes, the induction of 5-oxo-ETE synthesis is not maximal at 100 µM in neutrophils [75]. 
When we used 1 mM PMS for PMNL to convert NADPH to NADP+, the amounts of 
5-oxo-ETE being produced were reproducible and similar to that produced in monocytes 
stimulated with 100 µM PMS (Figure IV.13, page 60). The concentration for the effect of PMS 
on 5-oxo-ETE production by monocytes reached the maximum below a concentration of 
100 µM PMS (data not shown). We chose to use 100 µM PMS as the standard condition, 
because PMS tends to overload the extraction column, thus shortening its life-time and causing 
considerable peak broadening. 
In conclusion, both U-937 cells and HL-60 cells possess relatively high levels of 5h-dh, 
comparable to those found in circulating leukocytes. The activity of this enzyme is markedly 
increased in U-937 cells differentiated towards macrophages by treatment with PMA, and in 
HL-60 cells differentiated toward monocytes with dh-VitD3. As these cells are readily 
maintained in culture they could serve as useful models to examine the regulation of 5-oxo-
ETE synthesis from 5-HETE, especially since they lack ω-oxidation activity, which is the 
major pathway for the metabolism of 5-oxo-ETE in neutrophils. The presence of 5h-dh in 
undifferentiated immature leukocytes is very interesting, and raises the possibility that 5-oxo-
ETE could play a role in cell proliferation or differentiation. In this regard, 5-oxo-ETE has 
previously been found to stimulate the proliferation of prostate cancer cells and to act as a 
survival factor following induction of apoptosis with inhibitors of the 5-LO pathway [241]. 
Furthermore, 5-oxo-ETE has been shown to stimulate ERK-1/2 and Akt [27,36] pathways, 
which in turn have been implicated in pathways to modulate normal and abnormal 
hematopoiesis [242]. 
V.2. Regulation of 5-oxo-ETE Synthesis by Oxidative Stress 
Although 5h-dh has been detected in all leukocyte populations and platelets [7,22,68-70], 
the regulatory mechanisms leading to 5-oxo-ETE formation have only been described in 
leukocytes and monocytes [68,71]. In these cell types the activation of the NADPH oxidase 
complex by PMA leads to the formation of superoxide. This process utilizes NADPH as the 
electron donor leading to the provision of NADP+, the cofactor required by 5h-dh. As this 
mechanism is not present in platelets and lymphocytes, we wondered how 5-oxo-ETE synthesis 
may be regulated in these cells. We chose undifferentiated U-937 cells to approach this subject, 
because they contain levels of 5h-dh comparable to circulating neutrophils and monocytes, but 
do not convert either 5-oxo-ETE or 5-HETE to ω-oxidation products, as do neutrophils. 
Furthermore, they lack both 5-LO activity [203] and the NADPH oxidase system [243], which, 
if present, could complicate the interpretation of the data. 
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V.2.1 Oxidative Stress Enhances 5-oxo-ETE Synthesis 
Both H2O2 and tBuOOH strongly stimulated 5-oxo-ETE formation from 5-HETE by U-937 
cells, with EC50 values in the low µM range. tBuOOH was over 3 times more potent than H2O2 
and had a longer lasting effect, probably due to its resistance to metabolism. In contrast, the 
response to H2O2 declined after 5 min, presumably due to metabolism by catalase [244] and/or 
myeloperoxidase [245], both of which are present in U-937 cells, as its effect was prolonged 
considerably by the addition of azide, which inhibits both of these enzymes. To determine 
whether fatty acid hydroperoxides have similar effects, we used 13-HpODE, the 13-
hydroperoxy metabolite of linoleic acid, as a representative compound. Although it increased 5-
oxo-ETE formation substantially, it was clearly not as potent as H2O2, suggesting that such 
compounds may be of less importance than H2O2 in regulating 5-oxo-ETE synthesis. However, 
we cannot rule out the possibility that hydroperoxy metabolites of arachidonic acid, such as 12-
HpETE or 5-HpETE, may be more potent than 13-HpODE. 
Reactive oxygen species such as H2O2 can affect a variety of cellular processes that could 
potentially affect the synthesis of 5-oxo-ETE. H2O2 can act as a second messenger by oxidizing 
critical SH groups of certain proteins to sulfenic acid (-SOH) residues, resulting in altered 
activity. H2O2 inactivates lymphocyte protein tyrosine phosphatases in this manner, resulting in 
increased levels of activated intracellular signaling molecules [246]. H2O2 can also be 
converted to highly reactive hydroxyl radicals by the Fenton reaction or to hypochlorous acid 
by myeloperoxidase, both of which have toxic effects. In addition, hydroperoxides can 
stimulate lipid peroxidation, which could potentially result in the non-enzymatic formation of 
5-oxo-ETE. In this context, incubation of red cell ghosts with a very high concentration (10 
mM) of tBuOOH for 90 min induced the formation of substantial amounts of 5-oxo-ETE 
esterified to phospholipids [61]. However, such a mechanism would not explain the rapid 
conversion of 5-HETE to 5-oxo-ETE that we observed. Moreover, 5-HETE was not oxidized to 
5-oxo-ETE when incubated with H2O2 or tBuOOH in the absence of cells (data not shown). 
H2O2 also affects cellular redox status. Cells protect themselves from oxidative stress by 
maintaining a highly reducing environment. Hydroperoxides, including H2O2, are rapidly 
reduced by glutathione peroxidase, resulting in the concomitant oxidation of GSH to GSSG 
(Figure V.1). The GSSG is then reduced back to GSH by glutathione reductase, resulting in the 
formation of NADP+, the cofactor required by 5h-dh. Alternatively, H2O2 can be reduced by 
peroxiredoxin and thioredoxin in the following sequence [126]: 
H2O2 ? Peroxiredoxin ? Thioredoxin ? Thioredoxin reductase ? NADP+ 
As it leads to the generation of NADP+, this process could also explain the stimulatory effect 
of H2O2 on 5-oxo-ETE formation. The strong inhibitory effect of BCNU, which blocks both 
glutathione reductase and thioredoxin reductase, suggests the involvement of at least one of 
these pathways. This is supported by the inhibitory effect of NEM, which non-selectively 
alkylates thiol groups, thereby blocking both pathways. In contrast to BCNU, the potent 
thioredoxin reductase inhibitor auranofin had no effect on 5-oxo-ETE synthesis in response to 
H2O2 at concentrations well above those reported [135] to maximally inhibit this enzyme. This 
suggests that the effect of H2O2 is mediated by the GSH rather than the thioredoxin redox 
cycle. This is further supported by the finding that depletion of GSH by the γ-glutamylcysteine 
synthetase inhibitor BSO [247] significantly reduces the response to H2O2. 
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The capacity of cells to reduce hydroperoxides via the GSH redox cycle depends on the 
availability of NADPH, which is normally maintained at very high levels relative to NADP+ by 
the PPP [136]. For every molecule of glucose 6-phosphate that enters this pathway, two 
molecules of NADP+ are reduced to NADPH (Figure V.1, page 76). The increase in NADP+ 
levels expected following exposure of cells to oxidative stress would thus be tempered by its 
rapid reduction to NADPH by the PPP. The cytosolic concentration of NADP+ would depend 
on the relative activities of these two pathways. In the case of U-937 cells, activation of the 
PPP by addition of the substrate glucose strongly inhibits the effect of H2O2 on 5-oxo-ETE 
synthesis, presumably due to enhanced reduction of the NADP+ generated by glutathione 
reductase. This inhibitory effect was not shared by galactose, which is not a substrate for the 
PPP. Furthermore, the effect of glucose could be completely blocked by DHEA, which 
prevents its metabolism by the PPP by inhibiting the key enzyme G6P-dh (Figure IV.11B) 
[137]. 
V.2.2 Effects of Oxidative Stress in Different Leukocyte Populations 
Although our initial studies were performed using U-937 cells as a model, our ultimate goal 
was to examine the regulation of 5-oxo-ETE formation by peripheral blood cells. The effects of 
oxidative stress on monocytes, lymphocytes, and platelets were very similar to those observed 
using U-937 cells, with H2O2, tBuOOH, and diamide all dramatically increasing 5-oxo-ETE 
synthesis (Figure IV.13). The only exception was neutrophils, in which 5-oxo-ETE formation 
was not increased significantly by peroxides or by diamide. 
H2O2 also stimulated the formation of 5-oxo-ETE from both 5-HETE and 5-HpETE by 
PBMC. Whereas oxidation of 5-HETE would appear to be solely due to the action of 5h-dh 
[22], oxidation of 5-HpETE to 5-oxo-ETE could occur by two distinct mechanisms. 5-HpETE 
could initially undergo peroxidase-induced reduction to 5-HETE, followed by oxidation to 5-
oxo-ETE by 5h-dh. Alternatively, it could undergo direct dehydration to 5-oxo-ETE, as 
reported by Zarini and Murphy to occur in murine macrophages [79]. It is difficult to 
completely distinguish between these two pathways because of the very rapid peroxidase-
induced conversion of 5-HpETE to 5-HETE, which in the case of PBMC was nearly complete 
by 5 min (Figure IV.14B). H2O2 reduced the amount of 5-HETE detected following incubation 
of 5-HpETE with PBMC. This is probably due to (i) increased metabolism of 5-HETE to 5-
oxo-ETE by 5h-dh and (ii) reduced formation of 5-HETE due to competition between H2O2 and 
5-HpETE for glutathione peroxidases. H2O2 could also prolong the lifetime of 13-HpODE in 
this way, thereby promoting its conversion to 13-oxo-ODE. 
Hydroperoxy-fatty acids are known to decompose to their oxo derivatives in the presence of 
heme proteins [248], but it is unlikely that this process would exhibit a high degree of substrate 
selectivity. To evaluate the direct conversion of hydroperoxy-fatty acids to oxo-fatty acids we 
therefore incubated 13-HpODE with PBMC, as 13-HODE, unlike 5-HETE, is not a substrate 
for 5h-dh [22]. The fact that conversion of 13-HpODE to its oxo derivative proceeds at a much 
slower rate than the corresponding reaction with 5-HpETE would suggest that 5-oxo-ETE is 
formed from 5-HpETE by human PBMC primarily through the action of 5h-dh. However, the 
direct dehydration of 5-HpETE could also make a smaller contribution to the formation of 
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Figure V.1  Regulation of 5-oxo-ETE synthesis by Oxidative Stress 
Within the GSH-redox cycle, H2O2 or lipid hydroperoxides (LOOH) are reduced by GPx family 
members to water or their corresponding alcohols using GSH as the electron donor which is 
oxidized to GSSG. GSSG is in turn recycled at the expense of NADPH by GRed, thus providing 
the cofactor NADP+ for 5h-dh. In phagocytes, NADPH oxidase (NOX) can also provide significant 
amounts of NADP+ after respiratory burst induction. The oxidative part of the PPP is 
reestablishing a low redox state within the cell by reducing NADP+ to NADPH, while oxidizing 
G6P, which is formed of glucose by hexokinase (HK), to Ru5P. MPO/EPO and catalase also 
metabolize H2O2. Note that two 5-oxo-ETE-metabolizing pathways, ∆6 –red and ω-ox use NADPH 
as cofactor. 
Figure V.2  Principal regulatory pathways of 5-
oxo-ETE formation in blood cells and U-937 cells 
The induction of oxidative stress upregulates the 
formation of 5-oxo-ETE in U-937 cells, monocytes 
(Mc), lymphocytes (Ly), and platelets. The PPP 
inhibits the formation of 5-oxo-ETE synthesis in 
neutrophils (Ne), monocytes, and U-937 cells but not 
in lymphocytes or platelets. The induction of the 
respiratory stimulates 5-oxo-ETE synthesis only in 
neutrophils and monocytes but not in the other cell 
types tested. 
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5-oxo-ETE. It is interesting that in the absence of H2O2, 5-oxo-ETE is formed more efficiently 
from 5-HpETE than from 5-HETE (Figure IV.14A). This may be due to a stimulatory effect of 
5-HpETE on the 5h-dh-catalyzed oxidation of 5-HETE by PBMC. Lymphocytes, the main 
component of PBMC, are very sensitive to the effects of hydroperoxides, as concentrations of 
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H2O2 as low as 1 µM dramatically increase 5-oxo-ETE formation (Figure IV.12). This is 
supported by the results of preliminary experiments that showed that 13-HpODE (1 µM) 
stimulates the conversion of 5-HETE to 5-oxo-ETE by PBMC from 12.1 ± 1.8 to 30.1 ± 1.8 
pmol/ml, respectively (n=2). 
Most of the above studies were performed using exogenous 5-HETE as the substrate. We 
wanted to determine whether oxidative stress could also promote the production of 5-oxo-ETE 
from 5-HETE provided by the metabolism of arachidonic acid by 5-lipoxygenase. As shown in 
Figure IV.15, tBuOOH stimulated 5-oxo-ETE formation by PBMC following incubation with 
arachidonic acid and the calcium ionophore A23187, increasing the ratio of 5-oxo-ETE to 5-
HETE from 0.17 to 1.2. This demonstrates that oxidative stress can stimulate 5-oxo-ETE 
formation not only from exogenous 5-HETE, but also from 5-HETE generated by 5-
lipoxygenase. The effect of tBuOOH was specific for 5-oxo-ETE, as it had no effect on the 
formation of the related 5-LO product LTB4. 
Powell and coworkers previously showed that initiation of the respiratory burst in 
neutrophils with PMA or opsonized zymosan strongly stimulates 5-oxo-ETE synthesis [74]. 
However, the present study suggests that this mechanism may be restricted to neutrophils and 
monocytes because of the highly active NADPH oxidase systems present in these cells. The 
unresponsiveness of U-937 cells to PMA is presumably due to the lack of a functional NADPH 
oxidase system [243], confirming the prior conclusion that the effect of PMA is mediated by 
this pathway [74]. Reduced or absent NADPH oxidase activity in lymphocytes and platelets 
would also explain their lack of response to PMA. 
There were also considerable differences in the responses of different cells to glucose. 
Glucose was most effective in U-937 cells, inhibiting H2O2-elicited 5-oxo-ETE production by 
85%. It was somewhat less effective in neutrophils and monocytes, inhibiting the formation of 
5-oxo-ETE in response to H2O2 and/or PMA by approximately 50%. In contrast, lymphocytes 
and platelets were resistant to the inhibitory effect of glucose under the conditions employed. 
Thus, it would appear that the PPP plays a considerably more important role in limiting 
5-oxo-ETE formation in neutrophils and monocytes compared to lymphocytes and platelets 
(Figure V.2). A relatively high PPP activity is important for  these cells as they need large 
amounts of NADPH for ROS generation by NADPH oxidase. Neutrophils are probably the 
strongest producers of ROS and it is plausible that these cells do not utilize NADPH to defend 
themselves against oxidant damage through the GSH redox cycle. Instead they use other 
mechanisms which do not affect the redox state and do not consume NADPH, such as catalase. 
Furthermore, as they are effector cells, their lifetime at inflammatory sites is limited and 
cellular damage to them has no further consequences. 
The regulation of 5-oxo-ETE synthesis in neutrophils is clearly quite different from that in 
other types of blood cells. Whereas PMA is a potent stimulus of 5-oxo-ETE formation by these 
cells, H2O2 and tBuOOH have only modest effects. The diminished response of neutrophils to 
H2O2 could potentially be due to their high levels of myeloperoxidase, which is not present in 
mature monocytes, and catalase, which is much more active in neutrophils than monocytes 
[175]. However, this would not explain the lack of response to tBuOOH, which is not a 
substrate for catalase and is a poor substrate for myeloperoxidase [249]. Furthermore, neither 
the catalase inhibitor 3-AT nor azide, which inhibits both catalase and myeloperoxidase, 
enhanced the response of neutrophils to H2O2. It would seem more likely that the modest 
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response of neutrophils to hydroperoxides is due to their relatively low GSH levels and 
glutathione peroxidase activity compared to monocytes [175]. 
In conclusion, 5-oxo-ETE synthesis is strongly stimulated by oxidative stress in U-937 
monocytic cells, blood monocytes, lymphocytes, and platelets, and this effect is mediated by 
the GSH redox cycle. The respiratory burst plays a significant, but less prominent role in 
monocytes, but is the major pathway involved in regulation of 5-oxo-ETE synthesis in 
neutrophils. Withdrawal of glucose also enhances 5-oxo-ETE synthesis in neutrophils and 
monocytes, but has little effect in lymphocytes and platelets. The regulation of 5-oxo-ETE 
synthesis by oxidative stress and glucose may be highly relevant in pathological situations 
accompanied by inflammation. Under such conditions, inflammatory cells are activated and 
release superoxide, which would be rapidly converted to H2O2 by superoxide dismutases. 
Oxidative stress is associated with a number of such conditions, including asthma [110], 
ischemia-reperfusion injury [250], and atherosclerosis [251]; this could lead to increased 
synthesis of 5-oxo-ETE, which could then act to induce the further infiltration of inflammatory 
cells, leading to prolongation of the inflammatory response. In agreement with this, a recent 
study reported elevated levels of both 5-oxo-ETE and markers of oxidative stress in lung tissue 
from patients with pulmonary hypertension, although the nature of this relationship was not 
investigated [252]. Glucose deprivation, as would occur in ischemia, could also promote the 
formation of 5-oxo-ETE due to a failure to maintain a high ratio of intracellular NADPH to 
NADP+. Induction of 5-oxo-ETE synthesis by oxidative stress, low glucose, and the respiratory 
burst may thus be an important mechanism in sustaining the inflammatory reaction, making 5h-
dh and the 5-oxo-ETE receptor attractive targets for the development of novel anti-
inflammatory drugs. 
V.3. Formation of 5-oxo-ETE in Structural Cells 
V.3.1 5h-dh is Present in Epithelial and Endothelial Cells 
It has been shown that the epithelium and the endothelium are involved in leukotriene 
synthesis by means of transcellular metabolism.  
Although structural cells, such as epithelial and endothelial contain low levels or no 
5-LO,they contain enzymes required to convert leukocyte derived LTA4 to LTB4 and LTC4 
[9,10,21,235,253-255]. Epithelial and endothelial cells have furthermore been shown to release 
inflammatory mediators such as chemokines (IL-8) and prostaglandins (PGE2) by themselves 
[12,45,256-259]. We hypothesized that these cells do also contain 5h-dh. We were particularly 
interested in epithelial and endothelial cells, as they are in constant contact with phagocytes, 
especially 5-LO-containing neutrophils and macrophages, which may act as a source for 
5-HETE in vivo. Under non-pathological circumstances, lung epithelial cells are in close 
contact to alveolar macrophages. After stimulation of the lung by irritants, such as smoke and 
allergens, or pathogens like respiratory synovial virus, further leukocytes infiltrate the lung. 
The first wave consists mainly of neutrophils, which  may be replaced by eosinophils if the 
inflammatory response persists. Endothelial cells are in constant contact with circulating 
peripheral blood leukocytes and assist in inflammation. 
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The present study shows for the first time that 5-oxo-ETE can be formed by non-myeloid 
cells. We found high activity of this enzyme in all epithelial cell lines (A549, BEAS-2B, T84, 
and HEp-2 cells) investigated as well as in HAEC. On a cellular basis these cells produced 
similar amounts of 5-oxo-ETE when stimulated with PMS and 5-HETE as do human blood 
derived monocytes and neutrophils. Several lines of evidence suggest that the enzyme 
responsible for this activity is identical to leukocyte 5h-dh. First, as described in neutrophils 
[22] the cofactor required as an electron acceptor for the oxidation of 5-HETE is NADP+ and 
not NAD+. Second, the specific activity is mainly located in the microsomal fraction of A549 
cells and to a certain extent in the granules, but not in the cytosol. Third, the enzyme is highly 
specific for a hydroxyl-group in the S-configuration in position 5, since 5R-HETE, 12S-HETE, 
and 15S-HETE are poor not metabolized to a significant extent. Fourth, the KM value 
describing the binding affinity of this enzyme for the substrate 5-HETE is similar to that found 
in neutrophils and U-937 cells. 
V.3.2 Oxidative Stress Enhances 5-oxo-ETE Formation By Epithelial and 
Endothelial Cells 
Oxidative stress enhances the formation of 5-oxo-ETE from 5-HETE in epithelial and 
endothelial cells as being demonstrated by the stimulatory effects of H2O2 or tBuOOH (Figure 
IV.19 and Figure IV.22). This effect is presumably mediated through the GSH redox cycle, as 
in leukocytes and platelets, as it can be mimicked by diamide. In HAEC, the stimulatory effect 
of H2O2 on 5-oxo-ETE formation was inhibited by BCNU. HAEC had to be incubated in Hanks 
buffer, which contains 5.6 mM glucose, because they became detached from the plastic within 
30 min if incubated with PBS+. Even in the presence of glucose, HAEC produced substantial 
amounts of 5-oxo-ETE. The addition of DHEA further stimulated 5-oxo-ETE synthesis. In 
contrast to its transient effect on 5-oxo-ETE synthesis in U-937 cells, H2O2 had longer lasting 
effects in HAEC. This difference may be due to the reduced contribution of competing 
pathways, such as catalase or MPO, which would degrade H2O2. This suggests that the major 
pathway for the metabolism of H2O2 in endothelial cells is the glutathione redox-pathway and 
that the PPP maintains the redox state of the cells. 
Whereas oxidative stress had a significant effect on 5-oxo-ETE synthesis in A549 and 
BEAS-2B cells as in lukocytes, the role of the PPP is less clear in these cells. Similar to U-937 
cells, glucose inhibited the stimulatory effect of H2O2 in A549 and in BEAS-2B cells. In 
contrast to U-937 cells and HAEC however, 100 µM DHEA failed to overcome this inhibitory 
effect in BEAS-2B and A-549 cells. This difference could be possibly due to a different 
potency of DHEA in inhibiting G6P-dh in epithelial cells, perhaps due to a difference in its 
cellular uptake or metabolism. It is also possible that other pathways exist that reestablish high 
NADPH levels in these cells. Further experiments would be required to examine the effect of 
higher concentrations of DHEA on 5-oxo-ETE production in epithelial cells. If higher DHEA 
concentrations do not overcome the inhibitory effects of glucose, other pathways would have to 
be evaluated. For example, NADP+-dependent isocitrate dehydrogenases (ICDH) may play an 
important role in maintaining a low intracellular redox-state [260]. The ICDHs catalyze the 
oxidative decarboxylation of isocitrate to 2-oxoglutarate. However, the NAD+-dependent 
mitochondrial ICDH is a member of the tricarboxylic acid cycle. The cytosolic and 
mitochondrial isoenzymes instead require NADP+ and could therefore reestablish high ratios of 
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NADPH/NADP+ and GSH/GSSG following treatment with H2O2. Oxalomalate is a competitive 
inhibitor of ICDHs and may be useful to examine the involvement of ICDH in the antioxidant 
pathways in epithelial cells. Although oxalomalate has been shown to enhance 2,20-azobis(2-
amidinopropane) hydrochloride-induced lipid peroxidation in U-937 cells [261], I am not aware 
of a study that examines its effects on H2O2 induced oxidative stress. 
5-oxo-ETE may act as an autocrine mediator on epithelial cells. It has been shown that 
5-oxo-ETE induces the opening of Cl- channels in crypt jejunal epithelial cells in porcine, 
suggesting that this eicosanoid is potentially involved in diarrhea [50]. To date it is not clear 
whether 5-oxo-ETE is expressed in human non-myleoid tissue. Additional experiments are 
needed in order to answer this question. In the first report of OXE cloning, Hosoi and 
colleagues did not detect any OXE mRNA in A549 cells [48]. This is however not a final 
statement, as functional assays are needed to investigate potential biological effects of 
5-oxo-ETE on epithelial cells. For example, 5-oxo-ETE diminishes the growth inhibitory 
effects of MK-886 on human prostate epithelial cells [36,54,55]. It is further possible that 
5-oxo-ETE signals through mechanisms independent of OXE. O’Flaherty and colleagues 
proposed that 5-oxo-ETE signals through a putative 5-HETE receptor in the human prostate 
cancer cell line PC-3 [36]. It is also possible that 5-oxo-ETE acts, similar to LTB4, by 
stimulating PPARs. 
V.4. Metabolism and Inactivation of 5-oxo-ETE and 5-HETE 
The concentration of 5-oxo-ETE is regulated by its formation as well as by its half-life in 
tissue. Since it is comparably stable in buffer, its biological half-life depends on its rate of 
metabolism by resident tissue cells. As indicated above, 5-oxo-ETE catabolism has been so far 
extensively studied in human neutrophils and murine macrophages, but little is known about 
other cell types. During our investigations 5-oxo-ETE production by leukocytes and epithelial 
cells we observed a considerable loss of substrate and product. After 20 min incubations the 
amounts of 5-HETE and 5-oxo-ETE together accounted for less than 50% of the 5-HETE 
originally added to the BEAS-2B, A549, HL-60, and U-937 cells. We therefore investigated the 
underlying mechanisms for the disappearance of these substances.   
As we did not detect any UV-absorbing metabolites other than 5-HETE and 5-oxo-ETE, 
there seemed to be two possibilities for the loss we observed: (i) non-UV absorbing metabolites 
were formed and (ii) metabolites were formed that were excluded by our precolumn extraction 
procedure. There are two known pathways for the formation of non-UV absorbing metabolites 
of 5-oxo-ETE. The first is a metabolism by a ∆6 reductase to 6,7,-dihydro-5-oxo-ETE, which 
has been shown to occur in human neutrophils [93] and the second is conjugation of 
5-oxo-ETE with GSH to form FOG7. In both cases the 6-double bound that is the center of the 
dienone chromophore in 5-oxo-ETE is lost resulting in a loss of maximal absorbance above 
200 nm. To circumvent the problem we conducted experiments with 3H-labeled 5-oxo-ETE. 
Pilot studies conducted with 5-oxo-[11,12,14,15-3H]ETE showed no additional radioactive 
peaks within the HPLC chromatogram. This result strongly argues against the substantial 
contribution of either of the above pathways to the recovery loss of 5-HETE / 5-oxo-ETE.  
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Loss of 5-oxo-ETE / 5-HETE through esterification into lipids 
We hypothesized that 5-oxo-ETE is directly incorporated into lipids via an acyl-CoA 
synthetase-, most likely through an arachidonoyl-CoA synthetase-dependent pathway. 
O’Flaherty and colleagues [59] demonstrated that 5-oxo-ETE can be taken up in neutrophils 
and esterified into triglycerides. In their setting, using low concentrations of 5-oxo-ETE in the 
pM range, this eicosanoid was first reduced to 5-HETE by 5h-dh, and then esterified to 
coenzyme A by a triacsin C sensitive acyl-CoA synthetase. The 5-HETE adduct is presumably 
then incorporated into triglycerides by a transacylase. We investigated whether the uptake of 
5-oxo-ETE is mediated in a similar manner in U-937 cells.  
In U937 cells, the main metabolic pathway for 5-oxo-ETE appears to be direct esterification 
and does not appear to be conversion into 5-HETE. This hypothesis is supported by four lines 
of evidence: i) the loss of 5-oxo-ETE is more rapid than that of 5-HETE; ii) the kinetics of the 
forward and he backward reactions in U937 cells are comparable in the absence of any 
stimulus; iii) this pathway is inhibited by triacsin C; and iv) this pathway is also inhibited by 
AA or DHA. It seems unlikely that U-937 cells reduce 5-oxo-ETE to 5-HETE prior to further 
metabolism, since the rate of 5-oxo-ETE loss is more rapid than that of 5-HETE. Furthermore, 
the amount of 5-oxo-ETE formed in U-937 cells from 5-HETE was similar to that of 
5-oxo-ETE formed from 5-HETE, indicating that the kinetics of forward and backward reaction 
in whole cells are comparable. Triacsin C enhanced the recovery of 5-oxo-ETE, 5-HETE, and 
AA, presumably by inhibiting the arachidonate-CoA synthetase [59,101]. High amounts of AA 
or DHA had similar effects, most probably by saturating this pathway and competing with the 
other substrates. Similarly, AA has been shown to inhibit the uptake of 3H-AA [262] and 
15-HETE [102] in a dose dependent manner. We have conducted preliminary experiments to 
compare the rate of the loss of 5-oxo-ETE and 5-HETE with that of 14C-AA. Initial results 
suggest that AA may be a better substrate for this pathway than 5-oxo-ETE or 5-HETE in 
U-937 cells. The more hydrophilic LTB4 was not taken metabolized by this pathway. This is in 
agreement with a study from Stenson and coworkers, who examined the incorporation of 
arachidonic acid and various metabolites into lipids of a murine macrophage cell line [98]. In 
their setting, LTB4 was also not incorporated into lipids and AA was incorporated at a higher 
rate than 5-HETE, 12-HETE, or 15-HETE.  
Although our results suggest an involvement of an acyl-CoA synthetase-dependent pathway 
for the uptake of 5-HETE, 5-oxo-ETE, and AA, we have not yet investigated the lipid class into 
which these fatty acids are incorporated. There are considerable differences regarding the 
uptake of HETEs into lipids among cell types as different position isomers may be incorporated 
into different lipid subclasses (page 26). It is possible that the pathway for 5-oxo-ETE 
esterification in U-937 cells differs from that in A549 cells. It is notable, that rate of 
disappearance of 5-oxo-ETE is considerably faster than 5-HETE in U-937 cells, but is the same 
than that of 5-HETE in A549 cells. 
Potential effect of H2O2 on fatty acid uptake by esterification 
Sporn and colleagues showed [196] that H2O2, but not zymosan or A23187, almost 
completely inhibits the incorporation of AA into lipids of alveolar rat macrophages. H2O2 did 
not directly inhibit arachidonate-CoA synthetase or arachidonate-CoA:lysophosphatide 
acyltransferase, which catalyze the esterification of AA into phospholipids or stimulate cPLA2 
activity. Instead, it markedly depleted these macrophages of ATP, which is the required 
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cofactor of acyl-CoA synthetase. It was further  postulated that ATP depletion is the mechanism 
whereby H2O2 inhibits the acylation of AA. 
The incorporation of 5-oxo-ETE into lipids may represent a pathway to limit the biological 
effects of this inflammatory mediator. It may be postulated that oxidative stress not only 
enhances the concentration of 5-oxo-ETE by inducing its production, but also potentially by 
prolonging its half-life at sites of inflammation. In the studies of the effects of oxidative stress 
on 5-oxo-ETE synthesis from 5-HETE we observed some inhibition of the fatty acid (data not 
shown). However, a preincubation may be needed to efficiently lower intracellular ATP levels. 
Oxidative stress could also stimulate the production of 5-oxo-ETE by inhibiting the uptake of 
AA, resulting in increased availability of its precursor 5-HETE. Further experiments would also 
be required to address these issues. 
V.5. Conclusion 
V.5.1 Potential Roles of 5-Oxo-ETE in Diseases 
Within the past several years, the research on 5-oxo-ETE made considerable progress. The 
5-oxo-ETE receptor was cloned by two groups, allowing further studies regarding its tissue 
distribution and potentially the regulation of its expression [47,48]. 5-oxo-ETE was recently 
detected for the first time in human tissue extracts at concentrations possibly higher than those 
of LTB4; first evidence that this compound exists at biologically active concentrations in the 
body [252]. The major finding of the present thesis, including the regulation of 5-oxo-ETE 
synthesis by oxidative stress and the PPP and the wide tissue distribution of 5h-dh in both 
immature myeloid and structural cells should open new avenues of research of this 
inflammatory mediator. 
To date it is premature to appraise the physiological role of 5-oxo-ETE, although the 
biological effects of this eicosanoid suggest that it acts primarily as an inflammatory mediator. 
To evaluate potential disease areas for the involvement of 5-oxo-ETE, one can focus on areas 
in which 5-LO plays a pathophysiological role, because 5-oxo-ETE synthesis depends on this 
enzyme. The 5-LO pathway appears to be a promising pharmacological target in many 
pathological settings. Funk and Chen reviewed studies based on 5-LO knockout mice in models 
of inflammation [263]. In six models of inflammation, 5-LO played a detrimental role, which 
means that the knockout mice fare much better than the wild-type littermates. In only one study 
(pneumonia), 5-LO-deficient mice exhibited a poorer outcome than wild-type mice, while 
5-LO deficiency had no impact in five additional models. Presumably, 5-oxo-ETE, as one 
mediator of the 5-LO pathway, did not evolve to perform detrimental actions to the host. As 
5-LO is mainly expressed in leukocytes and 5-oxo-ETE synthesis is absolutely dependent on 
this enzyme to provide its precursor, 5-oxo-ETE may protect against infection or invasion of 
the host against by specific pathogens whose identity has yet to be determined. However, in 
many pathological settings, such as asthma, host defense mechanisms induce collateral damage 
to the tissue by inducing the response of very active cells such as eosinophils, which evolved in 
order to defend the body against parasitic worms and not pollen.   
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Strategies to Evaluate the Pathophysological Role of 5-oxo-ETE   
One can draw an analogy from Koch’s postulate, which describes a set of procedures to 
isolate and identify the causative agent of a particular microbial disease, to determine whether a 
particular inflammatory mediator is a critical pathological agent. The role of an agent has to be 
studied on several levels. First, the presence of the agonist or the corresponding receptor needs 
to be established. Second, the expression of the agonist should correlate with the severity of the 
disease state and the biological activity of the agonist should reflect the pathological condition. 
This implies that the presence of the agonist is at least in part responsible for pathological 
effects rather than a byproduct of the disease. Fourth, when the agent is introduced into a 
susceptible organism, it must reflect disease conditions. The final proof to establish the 
pathological role of an agent comes at the bedside; is the inhibition of its production or 
biological effects beneficial for the medical outcome of the patient? 
Based mainly on in vitro assays, the main function of 5-oxo-ETE appears to be as an 
proinflammatory mediator. Intradermal and intratracheal administration of this eicosanoid 
cause leukocyte infiltration in vivo [56,57]. This response is paralleled in in vitro assays in 
which 5-oxo-ETE proved to be a potent chemoattractant for eosinophils and neutrophils and a 
weak inducer of monocyte chemotaxis [7,26,31]. Besides chemotaxis, addition of 5-oxo-ETE 
elicts a variety of inflammatory responses, including AA and ROS release, CD11b 
upregulation, actin polymerization, and rise of intracellular Ca++. However, due to technical 
difficulties the pathophysiological role of 5-oxo-ETE has not been established. The study of 
this agonist in pathophysiological settings has been hampered by the fact that the receptor was 
not known until recently and there are no OXE receptor antagonists or 5h-dh inhibitors. 
Furthermore, the detection of 5-oxo-ETE is difficult for technical reasons.  
In contrast to 5-oxo-ETE, the involvement of the Cys-LTs and LTB4 have been studied in 
many diseases. They are easier to measure than 5-oxo-ETE or 5-HETE, because their complex 
structure allowed the development of reliable ELISA assays, which are economical and easy to 
perform. The situation is far more difficult with 5-oxo-ETE. It will prove very difficult to raise 
a monoclonal antibody against this eicosanoid that possesses a low cross-reactivity with related 
molecules. Eicosanoids are too small to be used as inducers of antibody production. They have 
to be coupled to a larger carrier molecule, in order to induce a proper immune response. The 
ligation to these larger molecules, known as haptenation, is usually accomplished through the 
formation of an amide bound between the carboxy-terminus of the eicosanoid and amino 
groups of the carrier. Since the 5-oxo specific region is fairly close to this locus, antibody 
development may be difficult due to cross-reactivity with other closely related fatty acids. 
With ELISA-test presently unavailable, one has to rely on mass-spectrometry to measure 
5-oxo-ETE in biological fluids. Powell and coworkers developed a reliable way to detect 
5-oxo-ETE by this powerful technology using deuterium-labeled 5-oxo-ETE as an internal 
standard [264]. This is a promising technology and Bowers and colleagues used this technique 
to detect 5-oxo-ETE in lung tissue extracts from several patient groups [252]. LC-MS/MS is a 
very powerful, but also very expensive tool and demands well-trained technicians. For those 
reasons, it appears unlikely that 5-oxo-ETE will be measured in the near future in large scale in 
clinical settings. This however is important to estimate the clinical relevance of this compound. 
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The knowledge of the GPCR for 5-oxo-ETE will allow investigation of the expression 
patterns of this receptor. It will be important to study potential correlations of OXE expression 
and pathological conditions such as cardiovascular diseases or asthma (see below). 
Does 5-Oxo-ETE Play a Role in Asthma? 
The importance of the 5-LO pathway is well established in asthma, and drugs inhibiting LTs 
have been developed for treating this disease [21]. Montelukast (Singulair®) and Zafirlukast 
(Accolate®) are cysLT1 receptor antagonists and in clinical use in asthma [21]. LTB4 is a potent 
inflammatory mediator, it primarily targets neutrophils and does not appear to play a major role 
in asthma [21]. For that reason it was justified to focus on the cys-LTs as drug targets in this 
disease. This strategy, however, does not take the other arm of the 5-LO metabolism into 
account: 5-HETE and 5-oxo-ETE. 5-HETE was for a long time ignored as it induces only weak 
biological responses. However, 5-oxo-ETE is a much more potent and efficacious eosinophil 
chemoattractant than the cys-LTs or LTB4 and induces eosinophil infiltration in Brown Norway 
rat lungs after intratracheal administration. It was found recently that 5-oxo-ETE induces 
contraction of guinea pig ASM cells in vitro by inducing thromboxane A2 release [53,56]. This 
suggests that 5-LO inhibitors could have some advantage over selective cysLT1 antagonists in 
treating asthma.  
Our finding of high 5h-dh activity in lung epithelial cells may describe a new pathway for 
the formation of 5-oxo-ETE by transcellular biosynthesis in the lung. 5-HETE may be released 
from resident macrophages or invading neutrophils and eosinophils and converted by epithelial 
cells to 5-oxo-ETE. This process could be enhanced by oxidative stress, which is associated 
with asthma and other allergic diseases [110].  
Is 5-Oxo-ETE Involved in the Pathogenesis of Cardiovascular Diseases? 
Although cardiovascular diseases are a leading cause of death in the developed world, the 
mechanism of arterial wall inflammation in atherogenesis are only partially understood. Based 
on two patient-based studies, 5-LO was recently identified as a potentially important novel 
target for interrupting the inflammatory cascade in atherosclerosis. Spaenbroek and colleagues 
found that the expression of 5-LO, but not that of 15-LO, is positively correlated to the disease 
state [265]. This study shows that in the arterial wall exist inflammatory circuits that expand 
during the late stage of atherogenesis. Additional support for the role of 5-LO comes from the 
geneticist Stefansson and his team. Studying a large population in Iceland, they have now 
identified a mutation in the gene encoding for FLAP that is associated with a two fold greater 
risk of both heart attacks and strokes [266]. The result of this study was also confirmed in 
another patient group from the UK [266]. Even though the mutation of the FLAP gene found in 
the UK was different from that in Iceland, the outcome, a higher rate of LTB4 synthesis by Ca++ 
ionophor stimulated neutrophils was similar. 
Neutrophils and monocytes play important roles in cardiovascular disease. Although 
5-oxo-ETE is less potent than LTB4 in stimulating neutrophils, its effects on these cells are 
markedly enhanced following priming with GM-CSF [35]. Since 5-oxo-ETE can induce 
GM-CSF release from monocytes, this could result in amplification of the response of 
neutrophils to this substance in a paracrine manner [37]. In the narrow space of the vasculature, 
5-oxo-ETE could be formed by means of intercellular eicosanoid biosynthesis between 
leukocytes and the endothelium as been shown for cys-LTs [10]. In this setting 5-HETE may be 
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released from neutrophils and converted into 5-oxo-ETE by surrounding endothelial cells. 
Oxidative stress, which appears to be a common feature of cardiovascular disease, may 
enhance the conversion of 5-HETE to 5-oxo-ETE [105,251], as suggested by our finding that 
exposure of HAEC to H2O2 strongly enhances this process in vitro at physiological glucose 
concentrations.  
V.5.2 Prospects for Future Studies 
The findings of the present study suggest a variety of avenues for further research, which we 
were so far unable to explore due to time restraints. Some results have been only briefly 
discussed above and much preliminary data have been omitted by the author. In some cases 
further experiments are required to gain statistical significance and other instances more work 
is necessary to explain the underlying mechanisms. 
Mechanism of 5h-dh Catalysis 
In unstimulated U-937 cells, the rates of the forward (5-HETE ? 5-oxo-ETE) and backward 
(5-oxo-ETE ? 5-HETE) reactions are identical. This differs from platelets, in which the 
backward reaction is favored [70]. As the NADPH/NADP+ ratio is high in unstimulated cells, 
which would favor the reverse reaction, it would appear that 5h-dh favors the forward reaction. 
Direct studies with semi-purified 5h-dh would help to clarify the biochemical properties of this 
enzyme. Preliminary studies (data not shown) with U-937 cell microsomes demonstrated that 
the Vmax of 5h-dh is higher for the forward reaction than for the reverse reaction. However, the 
KM of 5h-dh was higher for 5-HETE than for 5-oxo-ETE when microsomes were incubated 
with similar amounts of NADP+ or NADPH, respectively. Although this finding suggests that 
5h-dh may have a higher affinity for 5-oxo-ETE than for 5-HETE, additional studies are 
needed to confirm this and the protocol needs to be optimized. Further studies are also 
necessary to examine the underlying reaction mechanism of this enzyme. Many NADP+ or 
NAD+-dependent dehydrogenases follow an ordered Bi-Bi reaction mechanism with the 
nucleotide initiating the binding sequence. To study the KM values of this enzyme for 5-HETE, 
it is then sufficient to saturate NADP+ and vary [5-HETE]. To gain more information a wider 
approach has to be taken, by varying the concentrations of both the substrate and the cofactor 
[267]. Under these circumstances, it is possible to determine both the reaction mechanism of 
5h-dh (sequential Bi-Bi or Ping-Pong Bi-Bi) and the binding affinities of 5h-dh for NADP+ and 
5-HETE and possibly for 5-oxo-ETE and NADPH. If these results confirm the higher binding 
affinity of 5h-dh for 5-oxo-ETE, 5h-dh may be subject to product inhibition. 
Subcellular Localization of 5h-dh 
5h-dh has been shown to be located primarily in the microsomal fraction. This fraction 
includes parts of all membrane-containing subcellular fractions of the cell, including primarily 
the endoplasmatic reticulum, plasma membrane, and Golgi. However, other membranes such as 
the nuclear envelope and granule membrane can also be included depending on the severity of 
the cell disruption procedure. To further investigate this issue an alternative disruption 
procedure would be preferable. For subcellular studies, cells can be destabilized in a hypotonic 
buffer and then disrupted by nitrogen caviation or with a glass tissue homogenizer. The 
different membrane fractions are then separated over Percoll or sucrose gradients. Marker 
proteins have to be measured to evaluate the purity and identity of the derived fractions. 
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Another procedure to purify specific fractions is based on a modified magnetic antigen cell 
sorting technology. In this case, monoclonal antibodies against specific subcellular marker 
proteins are bound to superparamagnetic micro-beads. After binding to the beads the fraction of 
interest is then retained on separation columns in a high-gradient magnetic field generated by a 
permanent magnet. By simply rinsing the column with buffer, all the unlabeled fractions are 
removed and the bound organelles are then eluted by simply removing the separation column 
from the magnet. In this way fractions of interest can be retained on the column (positive 
selection), or antibodies against proteins which mark contaminating fractions can be used to 
retain those impurities (negative selection).  
Potential Upregulation of 5-oxo-ETE Synthesis during apoptosis 
The formation of 5-oxo-ETE by may be enhanced during apoptosis because of its 
association with oxidative stress. The molecular events within a cell during apoptosis are often 
distributed into three phases [268]. The first is a pre-mitochondrial initiation phase, which can 
be induced by several apoptotic signals. The second is the mitochondrial phase that integrates 
these signals into one common pathway, which is irreversible and commits the cell to 
apoptosis. It involves the loss of the inner mitochondrial membrane potential (∆ψm), a dramatic 
decrease of the NADPH/NADP+-ratio, and GSH oxidation. Only after these events, are 
downstream caspases activated in the third phase of apoptosis. Although it is artificial, this 
division provides an attractive framework for the study of apoptosis. Of special interest for us is 
the second phase, as it leads to the oxidation of NADPH, thus potentially providing the cofactor 
of 5h-dh needed for the conversion of 5-HETE to 5-oxo-ETE.  
Although the decrease of the NADPH/NADP+- ratio is a common feature of early apoptosis, 
the underlying molecular cause is not well understood. Gendron and colleagues examined the 
molecular sequence of apoptosis with special focus on the NAD(P)H-levels by auto-
fluorescence and HPLC [269]. The results of their study showed that NAD(P)H decreases in 
parallel to GSH, and is closely related to mitochondrial pore formation and to the loss of ∆ψm. 
The decrease of NADPH is correlated to an increase in NADP+, thus rising the redox state of 
the cell. As the measurement of NADP+ is more difficult to estimate, due to the absence of a 
fluorescent group which be detected by FACS, NADP+ is not routinely examined. However, 
this report lacks a proper explanation for the increase of the redox state within the cell during 
apoptosis, as O2•− formation appeared after the decrease of the NAD(P)H levels. Mitochondrial 
pore formation is known to uncouple the electron chain from the H+ gradient and subsequently 
to lead to enhanced formation of O2•−. The authors used hydroethidin to measure O2•− 
formation, which is a cell permeable agent that can be oxidized by superoxide to ethidium, a 
fluorescent compound that is retained within the cell. The authors did not elaborate in their 
studies whether the GHS redox cycle is a more efficient scavenger than the O2•− detecting dye 
hydroethidin. The dye is potentially only oxidized by O2•− when the redox capacity of GSH and 
NADPH is diminished. 
We initiated experiments to investigate whether apoptosis leads to a higher capacity of 
5h-dh-containing cells to produce 5-oxo-ETE. Preliminary experiments with cultured 
neutrophils suggest that an enhanced percentage of necrotic/apoptotic cells result in a higher 
conversion of 5-HETE to 5-oxo-ETE. This process can be diminished when lipopolysaccharide 
or GM-CSF, two compounds which are known to delay the onset of neutrophil apoptosis, are 
added to the culture medium. We are also planning to induce apoptosis in cell lines and blood 
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cells with different stressors and apoptosis inducers such as ceramide and αCD95 antibodies. 
To correlate the molecular events with 5-oxo-ETE formation, we will examine the relationship 
of its formation with Annexin V staining (e.g. the appearance of phosphatidylserine on the 
outer membrane leaflet) and the ∆ψm using flow cytometry. We are also setting up protocols to 
measure the content of purine and adenine nucleotides by HPLC as well as GSH and GSSG by 
HPLC using a fluorescence detector in conjunction with derivatization of these cofactors to 
fluorescent analogs. 
Determination of 5-oxo-ETE metabolites in U-937 and A549 cells 
Although we have strong pharmacological evidence that 5-oxo-ETE and 5-HETE are 
esterified to CoA, we do not know the lipid class into which these substances are incorporated. 
It is impossible to predict this from other studies, as there are wide differences in lipid 
metabolism from one cell type to another. This process is most likely to be substrate dependent, 
as AA, 5-oxo-ETE and 5-HETE may be handled differently from one another [97-99,102,270]. 
It is therefore important to identify the final metabolite to further study this pathway. As a first 
step cells should be labeled with 3H-5-oxo-ETE and the lipid fraction should be analyzed by 
thin layer chromatography to determine if 5-oxo-ETE is taken up into phospholipids or 
triglycerides.   
Future Co-Culture Experiments 
The specific activity of 5h-dh is very high in A549 cells and the basis of our studies with 
both whole cells and microsomal fractions. Similarly, HAEC also have a high capacity to 
produce 5-oxo-ETE, presumably via 5h-dh. These findings suggest that the epithelium and the 
endothelium may be sources for 5-oxo-ETE in vivo. As epithelial and endothelial cells lack 
significant 5-LO activity, we have to investigate whether 5-oxo-ETE can be formed by means 
of transcellular biosynthesis. To study transcellular metabolism, 5-LO containing phagocytes 
(monocytes or granulocytes) should be co-stimulated with epithelial or endothelial cells. 
Co-culture of neutrophils with epithelial cells does not automatically lead to an enhanced 
formation of eicosanoids. It has been shown before by Klockmann and coworkers [259] that 
epithelial derived PGE2 can diminish LTB4 release from human neutrophils. Since A549 cells 
express COX-2 and can produce PGE2 [13], it possible that A549 cell derived PGE2 could 
inhibit neutrophilic 5-LO. For that reason, indomethacin, a non-specific COX inhibitor, should 
be added to avoid PGE2 synthesis from A549 cells. Another potential problem is the 
esterification of AA in A549 cells, which would lower the available substrate concentration for 
5-LO. Furthermore, we showed here for the first time that A549 cells have a high capacity to 
retain 5-oxo-ETE and 5-HETE, which could counteract the stimulatory effects of transcellular 
metabolism. 
 
“We have a habit in writing articles published in scientific journals to make the work 
as finished as possible, to cover up all the tracks, to not worry about the blind alleys 
or describe how you had the wrong idea at first, and so on. So there isn't any place to 
publish, in a dignified manner, what you actually did in order to get to do the work.” 
Richard Feynman 
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VII  APPENDIX 
VII.1. Selected Eicosanoids and Fatty Acids 
CO2H
 
Arachidonic Acid 
5Z,8Z,11Z,14Z-eicosatetraenoic acid 
CO2H
 
DHA 
4Z,7Z,10Z,13Z,16Z,19Z-Docosahexaenoic acid 
CO2H
 
EPA 
5Z,8Z,11Z,14Z,17Z-Eicosapentaenoic acid 
Synonyms: Timnodonic acid 
NH2
HO2C
O
N
H
CNCH2COOH
CH2
S O
CO2H
 
FOG7  
5-oxo-7-glutathionyl-8Z,11Z,14Z-eicosatrienoic acid  
CO2H
OH
 
5-HETE 
5S-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid 
OH
CO2H
 
12-HETE 
12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid 
OH
CO2H
 
15-HETE 
15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid 
CO2H
OH  
13-HODE 
13S-hydroxy-9Z,11E-octadecadienoic acid 
CO2H
O OH
 
5-HpETE 
5S-hydroperxy-6E,8Z,11Z,14Z-eicosatetraenoic acid 
CO2H
 
Linoleic Acid 
9Z,12Z-octadecadienoic acid 
OH
CO2H
OH OH
 
Lipoxin A4 
5S,6R,15S-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid 
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CO2H
OH OH
OH
 
Lipoxin B4 
5S,14R,15S-trihydroxy-6E,8Z,10E,12E- eicosatetraenoic acid 
O
CO2H
 
LTA4  
5S-trans-5,6-oxido-7E,9E,11Z,14Z-eicosatetraenoic acid 
OH OH
CO2H
 
LTB4 
5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid 
OH OH
CO2H
 
12-epi-LTB4  
5S,12S-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid 
OH
CO2H
OH
 
6-trans-LTB4 
5S,12R-dihydroxy-6E,8E,10E,14Z-eicosatetraenoic acid 
OH
CO2H
OH
 
6-trans-12-epi-LTB4 
5S,12S-dihydroxy-6E,8E,10E,14Z-eicosatetraenoic acid 
CO2H
OH
S
CysGlu Gly
 
LTC4
5S-hydroxy-6R-(S-glutathionyl)-7E,9E,11Z,14Z-eicosatetraenoic acid 
 
LTD4
5S-hydroxy-6R-(S-cysteinylglycinyl)-7E,9E,11Z,14Z-
eicosatetraenoic acid 
CO2H
OH
S
Cys GlyNH2
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CO2H
O
 
5-oxo-ETE 
5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid 
CO2H
O
 
5o-EtrE 
5-oxo-8Z,11Z,14Z-eicosatrienoic acid 
OH
CO2H
O
 
5-oxo-12-HETE 
5-oxo-12-hydroxy-6E,8Z,10E,14Z-eicosatrienoic acid 
OH
CO2H
O
 
5-oxo-15-HETE 
5-oxo-15-hydroxy-6E,8Z,11Z,13E-eicosatrienoic acid 
O
OH
CO2H
 
8-trans-5-oxo-12-ETE 
5-oxo-12-hydroxy-6E,8E,10E,14Z-eicosatrienoic acid 
O
CO2H
OH  
PGB2 
9-oxo-15S-hydroxy-prosta-5Z,8(12),13E-trien-1-oic acid 
O
CO2H
OH
OH
 
PGE2
Prosta-5Z,13E-dien-11 α,15S-dihydroxy-9-oxo-1-oic acid 
CO2H
OH
OH
OH  
PGF2α 
9α,11α,15S-trihydroxy-prosta-5Z,13E-dien-1-oic acid 
CO2H
O
O
OH  
PGH2
9α,11α-epidioxy-15S-hydroxy-prosta-5Z,13E-dien-1-oic- acid 
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VII.2. Some Frequently Used Chemicals 
N
N
N
H
NH2
 
3-AT 
3-Amino-1,2,4-triazole 
Cl
N
H
N
N
O
O
Cl  
BCNU 
1,2-bis[2-chloroethyl]-1-nitrosourea; carmustine 
 
 
DHEA 
Dehydroepiandrosterone 
CH3
N
CH3
C N
O
N C N
O CH3
CH3  
Diamide 
N,N,N',N'-Tetramethylazodicarboxamide 
    
S O
 
DMSO 
dimethylsulfoxide 
OH OH  Hydrogen peroxide, H2O2, 
N OO
CH2 CH3  
NEM 
N-Ethylmaleimide 
CH3
CH3
CH3
OOH
 
tBuOOH  
tert-butyl hydroperoxide 
CH3
O
CH3
OCH3
O
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VII.3. Claims to Original Research 
The following summary lists research, which was undertaken for the first time over the 
course of this thesis. To the best knowledge of the author, none of these findings has been 
presented by other researchers. 
• We are the first to demonstrate that undifferentiated myeloid cell lines (U-937 and 
HL-60) express 5h-dh at levels comparable to human peripheral blood leukocytes 
and that its activity can be upregulated by differentiation towards 
monocytes/macrophages.  
• We present, for the first time, a novel regulatory pathway by which 5-oxo-ETE 
synthesis is stimulated. Oxidative stress simulated by hydroperoxide addition 
dramatically enhances NADP+ levels, the cofactor of 5h-dh, thus enhancing the 
formation of 5-oxo-ETE from 5-HETE. Using different pharmacological approaches 
we were able to show that this stimulatory effect is carried into execution by the 
GSH redox cycle. Oxidative stress dramatically enhances the formation of 
5-oxo-ETE from endogenous 5-HETE by all cell types studied except by neutrophils, 
which proved to be more resistant to this effect. We also found that tBuOOH induces 
5-oxo-ETE synthesis from endogenous 5-HETE in AA and Ca++ ionophore 
stimulated PBMC. 
• We show here for the first time that glucose diminishes the stimulatory effect of 
oxidative stress on 5-oxo-ETE synthesis and can affect the baseline conversion of 
5-HETE to 5-oxo-ETE in some cell types. This effect is mediated through the PPP 
by reducing NADP+ to NADPH, thus depleting the cofactor needed for the reduction 
of 5-HETE to 5-oxo-ETE by 5h-dh.  
• This thesis presents for the first time that the epithelial cell lines A549, BEAS-2B, 
T84, and HEp-2G have the ability convert 5-HETE to 5-oxo-ETE. Further studies 
with A549 cells revealed that the enzyme catalyzing this reaction appears to be 
5h-dh, which had been previously only described in peripheral blood leukocytes and 
platelets. 5-oxo-ETE synthesis is also stimulated by oxidative stress in epithelial 
cells and inhibited by glucose. However, to date we were not able to show that the 
inhibitory effect of glucose is due to the action of the PPP. 
• We further demonstrated that human aorta endothelial cells (HAEC) also convert 
5-HETE to 5-oxo-ETE. Due to the limited availability of those primary cells, we 
could not rule out that an enzyme other than myeloid 5h-dh is responsible for this 
reaction. However, the regulation of 5-oxo-ETE synthesis by oxidative stress appears 
to be similar to that found in myeloid cells. 
• We further examined forward and the backward reaction U-937 cell derived 5h-dh. 
For the first time we examined the pH-dependence of this catalysis and found the 
forward reaction to be favored above pH 6.5. There is a dramatic increase in 
5-oxo-ETE formation by U-937 microsomes at pH 9, with a maximum at pH 10. The 
5h-dh-mediated reaction is inhibited at extreme pHs (pH ≤ 4.0 and pH ≥ 11.4). 
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